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ABSTRACT 
 Osteoarthritis (OA) is characterised by cartilage degradation, inflammation 
and pain within synovial joints. OA is a major cause of morbidity in the elderly human 
population and in companion animals such as horses. Changes in expression and 
activity of pro-inflammatory cytokines, chemokines and catabolic mediators contribute 
towards OA progression, which can be studied using in vitro culture models and 
proteomic approaches. This project studied the secretome from an in vitro model of 
equine articular cartilage, aiming to develop understanding of cartilage biology and 
degradative processes. These studies also aimed to identify protein markers relevant 
to this explant model for screening anti-inflammatory properties of novel therapeutics. 
 To evaluate responses to OA associated pro-inflammatory IL-ȕDQGWKHQRQ-
steroidal anti-inflammatory drug (NSAID), carprofen, time courses of protein release 
were established in the explant model. The cartilage secretome contained cartilage 
extracellular matrix (ECM), non-ECM and intracellular proteins, all of which were 
identified by high-throughput mass spectrometry (MS). Semi-quantitative differences 
in protein release were reported between untreated control and IL-ȕ VWLPXODWHG
cartilage by MS. The release of glycosaminoglycans (GAGs) initiated by IL-ȕ ZDV
delayed when carprofen was present.  
 The proteomic sample preparation method was adapted to deplete high 
abundance proteins that can hinder the detection of low level proteins in high-
throughput MS analysis. Three depletion approaches were applied: CPC precipitation, 
concanavalin A lectin chromatography and 3URWHRPLQHU technology. These 
approaches provided additional identifications of the non-ECM secreted proteins 
MMP-10 and IL-9, and of additional intracellular proteins. Further optimization of these 
methods could further enhance the detection of low level proteins. 
 Proteins identified by MS analysis of the cartilage secretome were assessed 
using quantitative western blotting analysis. Carprofen significantly reduced IL-ȕ
stimulated release of MMP-1, MMP-3, MMP-13 and a fibronectin degradation product. 
Levels of clusterin were reduced by IL-ȕ DQG FDUSURIHQ WUHDWPHQWV These specific 
proteins were shown to be markers of IL-ȕVWLPXODWHGLQIODPPDWLRQand degradative 
processes, which can be significantly reduced by an anti-inflammatory such as 
carprofen. 
This thesis describes the use of proteomics with other approaches to study 
the effects of IL-ȕDQGFDUSURIHQon release of several important structural, metabolic 
and inflammatory related components from cartilage. Carprofen was beneficial in 
decreasing certain aspects of inflammation and degradation, including significantly 
reducing release of MMPs and their catabolic products (fibronectin and GAGs) from 
the ECM. The equine explant model can be further studied with high-throughput MS to 
assess responses to various stimuli and detect released proteins. In conclusion, anti-
degradative effects and MMP inhibition can be specifically monitored within this in 
vitro equine cartilage model, to screen efficacy of therapeutics and putative anti-
inflammatories to relieve OA.  
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CHAPTER 1 
INTRODUCTION 
 The aim of the work described in this thesis was to assess a high-throughput 
proteomic approach to evaluate the secretome of an equine articular cartilage explant 
model, and to monitor responses to pro-inflammatory stimuli or anti-inflammatories. 
Studying cartilage biology and degradation in vitro will provide scientific understanding 
that is relevant to and can be applied to osteoarthritis (OA) research. This introductory 
chapter describes the background to OA, articular cartilage structure, pathogenesis 
and inflammation in this disease. The introduction will then focus on the advantages of 
cartilage explant studies models for studying OA and the other research models 
available. Proteomic and secretome strategies to study OA associated tissues will 
also be focused upon and reviewed. Available treatments for OA will next be 
discussed, concentrating on carprofen that was studied throughout this thesis. The 
details of the aims and hypothesis for the whole thesis and specific chapters will then 
be explained. 
1.1 Osteoarthritis 
OA is a prevalent physiological disease affecting large proportions of the 
elderly population and is expected to become an increasing burden on the healthcare 
system as people continue to live longer. OA is a major cause of pain, disability and 
has economic implications through affecting D SHUVRQ¶V DELOLW\ WR ZRUN ,W ZDs 
estimated in 2008 that 26.9 million people had clinical OA in at least one joint in the 
United States (Lawrence et al., 2008). This condition is also a major cause of 
morbidity in companion animals like dogs (Henrotin et al., 2005) and horses (Goodrich 
and Nixon, 2006) leading to lameness and substantial veterinary costs. OA is a 
degenerative disease of the entire synovial joint, mainly characterised by synovial joint 
inflammation and progressive destruction of the extracellular matrix (ECM) of articular 
cartilage (Buckwalter and Mankin, 1998a). A diagrammatic representation of the 
synovial joint and its tissues is displayed in Figure 1. Synovial joints are located at the 
  
2 
 
ends of articulating bones and allow controlled movement. The joint capsule contains 
lubricating synovial fluid and is a defining feature of this type of joint. Articular cartilage 
covers the ends of bones within the joint, providing a protective surface. Knee joints 
are most commonly affected but OA can occur in any synovial joint (Cushnaghan and 
Dieppe, 1991). In general, weight-bearing joints are worst affected. The causes of OA 
are not currently fully understood but risk factors include age, gender, genetics, 
obesity, poor nutrition and joint injury or instability (Lee et al., 2013). 
  
 
Figure 1. Simplified diagram of a synovial joint 
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 Loss of cartilage will affect the integrity of the smooth articular surface 
(Figure 2), therefore affecting the usual flowing movement of synovial joints. This 
ultimately has implications on quality of life, as movement and mobility becomes 
increasingly painful. Other characteristics of OA can include subchondral bone 
sclerosis (hardening) and osteophyte (bony outgrowth) formation (Goldring and 
Goldring, 2007). Treatment for OA relies on symptomatic relief with analgesics, 
steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) often being prescribed, 
or the surgical replacement of joints in more serious cases. Current treatments only 
reduce the levels of pain and inflammation, but have no impact on slowing cartilage 
loss and destruction. Effective disease modifying OA drugs (DMOADs) continue to be 
elusive therefore there is extensive interest to advance the discovery of treatments to 
stimulate cartilage repair and to reverse disease progression. Herbal medicinal 
products or nutraceuticals with intrinsic anti-inflammatory properties may have 
potential to provide alternatives to conventional treatments (Cameron et al., 2009). 
The effectiveness of herbal treatments for OA has not yet been proven and further 
carefully designed clinical trials are required. 
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Figure 2. Histological sections of human articular cartilage 
(A) Healthy normal articular cartilage with a smooth surface. 
(B) OA affected articular cartilage showing signs of 
degeneration and an irregular surface (Afif et al., 2007). 
(A) 
(B) 
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Cartilage damage occurring in OA can be detected radiographically by a 
decrease in joint space width, but this is only seen once considerable cartilage 
degradation has already happened. Collagen and proteoglycan fragments can be 
detected in the blood, synovial fluid and urine acting as biomarkers after significant 
degeneration of cartilage (Mobasheri and Henrotin, 2010). These biomarkers can 
detect changes occurring to cartilage and are consistent with joint space narrowing 
being observed, although as already mentioned by this point in time the disease has 
already progressed considerably. Once OA has reached the stage where it can be 
diagnosed by these methods, any treatment intervention is too late to affect disease 
progression. Therefore a biomarker (or group of biomarkers) that signifies early OA 
would be a useful tool to allow screening of individuals, particularly those with a high 
risk of developing joint disease, so that early detection may facilitate individualized 
treatment. A protein biomarker specific to early OA that can be easily identified in 
blood or urine would be ideal since diagnostic tools such as specific antibodies can be 
developed to proteins that are sufficiently sensitive to allow accurate detection. 
Diagnosing OA early will allow timelier interventions and lifestyle changes to be 
introduced, which may be beneficial to patient prognosis.  
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1.2 Articular cartilage 
The ends of long bones within synovial joints are covered with articular 
cartilage to protect the bone underneath and allow smooth movement of joints (Figure 
1). Articular cartilage consists primarily of the extracellular matrix (ECM), water and a 
single cell type known as the chondrocyte (Archer and Francis-West, 2003) (Figure 3). 
It is an avascular, aneural and alymphatic connective tissue with unique biological and 
mechanical properties. These include the ability to be durable and compressed while 
maintaining tensile strength. The load-bearing function of cartilage is determined by 
the constituents of the ECM and its interactions with chondrocytes (Buckwalter and 
Mankin, 1998b). Due to the absence of vasculature, cartilage is maintained and 
functions within a hypoxic environment as there is a very low oxygen supply to the 
tissue (Schipani et al., 2001). Chondrocytes are therefore adapted to survive and 
preserve the ECM in this hypoxic environment (Wilkins et al., 2000). 
  
 
Figure 3. Electron micrograph of an articular chondrocyte  
Chondrocytes usually show a rounded morphology and are 
highly metabolically active, primarily functioning to maintain the 
ECM and synthesize its specialised proteins (Archer and 
Francis-West, 2003). 
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There are four different zones within the full thickness of articular cartilage 
known as the superficial, transitional, deep and calcified zones (Pearle et al., 2005) 
(Figure 4). Explant discs cultured throughout this thesis, were taken from full thickness 
healthy cartilage, and therefore will contain all four cartilage zones. Chondrocytes 
display different metabolic activities and morphology throughout the individual layers. 
Closest to the joint surface is the superficial zone (10-20% thickness) that provides a 
smooth sliding surface vital for synovial joint function and has the ability to resist shear 
forces. This zone has high collagen content, containing collagen fibrils organised 
parallel to the surface, and with relatively low proteoglycan concentrations compared 
to the other layers. Chondrocytes here primarily produce proteins for protection and to 
aid lubrication. Within the superficial zone, chondrocytes have a histologically 
elongated appearance (Pearle et al., 2005). Lubricin (which is also known as 
superficial zone protein (SZP) or proteoglycan 4) is an important protein that functions 
to lubricate synovial joints. Chondrocytes in the superficial zone can be characterised 
phenotypically by high levels of lubricin synthesis, compared to chondrocytes in the 
underlying cartilage layers (Schumacher et al., 1999). Cytokine stimulation can 
modulate expression of lubricin, therefore inflammation during OA could affect release 
of this essential protein (Lee et al., 2008).  
Beneath the superficial zone, is the transitional (middle) zone that makes up 
40-60% of cartilage thickness and has a considerably higher proteoglycan content 
(Pearle et al., 2005) compared to the superficial zone. The middle zone therefore has 
increased compressibility than the superficial zone. Collagen content here contains 
thicker collagen fibres, but these are less densely concentrated and organized than in 
the superficial zone. Whilst superficial zone chondrocytes are elongated, within the 
middle zone they have a rounder morphology (Pearle et al., 2005). 
 Next, the deep zone (30% thickness) has the lowest water concentration and 
highest proteoglycan concentration of all cartilage zones. Chondrocytes and collagen 
fibres in deep zone are arranged into columns running perpendicular to the cartilage 
surface. The final layer is the calcified (tidemark) zone providing direct contact with 
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subchondral bone. Chondrocytes in this zone are small and the matrix is rich in 
apatite crystals (Pearle et al., 2005). The calcified zone mostly contains collagen II 
and hydroxyapatite, along with calcium phosphate, calcium carbonate and collagen 
type X (Zhang et al., 2012b). Large collagen fibre bundles from the deep zone, cross 
over into the calcified zone to anchor cartilage in place (Mow et al., 1989). Thickening 
of the calcified zone and multiple tidemarks are observed in OA, which causes the 
cartilage to become stiff and unable to absorb compressive forces (Henrotin et al., 
2012c). 
 
 
 
Figure 4. Schematic diagram of the defined layers of full thickness articular cartilage 
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The load-bearing function of cartilage is achieved by its structural design and 
interactions between the chondrocytes and ECM (Buckwalter and Mankin, 1998b). 
Chondrocytes synthesise the macromolecular framework of ECM from three distinct 
classes of macromolecules: fibrillar and non-fibrillar collagens, proteoglycans and 
non-collagenous proteins (Muir, 1995). The tensile stiffness and strength of cartilage 
are provided by a fibrillar meshwork of collagen types II, IX, and XI (Eyre, 2004, 
Kuettner et al., 1991). Chondrocytes are surrounded by a pericellular/territorial matrix, 
which contains a high proportion of collagen type VI filaments (Figure 5). Pericellular 
matrix acts as a transducer of biomechanical and biochemical signals between 
chondrocytes and the ECM (Guilak et al., 2006, Roughley and Lee, 1994).  
Throughout the cartilage ECM are large aggregating proteoglycans 
(aggrecan), which give cartilage its stiffness to compression, its resilience and 
contribute to its long-term durability (Kiani et al., 2002, Luo et al., 2000). Hyaluronan 
chains form the backbone of aggrecan, from which the glycosylated side chains are 
attached with the support of link proteins. Aggrecan contains numerous side-chains of 
chondroitin sulphate and keratin sulphate that are highly negatively charged and 
therefore attract positively charged cations, which in turn draw water molecules into 
the ECM (Buckwalter and Mankin, 1998b). Cartilage therefore swells and when 
compressed, water is displaced providing a cushioning effect. Decorin, biglycan and 
fibromodulin are small proteoglycans that bind other components therefore aiding 
formation of the ECM (Heinegard, 2009). Decorin and fibromodulin have binding roles 
in fibrillogenesis and interfibril interactions via connections with type II collagen fibrils 
in the matrix. Biglycan may interact with collagen type VI (Buckwalter and Mankin, 
1998a, Roughley and Lee, 1994) that is mainly located in the immediate surroundings 
of chondrocytes. Non-collagenous proteins are also found in articular cartilage 
including cartilage oligomeric matrix protein (COMP), which has been studied as a 
biomarker of ECM turnover and cartilage degeneration (Di Cesare et al., 1996). 
Fibronectin and tenascin also have a role in influencing exchanges between 
chondrocytes and the ECM (Roughley and Lee, 1994). Figure 5 illustrates many 
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important proteins contained within cartilage ECM that help to produce its specialised 
tissue structure. 
 
 
Figure 5. Schematic illustration of the major protein constituents of the ECM of 
articular cartilage 
Chondroadherin = CHAD, proline/arginine-rich end leucine-rich repeat protein = 
PRELP, chondroitin sulphate = CS, keratan sulphate = KS, hyaluronan = HA, cartilage 
intermediate layer protein = CILP (Williams et al., 2011). 
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1.3. Chondrocytes and their role in pathogenesis of OA 
The ECM of cartilage is sustained and built by chondrocytes living within this 
specialised tissue. Chondrocytes have to survive in the ECM environment that is 
highly hypoxic, acidic and hypertonic (Mobasheri et al., 2005, Mobasheri et al., 2008), 
whilst also having the ability to carry out their biological functions. This hypoxic 
HQYLURQPHQWOHDGVWRUHOHDVHRIK\SR[LDLQGXFLEOHIDFWRUĮ+,)-Į). Activity of HIF-1 
is important for differentiation and survival of chondrocytes both during foetal growth 
and development, and also after skeletal development is complete (Murphy et al., 
2009). 
Chondrocytes synthesize and secrete macromolecules assembled together 
into the ECM (Archer and Francis-West, 2003). Appropriate homeostatic balance 
between the rates of synthesis and degradation of ECM components is required to 
maintain cartilage. This delicate balance is controlled by both anabolic and catabolic 
factors expressed by chondrocytes. In OA there is excess degradation of ECM, with 
chondrocytes implicated in this process because they no longer are maintaining 
correct levels of cartilage metabolism. Differing patterns of protein expression can be 
measured in chondrocytes isolated from OA cartilage, compared to healthy articular 
chondrocytes (Iliopoulos et al., 2008, Lambrecht et al., 2009), which could effectively 
lead to cartilage metabolism alterations occurring in OA. As chondrocytes age, they 
have been demonstrated to respond differently to stimuli such as growth factors 
(Hudelmaier et al., 2001, Loeser, 2009). Growth, regulation, differentiation and protein 
expression within chondrocytes are influenced by these stimuli, therefore altered 
responses can cause changes in the maintenance and composition of ECM 
(Shakibaei et al., 1999). This could contribute to increased cartilage degeneration 
associated with OA and explain how it develops in older people (Ralphs and 
Benjamin, 1994). Once cartilage in OA affected joints begins to degenerate, ECM 
degradation products (for example: type II collagen and aggrecan fragments (Frisbie 
et al., 2008, Struglics et al., 2006)) are released into surrounding synovial fluid. Both 
synoviocytes (found in the synovial membrane) and chondrocytes express receptors 
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to detect these breakdown products stimulating release of proteins, including pro-
inflammatory cytokines (IL-ȕ 71)-Į DQd chemokines (IL-8). For example, 
degraded fragments of fibronectin and hyaluronan can stimulate catabolic signalling 
(Taylor et al., 2004, Homandberg et al., 1998). As OA progresses, there are 
decreases in chondrocyte numbers. This impinges on the normal cartilage 
maintenance processes that occur in healthy cartilage. A cycle of further chondrocyte 
death, inflammation, ECM degradation and cartilage loss therefore produces 
advancement of OA. 
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1.4. Inflammation in articular cartilage 
One of the major characteristics of OA is an inflammatory component 
(Berenbaum, 2013). Acute inflammation is a healthy response in tissues to remove 
harmful stimuli, remove damaged tissue and help initiate healing processes. Chronic 
inflammation occurs during OA, where continuous inflammatory signalling causes 
excess degradation and gradual loss of cartilage. Inflammation associated with OA 
involves release of pro-inflammatory signalling compounds (prostaglandin E2 (PGE2), 
nitric oxide (NO)) and cytokines (IL-ȕ 71)-Į IURP WLVVXHV ZLWKLQ V\QRYLDO MRLQWs 
(Abramson and Attur, 2009) (Figure 6). IL-ȕDQG71)-ĮELQGYLDVSHFLILF UHFHSWRUV
(i.e. IL-1R and TNF-R) present on the surface of the plasma membrane of 
chondrocytes and synoviocytes. Downstream signalling after cytokine activation 
initiates degradation processes including release of catabolic proteins, increased 
breakdown of ECM, a reduction in synthesis of collagen and proteoglycans, and 
release of other inflammatory facilitators (Pelletier et al., 2001). 
The NF-ț% signalling pathway has a significant role in OA inflammation and 
concludes with active phosphorylated NF-ț% EHLQJ WUDQVORFDWHG LQWR WKH QXFOHXV 
(Rigoglou and Papavassiliou, 2013). This active form of NF-ț%LQGXFHVH[SUHVVLRQRI
a variety of pro-apoptotic and pro-inflammatory genes, including further release of IL-
ȕ DQG 71)-Į WKHPVHOYHV LQGXFLEOH QLWULF R[LGH V\QWKDVH L126 DQG
cyclooxygenase-2 (COX-2) (Lianxu et al., 2006). Pro-inflammatory cytokines 
effectively increase expression and release catabolic proteins including matrix 
metalloproteinases (MMPs), aggrecanases, cathepsins and ADAMTS (Sutton et al., 
2009, Lorenz and Richter, 2006, Martel-Pelletier et al., 2008a). Expression of the 
proteases MMP-1, MMP-13 and ADAMTS-4 are mediated initially in the synovium and 
ligament cells (Haslauer et al., 2013). 
1.4.1. Interleukin-ȕ 
IL-ȕ is an important inflammatory mediator associated with OA progression. 
Synthesis of pro-IL-ȕLVLQLWLDWHGE\1)-ț%signalling pathways, before caspase-1 or 
caspase-8 within an inflammasome activates IL-ȕ(Martinon et al., 2002, Gringhuis et 
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al., 2012). Levels of IL-ȕDUHVLJQLILFDQWO\ KLJKHU in synovial tissue during the early 
stages of OA, which can contribute to disease development (Benito et al., 2005). 
Chondrocytes stimulated with IL-ȕ VKRZ UHGXFHG H[SUHVVLRQ RI FDUWLODJH VSHFLILF
collagens type II and IX (Goldring et al., 1988). Stimulation of equine chondrocytes 
with IL-ȕLQLWLDWHs up-regulation of IL-ȕLWVHOI, IL-6 and IL-8 (David et al., 2007). The 
expression of catabolic enzymes MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 is 
increased by IL-ȕ LQ HTXLQH FKRQGURF\WHV (Busschers et al., 2010). Similar 
inflammatory responses have been recorded in vivo with horses injected into synovial 
joints with IL-ȕ RU bacterial lipopolysaccharides (LPS) (Ross et al., 2012). After 
stimulation, synovium and cartilage tissues produced higher levels of MMP-1, 
ADAMTS-4 and ADAMTS-5, and synovial fluid contained higher PGE2, neutrophil 
counts and MMP activity (Ross et al., 2012). 
1.4.2. Tumour necrosis factor-Į, IL-6 and additional cytokines 
 TNF-Į is another important pro-inflammatory cytokine that contributes 
towards OA disease processes, inflammation and cartilage degradation. TNF 
receptors and TNF-Į ZHUH REVHUYHG LQ DIIHFWHG DUWLFXODU FDUWLlage in a surgically 
induced canine model of OA (Kammermann et al., 1996). During early stages of OA, 
TNF-Į LV H[SUHVVHG DW KLJKHU OHYHOV in synovial joint tissues (Benito et al., 2005). 
Circulating levels of TNF-ĮDQG IL-6 in serum have also been found to be higher in 
knee OA sufferers (Stannus et al., 2010), while release of GAGs from cartilage 
explants is induced by TNF-Į VWLPXODWLRQ (Westacott et al., 2000). Inflammatory 
signalling mediators COX-2 and NO, chemokines and several MMPs are released in 
response to TNF-Įand IL-6 (Reboul et al., 1996, Lianxu et al., 2006, Rosengren et 
al., 2012).  
Leukaemia inhibitory factor (LIF), IL-11, IL-17 and IL-18 are additional pro-
inflammatory cytokines contributing to the complex inflammatory situation within 
synovial joints (Sutton et al., 2009). Visfatin, an adipokine has been reported to have 
cytokine like effects that could have a role in OA (Gosset et al., 2008). PGE2, MMP-3, 
MMP-13, ADAMTS-4 and ADAMTS-5 synthesis in chondrocytes was increased by 
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visfatin stimulation (Gosset et al., 2008). The role of adipokines in OA adds to 
evidence of obesity as a disease risk factor. The anti-inflammatory cytokines IL-4, IL-
10 and IL-13 are also detected in OA synovial fluid and function to counteract 
inflammatory processes (Pelletier et al., 2001). 
1.4.3. Chemokines 
Chemokines are classified into four subgroups based on the arrangement of 
cysteines and disulphides: C, CC, CXC and CX3C. They initiate chemotaxis by 
interaction with G protein coupled receptors, thus causing infiltration of inflammatory 
cells towards sites of inflammation. Macrophages and neutrophils will migrate into 
synovial joints and secrete cytokines like IL-ȕ DQG 71)-Į LQVWLJDWLQJ IXUWKHU
inflammation (Bondeson et al., 2006). Chemokines such as IL-8 are secreted by 
chondrocytes in response to cytokine stimulation (Lotz et al., 1992). Other 
chemokines related to OA include monocyte chemoattractant protein-1 and RANTES 
(Patel et al., 1998). OA synovial fluid showed differential levels of chemokines 
compared to normal synovial fluid (Endres et al., 2010). The effects of specific 
chemokines on recruitment of inflammatory cells or mesenchymal progenitors will 
have an impact on inflammatory conditions and progression of OA affected joints.  
1.4.4. Matrix Metalloproteinases 
Catabolic proteases implicated in cartilage breakdown during OA include the 
zinc-dependant endopeptidase MMPs (Becker et al., 1995). Activation of MMPs is 
achieved extracellularly by cleavage of pro-peptide domains from secreted inactive 
zymogens (Woessner, 1991). MMPs within the stromelysin classification have roles in 
catalysing removal of the pro-peptide domain to activate other MMPs. The normal 
function of MMPs is to degrade ECM during embryonic development (Hulboy et al., 
1997), bone development (Ortega et al., 2003) and cell migration (Vu and Werb, 
2000), along with maintaining healthy levels of cartilage turnover. There are 
associations with MMPs and disease states including cancer (Bourboulia and Stetler-
Stevenson, 2010), central nervous system (Agrawal et al., 2008) and lung diseases 
(Gueders et al., 2006), as well as arthritic conditions. In healthy cartilage there is a 
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delicate balance between MMPs and tissue inhibitors of MMPs (TIMPs), ensuring 
appropriate turnover of ECM proteins (Brew and Nagase, 2010). In OA cartilage, 
expression of MMPs is increased, while TIMP expression is decreased (Kevorkian et 
al., 2004). This results in increased breakdown of cartilage therefore contributing to 
progression of the disease.  
MMPs have the ability to degrade a range of ECM components including 
collagen fibrils, proteoglycans and fibronectin (Woessner, 1991). They are grouped 
based on their substrate specificity into collagenases, gelatinases, stromelysins, 
matrilysins, membrane type MMPs (MT-MMPs) and others (Nagase et al., 2006). 
Collagenases (MMP-1, MMP-8, MMP-13, MMP-18) can cleave collagen types I, II, III, 
VI and IX, but also have the ability to degrade further ECM proteins (Shiomi et al., 
2010). MMP-13 (collagenase-3) is believed to have a major role in collagen type II 
degradation during OA (Reboul et al., 1996) and has been highlighted as a 
differentially released protein which is up-regulated in OA cartilage (Iliopoulos et al., 
2008, Bau et al., 2002). Stromelysins (MMP-3 and MMP-10) can activate 
procollagenases by removal of their pro-peptide domains (Nagase and Woessner, 
1999). MMP-3 (stromelysin-1) can degrade fibronectin, aggrecan and smaller 
proteoglycans, gelatins and collagens III, IV, IX and X (Shiomi et al., 2010). As 
previously mentioned, MMPs are capable of degrading non-fibrillar proteins of the 
ECM, such as fibronectin. Various MMPs including MMP-1, MMP-3, MMP-13 and 
MMP-14 are known to degrade fibronectin (Zhang et al., 2012a). It has been shown 
that cartilage aggrecan degradation is reversible, while collagen loss due to MMPs is 
not reversible (Karsdal et al., 2008). This suggests that MMP mediated processes in 
OA could have a critical impact on development of this disease. 
1.4.5. ADAMTS 
Proteins belonging to the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) class are catabolic enzymes with central roles in mediation of 
cartilage breakdown. Aggrecan is cleaved at the interglobular domain by MMPs -1, -3 
and -13 (Fosang et al., 1991, Fosang et al., 1993, Fosang et al., 1996), but ADAMTS 
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proteases appear to be responsible for the majority of aggrecan and GAG release in 
OA (Sandy and Verscharen, 2001). This was deduced because the majority of 
aggrecan fragments found in OA synovial fluid were cleaved at sites targeted by 
ADAMTS. The most active ADAMTSs in vitro are reported to be ADAMTS-5 and 
ADAMTS-4 (Gendron et al., 2007).  
Constituents of the ECM are therefore broken down by a variety of 
proteinases including ADAMTSs and MMPs, which generate enzyme specific 
degradative products released into OA synovial joints. Treatments developed to target 
metabolic enzymes will therefore need to be effective against several mechanisms 
that mediate cartilage destruction. 
1.4.6. Prostaglandin E2 
PGE2 is produced via the arachidonic acid signalling pathway with the key 
enzyme responsible for PGE2 synthesis being COX-2 (Hardy et al., 2002). Elevated 
expression of COX-2 and PGE2 production has been observed in chondrocytes from 
OA affected cartilage (Amin et al., 1997). Potential treatments for OA include COX-2 
specific inhibitors to decrease PGE2 production, therefore alleviating pain and 
inflammation. Once PGE2 binds to its receptors (EP1-4), it effects release of MMP-1, 
MMP-13 and ADAMTS-5, increasing collagen and aggrecan loss, and also reduces 
proteoglycan synthesis (Attur et al., 2008). Induction of COX-2 and PGE2 by IL-ȕ
stimulation is one of the main mechanisms of cartilage breakdown associated with OA 
(Hardy et al., 2002). 
1.4.7. Nitric Oxide 
NO is a free radical molecule that is involved in cellular signalling. The 
functions of NO specifically related to OA include control of apoptosis, pain perception 
and catabolic signalling (Abramson, 2008). NO is produced at significantly higher 
levels in OA cartilage explants, compared to healthy cartilage (Amin et al., 1995). As 
previously mentioned, pro-inflammatory cytokines stimulate the release of iNOS, 
aiding NO synthesis. Apoptosis of chondrocytes can be initiated when exposed to NO, 
through mitochondrial deregulation. NO can also up-regulate activation of MMPs and 
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stimulate further activation of pro-inflammatory cytokines IL-1 and IL-18 (Boileau et 
al., 2002, Abramson, 2008). 
1.4.8. Influence of subchondral bone changes in OA  
Subchondral bone changes including sclerosis and osteopenia, are also 
known to have an important role in initiation and progression of OA (Henrotin et al., 
2012c). Turnover of the bone is controlled by osteoblasts and osteoclasts. 
Osteoblasts are responsible for synthesis and organisation of bone matrix proteins, 
and osteoclasts degrade and breakdown the bone matrix. The phenotype of 
osteoblasts is altered in OA, with unregulated expression of genes including MMP-13, 
and increased secretion of proteins such as IL-6. IL-8, TGF-ɴ1 and collagen type I 
(Sanchez et al., 2008). Inflammatory signalling from IL-6 and PGE2 initiate 
differentiation and activation of osteoclasts, increasing bone remodelling in the 
subchondral bone (Liu et al., 2006). These alterations to pro-inflammatory and pro-
angiogenic phenotypes cause release of signalling proteins that could interact with 
chondrocytes in the cartilage above, causing the changes observed in OA (Henrotin et 
al., 2012c).  
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Figure 6. The inflammatory mediators of OA within synovial joints  
Cartilage breakdown products stimulate the release of pro-inflammatory signals from 
synoviocytes. Chondrocytes respond to pro-inflammatory signals by secreting additional 
cytokines, chemokines and catabolic enzymes, therefore causing further cartilage 
degradation products (Abramson and Attur, 2009). 
 
Synoviocyte 
Chondrocyte 
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1.5. Explant cultures and alternative models available for studying OA 
1.5.1. In vitro models 
1.5.1.1. Advantages and limitations of explant cultures 
Relevant in vitro models for OA research include chondrocyte, synoviocyte 
and cartilage explant cultures. These models do not possess the complexity of whole 
biological systems, but offer a simplistic setting for initial studies. This thesis has 
utilised a cartilage explant culture model to study cartilage biology, degradation and 
the secretome. The explant culture model has several advantageous over other 
models used in cartilage and OA research. Utilizing cultured cartilage explants 
maintains the chondrocytes within a more physiologically relevant environment than 
chondrocyte monolayers. Within cartilage ECM, chondrocytes are not in high density 
cultures or rapidly dividing, as they are during monolayer or alginate bead cultures. 
Rather chondrocytes are usually distributed alone or in pairs throughout the ECM.  
The analysis of proteins released into explant conditioned media is beneficial 
for providing insights into a variety of degradative processes. ECM constituents and 
catabolic proteases released will deliver information on cartilage degradation products 
and insights into the mechanisms involved (Polacek et al., 2010). Further secretion of 
cytokines will indicate the signalling proteins and pathways utilised during 
inflammation. Due to the complexity of degradation where many different proteins are 
involved, proteomic analysis of cartilage explants in culture and proteins released can 
provide a wealth of biological information (Williams et al., 2011). Measurement of 
proteoglycan and protein release from explant cultures aids investigations into 
responses to pro-inflammatory cytokines and anti-inflammatory compounds. Cartilage 
degradation in response to cytokines TNF-Į DQG ,/-1 can be demonstrated by 
culturing explants (Kobayashi et al., 2005). Comparison of normal and OA affected 
cartilage explants within culture shows differences in proteoglycan synthesis in 
diseased tissue (Lafeber et al., 1992). The cartilage explant model can therefore be 
used to evaluate responses to anti-inflammatories in OA cartilage, or healthy cartilage 
stimulated with pro-inflammatory cytokines.  
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Explant models still lack the influence of surrounding synovial fluid, 
synoviocytes, and immune cells like neutrophils. The explant model applied in this 
thesis is also a static model therefore the dynamic movement of the joint and synovial 
fluid are not considered using this approach. Cartilage explant culture therefore 
provides a simplistic model, to perform initial studies with various experimentally 
induced perturbations on cartilage and chondrocytes within their natural ECM. Explant 
models are particularly effective at studying degradation of cartilage proteins, but do 
not provide significant information on newly synthesised proteins (Polacek et al., 
2010). Cartilage explant cultures offer an alternative to in vivo studies, and therefore 
can reduce, refine and replace the use of laboratory animals. 
1.5.1.2. Alternative in vitro models 
Alternative in vitro models for cartilage and OA research include chondrocyte 
monolayers and high-density alginate bead culture of chondrocytes. Chondrocytes 
grown in monolayer cultures secrete ECM proteins including collagen type II, 
proteoglycan and fibronectin (Dessau et al., 1981). One disadvantage to chondrocyte 
monolayer cultures, is their dedifferentiation into fibroblast-like cells over time 
(Grundmann et al., 1980). Chondrocytes lose the ability to express collagen type II 
and instead show increased expression of collagen type I (Benya et al., 1978). Thus, 
chondrocyte monolayers can only be applied in short term culture studies. 
Chondrocyte cultures are beneficial for studying newly synthesised proteins in both 
the chondrocyte secretome (chapter 1.6.2.3) and proteome (1.6.4). The chondrocyte 
secretome was shown to contain 90% newly synthesised proteins, highlighting the 
effectiveness of monolayers to study these new proteins in culture (Polacek et al., 
2010).  
Culturing chondrocytes in an agarose gel matrix can reverse the loss of 
chondrocyte phenotype (Benya and Shaffer, 1982). Alginate beads also provide a 
culture environment where the chondrocyte phenotype can be preserved, with 
spherical chondrocyte morphology being maintained (Guo et al., 1989). The ability to 
synthesize proteoglycan and collagen type II continues throughout long term cultures 
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of up to 8 months, allowing studies over longer time periods (Hauselmann et al., 
1994). Comparison of chondrocyte characteristics in monolayer, alginate or pellet 
cultures demonstrates that 3D cultures are most suitable for conserving chondrocyte 
phenotype (Caron et al., 2012). Culture of primary chondrocytes in alginate beads up 
to 28 days has shown a hypertrophic phenotype in the chondrocytes, which holds 
potential for studying the angiogenic of OA (Pesesse et al., 2013). Three dimensional 
scaffolds can be developed within which chondrocytes maintain expression of 
cartilage specific genes including COMP, aggrecan, collagen types II and XI (Li et al., 
2003). This holds future applications and opportunities for cartilage regeneration and 
replacement surgery in severe cases of OA. 
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1.5.2. In vivo models 
Cartilage biology research and investigations into the pathogenesis of OA 
take advantage of both in vivo and in vitro models. Potential OA treatments can be 
examined in vitro, but ultimately need to be tested in an appropriate animal model 
before clinical trials take place. Animals utilized in OA research include mice, rats, 
rabbits, guinea pigs, dogs, sheep, goats and horses (Gregory et al., 2012). There are 
advantages and disadvantages to each specific animal model, therefore a model must 
be chosen meeting the needs of a desired study (Gregory et al., 2012). Animal 
models of OA can be spontaneous, introduced with surgical procedures or with 
injection of degradative enzymes. Guinea pigs spontaneously develop cartilage 
degeneration that is histologically similar to humans (Bendele and Hulman, 1988). 
Surgical procedures such as anterior cruciate ligament (ACL) transection or 
meniscectomy cause instability in joints to produce cartilage degradation (Williams et 
al., 1982, Bendele, 1987). Cartilage breakdown can also be initiated by injection of 
iodoacetate (Guzman et al., 2003), collagenase (van der Kraan et al., 1990) or papain 
into synovial joints (Kopp et al., 1983). Genetic mouse models that develop the OA 
phenotype are available. Gene deletions of collagen types II and IX cause 
development of OA conditions in transgenic mice (Helminen et al., 1993, Fassler et 
al., 1994). Animal models provide opportunities to study new therapeutic approaches 
within the context of a whole living organism. The number of animals used in scientific 
investigations can be reduced by completing in vitro studies assessments prior to 
animal models. 
1.6. The secretome and proteomics in OA research and cartilage biology 
There are a wide range of omic approaches being studied in the OA research 
field, while this thesis concentrates on the secretome, which is a subsection of the 
proteome. Omic studies aim to characterise all specific biological molecules contained 
within a defined biological field, such as the genome, transcriptome, proteome or 
metabolome. The proteome is the complete set of proteins expressed in a cell, tissue 
or organism under certain defined conditions (Wilkins et al., 1996). This could be a 
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healthy or diseased state, or after exposure to a certain treatment. Proteomics 
involves large-scale and multi-dimensional studies of protein structure and function 
(Williams and Hochstrasser, 1997, Dhingra et al., 2005). Approaches to gain insight 
into proteomes utilize techniques including electrophoresis, mass spectrometry, 
bioinformatics and protein arrays. Proteomic techniques have the potential to make a 
significant contribution to biomarker searches in the OA research field. The majority of 
current and potential OA biomarkers are degraded ECM fragments and metabolic 
proteins (Rousseau and Garnero, 2012). Along with biomarker discovery, proteomics 
can also progress fundamental understanding of cartilage structure.  
Specialised analytical techniques are applied in proteomics allowing 
evaluation of the protein composition of tissues, cells and culture supernatants (De 
Ceuninck and Berenbaum, 2009, Ruiz-Romero et al., 2010a, Wilson et al., 2009). One 
dimensional SDS polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins 
in a complex sample according to molecular weight. More detailed expression profiles 
can be created by separating the proteins in two phases using two dimensional-
electrophoresis (2DE) (Rabilloud et al., 2010). During 2DE, isoelectric focusing 
separates proteins in the first dimension along a pH gradient before second dimension 
separation by molecular weight, which provides improved profiling over SDS-PAGE 
approaches. Gels can be fixed and stained with various stains, before scanning with a 
densitometer to provide a high-resolution image. Image analysis software can 
measure expression levels of specific protein spots to reveal proteins that differ 
between two or more sample types (e.g. comparison of healthy vs diseased tissue). 
Mass spectrometry analysis can provide identification of proteins 
corresponding to stained and visualised spots (Ruiz-Romero et al., 2010a, Wilson et 
al., 2009). Specific spots of interest are excised from gels and enzymatically digested, 
generating peptides. The peptides are first ionized by various methods including 
electrospray ionization (ESI), matrix-assisted laser desorption/ionization (MALDI) and 
surface enhanced laser desorption/ionization (SELDI) (Amstalden van Hove et al., 
2010) to create charged peptides. Charged peptides present are separated depending 
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on the mass/charge ratio (m/z) by a mass analyser. Peptides are detected and ion 
masses are recorded, producing a peptide mass fingerprint (PMF). Tandem MS 
(MS/MS) allows fragmentation of selected peptides, which can be compared with 
predicted/calculated masses of peptides in databases. This allows proteins in complex 
samples to be identified. Publically available databases include NCBInr and Swiss-
Prot.  
Proteins present in complex samples can also be profiled using protein 
antibody microarrays approaches (Borrebaeck and Wingren, 2009, Glökler and 
Angenendt, 2003). Sample media is incubated with an array membrane with 
antibodies directed against a range of proteins attached, so proteins present will be 
specifically bound to antibodies. Attached proteins can be detected by fluorescence or 
chemiluminescence to provide a quantitative measurement of protein levels. Cytokine 
antibody array membranes containing inflammatory related proteins relevant to OA 
could provide information on altered protein synthesis in OA synovial joints.  
OA affects the entire synovial joint and so many of the distinct tissues present 
are affected and potentially contribute to disease progression (Figure 7). Proteomic 
investigations have therefore been performed on a range of the tissues and cells 
present including: whole cartilage (Garcia et al., 2006, Wu et al., 2007, Guo et al., 
2008, Haglund et al., 2008, Perez et al., 2010, Ruiz-Romero et al., 2010a, Onnerfjord 
et al., 2012), chondrocytes (Ruiz-Romero et al., 2005, Cillero-Pastor et al., 2010, 
Iliopoulos et al., 2008, Lambrecht et al., 2008, Lambrecht et al., 2009, Koo et al., 
2010, Calamia et al., 2010, Ruiz-Romero et al., 2010b), synovium (Lorenz et al., 
2003, Tilleman et al., 2005), synoviocytes (Ruiz-Romero et al., 2010a, Bo et al., 
2009), along with studies on the secretome of these constituents. Biological fluids like 
serum, synovial fluid and urine from OA sufferers have also been analysed in the 
search for altered protein expression and biomarkers (Sinz et al., 2002, Yamagiwa et 
al., 2003, Drynda et al., 2004, Kamphorst et al., 2007, Gobezie et al., 2007, 
Nemirovskiy et al., 2007, Nemirovskiy et al., 2010, Li et al., 2007, Xiang et al., 2004, 
Jmeian and El Rassi, 2008, Chiaradia et al., 2012, Mateos et al., 2012, Gharbi et al., 
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2013, Ritter et al., 2013, de Seny et al., 2011, Fukuda et al., 2012, Fernandez-Costa 
et al., 2012).  
Extensive proteomic studies have revealed various biomarkers to evaluate 
OA. Current biomarkers being investigated in relation to OA have been reviewed by 
Lotz and colleagues (Lotz et al., 2013), (Figure 7). The OA biomarkers year review 
2013 summarises the range of OA biomarkers being evaluated in serum, plasma, 
urine and synovial fluid, including COMP, CTX-II, Coll2-1 and MMP-13 (Lafeber and 
van Spil, 2013). Biomarkers can be classified with the BIPED classification guidelines: 
burden of disease, investigative, prognostic, efficacy of intervention and diagnostic 
biomarkers (Bauer et al., 2006). As expected many of the potential biomarkers are 
degradation fragments of the ECM, including collagen, aggrecan and COMP (Lotz et 
al., 2013). Other biomarkers that have been investigated include metabolic proteins 
like MMPs that will influence cartilage turnover, and signalling proteins such as 
cytokines (Lotz et al., 2013). 
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Figure 7. Biomarkers for OA can originate from various tissues and be related to different 
processes 
(Lotz et al., 2013) 
Biomarker molecules can be products of cartilage breakdown or other ECM proteins 
related to matrix turnover. Signalling molecules may also be biomarkers, specifically 
those involved in pro-inflammatory signalling, along with the catabolic proteases released 
in response to inflammation could act as biomarkers of OA. 
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1.6.1. The secretome 
This thesis focuses on the secretome of cultured cartilage explants, aiming to 
develop understanding of cartilage biology and degradation. The secretome is a 
subsection of the proteome, and is used to describe proteins that are actively secreted 
from cells or tissues. The chondrocyte secretome is vital in regulation of cartilage, as 
they secrete all the components of the ECM before matrix assembly. Alterations in 
ECM or metabolic proteins secreted by chondrocytes will have consequences for 
cartilage structure, potentially contributing to cartilage loss. The cartilage secretome 
can be assessed by analysis of cartilage conditioned media, although many ECM 
proteins will be degraded by catabolic processes or simply leak out into the 
supernatant during the culture process and therefore are not being actively secreted. 
Proteomic techniques monitoring release of proteins from cultured cartilage under 
various conditions/treatments will still provide vital insights into cartilage biology and 
degradation that are relevant to OA. 
1.6.2. Cartilage and chondrocyte secretome 
1.6.2.1. OA cartilage secretome 
Degenerative processes during OA progression will be enhanced by 
disruption to the normal levels of protein secretion from chondrocytes within cartilage. 
By comparing healthy and OA cartilage secretome, several studies have identified 
proteins with either up-regulated or down-regulated release. OA affected articular 
cartilage explants secreted inhibin ȕ$ that is associated with inflammation 
(Hermansson et al., 2004). This study also showed connective tissue growth factor 
(CTGF) and cytokine-like protein C17 were released at higher levels, using medium 
containing [35S] on methionine and cysteine residues allowing identification of newly 
synthesized proteins (Hermansson et al., 2004). A antibody microarray study 
identified 11 secreted proteins in a OA donor sample, and also found 43 secreted 
proteins using SDS-PAGE and 2DE approaches combined with MS/MS (De Ceuninck 
et al., 2005). Secreted proteins included chitinase 3-like protein 2 (YKL-39), tissue 
inhibitor of metalloproteinase-1 (TIMP-1), tumour necrosis factor receptor 1 (TNF-R1), 
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vitamin D binding protein, pigment epithelium-derived factor (PEDF) and 
osteoprotegerin (De Ceuninck et al., 2005). Proteins highlighted in these studies on 
OA cartilage secretome all have roles in signalling pathways and metabolic control 
therefore differential changes could impact on cartilage maintenance. 
Stable isotope labelling with amino acids in cell culture (SILAC) allows 
existing and newly synthesized proteins to be differentiated, one such study showed 
that 71% of cartilage explant released proteins were not synthesized during incubation 
(Polacek et al., 2010). The 29% of proteins containing labelled amino acids (newly 
synthesized) included YKL-40 and TIMP-1, both of which are involved in ECM 
remodelling. The majority of the non-labelled proteins released were ECM 
constituents like COMP, aggrecan core protein and cartilage intermediate layer 
protein. Most ECM released proteins during explant cultures may simply be leaking 
out from the tissue rather than being actively synthesized by chondrocytes. Although it 
is possible that as ECM turnover occurs, newly synthesized ECM components to 
replace older proteins are incorporated straight into cartilage. 
Limited differences were discovered comparing human OA cartilage explant 
secretome before and after treatment with IL-ȕ DQDO\VHG ZLWK D 4FRQ&$7
quantitative approach (Peffers et al., 2013). Only decreases in TIMP-1 showed 
statistical alteration with IL-ȕ ZKLOH 003-1, MMP-3, plasminogen, COMP, 
fibromodulin and aggrecan were not significantly altered according to QconCAT 
(Peffers et al., 2013).  
1.6.2.2. Secretome of cytokine stimulated cartilage 
Studies in this thesis applied healthy equine cartilage that was stimulated with 
inflammatory cytokines, therefore it is of interest to compare findings with previous 
studies. MMP mediated degradation of OA cartilage shows release of collagen II 
neoepitope peptides after stimulation with IL-ȕDQGRQFRVWDWLQ0(Nemirovskiy et al., 
2007). Nemirovsky applied a similar method to this thesis, by culturing visually normal 
(healthy) human cartilage with cytokines before a high-throughput MS analysis, which 
identified collagen epitopes. Similar collagen degradation products could potentially 
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be identified in an equine cartilage model. A difference in-gel electrophoresis (DIGE) 
based study of mouse cartilage stimulated with IL-ȕRUDOO-trans-retinoic acid (Ret A), 
allowed accurate quantification of differentially released proteins (Wilson et al., 2008). 
Comparison of the protein profiles of untreated control media with the two treatments 
showed altered levels of a number of ECM components and metabolic proteins, which 
could have implications in OA. Significant increases in MMP-3, YKL-40, haptoglobin 
and neutrophil gelatinase associated lipocalin (NGAL) were stimulated by IL-ȕ 
(Wilson et al., 2008). Ret A treatment increased COMP, hyaluronan and proteoglycan 
link protein 1 (HAPLN1), aggrecan G1 domain proteins, matrilin-3, and serotransferrin 
(Wilson et al., 2008). 
Another aspect of OA is load-induced injury leading to damage of cartilage 
and degradation therefore secreted proteins in a bovine stifle model of cartilage injury 
with mechanical compression and stimulation with pro-inflammatory cytokines (IL-ȕ
and TNF-Įwere investigated (Stevens et al., 2008). Mechanical compression injury 
mostly caused higher levels of intracellular proteins associated with cell death 
including vimentin, pyruvate kinase, glucose-regulated protein 58kDa (GRP58) and 
glucose regulated protein 78kDa (GRP78). The cytokines IL-ȕ DQG 71)-Į both 
induced release of MMP-3, clusterin, YKL-39 and YKL-40 (Stevens et al., 2008). This 
bovine model and stimulatory treatments were further assessed in 2009 with iTRAQ 
and LC-MS/MS quantitative analysis (Stevens et al., 2009). Collagen fibre synthesis 
was reported to be reduced by all stimuli (IL-ȕ, TNF-ĮPHFKDQLFDO, while aggrecan 
domain release was increased by cytokines (Stevens et al., 2009). Six MMPs, TIMP-
1, -2, chemokines and cytokines also showed differential release due to IL-ȕ71)-Į
or mechanical compression (Stevens et al., 2009). By applying a LC-MS/MS approach 
to equine cartilage secretome, this thesis aims to discover if similar or additional 
proteins are identified in the secretome, to the previously mentioned human 
(Nemirovskiy et al., 2007) and bovine (Stevens et al., 2009) high-throughput MS 
analyses. 
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1.6.2.3. Chondrocyte secretome 
In contrast with the cartilage explant secretome, the chondrocyte secretome 
will contain predominantly newly synthesised proteins and not be complicated by 
release of pre-existing ECM components into supernatant. An antibody-based 
microarray identified cytokines, chemokines, angiogenic and growth factors increased 
by pro-inflammatory cytokine treatment (IL-ȕ 71)-Į LQ the human chondrocyte 
secretome (De Ceuninck et al., 2004). Eight proteins were identified from 2DE before 
techniques including CPC precipitation of GAGs, collagenase digestion and a Q 
sepharose resin batch column were applied (Catterall et al., 2006). Stimulation with 
IL-ȕ DQG RQFRVWDWLQ 0 FDXVHG LQFUHDVHV LQ 003-1, MMP-3 and cyclophylin A 
secretion, while calgizzarin, cofilin, <./ DQG ȕ-microglobin were identified in 
untreated control and cytokine 2DE gels (Catterall et al., 2006). Poorly resolved higher 
molecular weight protein regions on the 2DE maps limited the protein identifications 
possible in this study (Catterall et al., 2006). 
Studies have been completed on the chondrocyte secretome from rat articular 
cartilage treated with LPS, which is thought to be related to septic induced OA 
processes (Papathanasiou et al., 2010). Toll-like receptor activation by LPS is 
believed to contribute to OA, RA and crystal-induced joint damage (Ospelt et al., 
2009, Su et al., 2005, Liu-Bryan et al., 2005). Proteins related to initiation of cartilage 
remodelling (MMP-1, MMP-3, YKL-40) and immune response associated proteins 
were seen to be increased by LPS stimulation (Haglund et al., 2008). Chemokines 
MIP-Į &&/ DQG /,; &;&/ ZHUH FRQILUPHG WR VKRZ LQFUHDVHG H[SUHVVLRQ
using a rat cytokine antibody array (Haglund et al., 2008). These chemokines will 
recruit inflammatory cells to the synovial joint during OA contributing to inflammatory 
processes. 
SILAC approaches applied to chondrocytes in monolayer culture, displayed 
103 newly synthesized proteins were secreted and identified (Polacek et al., 2010). 
These were mostly ECM constituent proteins, while inflammatory mediators and 
MMPs were also present. Further work from this group examined chondrocyte and 
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mesenchymal stem cell secretomes using the SILAC approach, and studied the 
phenotypes of both cell types, and quantified release of MMPs and TIMPs (Polacek et 
al., 2011). The SILAC technique has also been applied to chondrocytes treated with 
IL-ȕ WR VKRZ TXDQWLWDWLYH DQG LGHQWLILFDWLRQ RI  SURWHLQV LQFOXGLQJ SUR-
inflammatory mediators and proteases, type VI collagen and TGF-ȕSDWKZD\SURWHLQV
(Calamia et al., 2011). 
The main aim of this thesis was to study responses in the cartilage secretome 
to stimuli, therefore a summary table of secretome studies of cartilage and 
chondrocyte cultures is presented Table 1. 
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Table 1. Secretome studies completed on cartilage and chondrocyte cultures 
Study Tissue/Cell Diseased or treated Techniques Proteins highlighted 
Studies on OA or 
normal tissue/cells 
    
(Hermansson et al., 2004) Cartilage  OA and healthy [35S] Methionine/Cysteine 
radiolabelling, CPC, 2DE, HPLC 
MS/MS 
,QKLELQȕ$ higher in OA 
(De Ceuninck et al., 2005) Cartilage OA SDS-PAGE, 2DE, MS/MS, Antibody 
microarray 
YKL-39, TNFR1 and TIMP-1 
identified 
(Polacek et al., 2010) Cartilage and 
chondrocyte  
Healthy SILAC quantification, SDS-PAGE, 
LC-MS/MS 
Cartilage: 25-30% proteins newly 
synthesised. 
Chondrocytes: 90% proteins newly 
synthesised. 
(Polacek et al., 2011) Chondrocyte and MSC  Compared normal 
chondrocytes with MSCs 
SILAC quantification, SDS-PAGE, 
LC-QTOF-MS/MS 
Clusterin, mimecan, proteoglycan-
4, tenascin, sushi from 
chondrocytes 
Studies with stimuli      
(Nemirovskiy et al., 2007) Cartilage  IL-ȕDQG2QFRVWDWLQ0 LC-MS/MS Collagen II neoepitopes 
(Wilson et al., 2008) Cartilage  IL-ȕ Ret A and 
untreated 
2DE, MS/MS MMP-3, NGAL increased by IL-ȕ
COMP, matrilin-3 increased by Ret 
A. 
(Stevens et al., 2008) Cartilage  Untreated, IL-ȕ7NF-Į
and mechanical stress 
SDS-PAGE, LC-MS/MS MMP-3, YKL-40, COMP and 
collagen VI release increased by 
treatments 
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(Stevens et al., 2009) Cartilage Untreated, IL-ȕ71)-Į
and mechanical stress 
iTRAQ, strong cation exchange 
chromatography, LC-MS/MS 
Differential release of aggrecan, 
collagens, MMPs, chemokines, 
cytokines 
(Clutterbuck et al., 2011) Cartilage Untreated, IL-ȕDQG
carprofen treatments 
nanoLC-MS/MS Western blotting of clusterin, CILP-
1, MMP-1, MMP-3 and TSP 
(Peffers et al., 2013) Cartilage Cartilage from OA 
patients IL-ȕRU
unstimulated 
QconCAT quantitative approach, 
LC-MS/MS 
Only differential protein: TIMP-1 
decreased with IL-ȕVWLPXODWLRQ 
(De Ceuninck et al., 2004) Chondrocyte  IL-ȕ71)-ĮWUHDWPHQW
compared with non-
stimulated 
Cytokine protein microarray Up-regulation of several cytokines 
and chemokines with treatments 
(Catterall et al., 2006) Chondrocyte Untreated, IL-1 and 
oncostatin M 
2DE, LC-MS/MS, CPC, Q 
sepharose, 
chondroitinase/hyaluronidase 
MMP-1, MMP-3, YKL-40, cofilin, 
6$ȕ-microglobulin 
identified 
(Haglund et al., 2008) Chondrocyte and 
cartilage  
LPS stimulated and 
unstimulated 
SDS-PAGE, LC-MS/MS, cytokine 
antibody array 
LPS induced YKL-40, and MMP-3, -
13 and various complement 
proteins. 
(Calamia et al., 2011) Chondrocyte  Normal and IL-ȕWUHDWHG SILAC quantification, SDS-PAGE, 
MS/MS 
IL-ȕLQFUHDVHGSUR-inflammatory 
mediators, collagen VI and TGF-ȕ
pathway. Decreased secretion of 
TSP, aggrecan and vitamin K-
dependant proteins. 
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1.6.3. Whole extracts of articular cartilage 
Proteomics of whole cartilage contributes to the understanding of structural 
alterations in cartilage composition occurring during OA. Proteins present in both the 
ECM and the chondrocytes within it will be studied in whole cartilage proteomics. The 
³PDWULVRPH´ defines all proteins that are structural components of extracellular 
matrices (Hynes and Naba, 2012). The mammalian matrisome is believed to contain 
around 300 proteins, with the possibly of degraded products of these being OA 
biomarkers (Hynes and Naba, 2012).  
A high percentage of proteins identified in previous whole cartilage studies 
are ECM components (Garcia et al., 2006) for example, COMP and fibromodulin 
(Ruiz-Romero et al., 2010a). Altered expression ECM components could ultimately 
lead to cartilage degradation. Comparison studies between healthy and OA affected 
cartilage have identified ECM components showing differential expression, including 
the fibulin family proteins (-1D, -2, -3) (Wu et al., 2007). In another comparison 
between healthy and OA cartilage, five energy production related enzymes were 
differentially expressed (alcohol dehydrogenase, adenosine kinase isoenzyme 1, 
flavin reductase, enolase 1 and pyruvate kinase 3 isoform 2), and 3 signalling proteins 
were present at differential levels (annexin A1, tubby protein homolog and 
phosphatidylethanol-binding protein) (Guo et al., 2008). This study also identified 
higher levels of collagen type I and VI and a reduced level of mitochondrial superoxide 
dismutase (SOD2) in OA cartilage (Guo et al., 2008). In another study, chitinase 3-like 
protein 1 (YKL-40) was up-regulated in cartilage by TNF-Į DQG /36 WUHDWPHQW
(Haglund et al., 2008). YKL-40 is associated with remodelling of the ECM and 
therefore could have roles in OA disease progression. During a proteomic analysis of 
rat articular cartilage, 47 proteins were identified in the cartilage proteome including 
latexin (Perez et al., 2010). This was the first cartilage proteome study to identify 
latexin, which is a protein inhibitor of zinc-dependent metallocarboxypeptidases 
(Perez et al., 2010).  
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$TXDQWLWDWLYHSURWHRPLFDQDO\VLVXVLQJL75$4RQcartilage from 8 separate 
anatomical locations, showed differences in protein patterns between the various 
cartilage types. These differences in protein distribution could contribute to the 
structure and function of each cartilage type (Onnerfjord et al., 2012). Another study 
applied quantitative L75$4 RQ 2$ DQG KHDOWK\ FDUWLlage DIWHU 3URWHRPLQHU
enrichment (Ikeda et al., 2013). This study reported three novel OA biomarkers: 
PRDX6 (peroxiredoxin-6), BAALC (brain and acute leukaemia, cytoplasmic) and 
LECT2 (leukocyte cell-derived chemotaxin-2) (Ikeda et al., 2013).  
In summary, whole cartilage proteomic studies have helped to provide 
improved understanding of cartilage biology. These studies have shown that OA 
changes the protein composition and structure of cartilage ECM.  
1.6.4. Chondrocyte proteome 
 Whole cell lysates of chondrocytes also contribute to OA research, with the 
first human articular chondrocyte 2DE proteomic profile completed in 2005 with 93 
proteins identified (Ruiz-Romero et al., 2005). Inflammatory stimulation of 
chondrocytes with cytokines IL-ȕ DQG 71)-Į EHIRUH 2DE analysis determined 
expression changes (35 proteins identified) that may occur in the inflamed OA 
environment (Cillero-Pastor et al., 2010). A reverse phase protein array also identified 
76 differentially expressed proteins that were altered by stimulation with the cytokines 
IL-ȕDQG71)-Į (Iliopoulos et al., 2008). Comparison between chondrocytes isolated 
from normal cartilage and OA affected cartilage has shown changes in expression of 
17 proteins (Lambrecht et al., 2008). Two proteins highlighted as differentially 
expressed in healthy and OA chondrocytes were vimentin (Lambrecht et al., 2008) 
DQGĮ%-crystallin (Lambrecht et al., 2009). 
 The ECM provides a hydrophilic and hypoxic environment that chondrocytes 
must function within, therefore studies have investigated how changes in these 
conditions effects protein expression. Incubation in culture media of different 
osmolarities (320 mOsm/kg compared to 400 mOsm/kg) found 20 protein spots with 
significantly altered expression (Koo et al., 2010). 400 mOsm/kg is the average 
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osmolarity of articular cartilage (Koo et al., 2010). A comparison of normal and OA 
chondrocytes cultured under hypoxic conditions found 42 proteins were differentially 
expressed (Ruiz-Romero et al., 2010b). These included increases in cyclophilin A and 
TNF receptor associated protein 1 (TRAP1) (Ruiz-Romero et al., 2010b).  
The proteome of chondrocytes exposed to popular treatments for OA, 
glucosamine (GluN) and chondroitin sulphate (CS) was studied to investigate 
mechanisms behind their reported therapeutic benefits (Calamia et al., 2010). There 
were 31 proteins with altered expression due to treatment with GluN or CS, alone or in 
combination, with SOD2 levels reduced by all treatments (Calamia et al., 2010). The 
chaperone GRP78 was up-regulated by GluN, but not by CS (Calamia et al., 2010). 
1.6.5. Chondrocyte mitochondria proteome 
 SOD2 is a mitochondrial protein involved in superoxide (a reactive oxygen 
species) metabolism, and has been reported to be reduced in proteomic studies of 
chondrocyte mitochondrial fractions (Ruiz-Romero et al., 2006, Ruiz-Romero et al., 
2009). These studies also identified significant differences in TRAP1, inner membrane 
mitofillin (IMMT) and optic atrophy 1 (OPA1) that could contribute to chondrocyte 
functioning disruptions and an increase in cell death. In another examination of 
proteins in mitochondrial extracts, the expression of dimethylarginine 
dimethylaminohydrolase 2 was found to be significantly increased when chondrocytes 
had been exposed to IL-ȕ (Cillero-Pastor et al., 2012). This enzyme could have a 
role in production of NO during inflammation and OA (Cillero-Pastor et al., 2012). 
1.6.6. Synovial fluid OA biomarker studies 
 Synovial fluid at joints is encapsulated by the synovial membrane, and is in 
contact with cartilage surfaces, allowing potential biomarkers of OA to be present 
KHUH )LEULQRJHQ ȕ-chain degradation products were found in synovial fluid from 
patients with OA, rheumatoid arthritis (RA) and reactive arthritis (Sinz et al., 2002). 
When OA synovial fluid and normal synovial fluid were compared, 18 protein spots 
were significantly altered in the 2$VDPSOHLQFOXGLQJLQFUHDVHGKDSWRJORELQĮFKDLQ
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that are associated with inflammation (Yamagiwa et al., 2003). Calcium binding 
proteins, S100A8 and S100A9, have a diverse range of cellular functions and were 
found to be significantly higher in synovial fluid in RA compared to OA (Drynda et al., 
2004). In another study, 29 proteins were identified in OA synovial fluid with use of 
ultracentrifugation and solid-phase extraction techniques, with 6 proteins suggested 
as possible OA biomarkers due to disease association (Kamphorst et al., 2007). 
Dermcidin, aggrecan and cystatin A all had reduced expression comparing normal 
and OA synovial fluid from the knee (Gobezie et al., 2007). A proteomic study on 
equine synovial fluid comparing healthy and OA horses provided identification of 17 
differentially regulated proteins, including serotransferrin, anti-thrombin III, vitamin D 
binding protein and apolipoprotein A-I (Chiaradia et al., 2012). Spectral counting 
analysis applied to RA and OA synovial fluid after LC-MALDI TOF/TOF analysis, 
revealed 136 differential proteins (Mateos et al., 2012). Proteins highlighted in OA 
synovial fluid included COMP, aggrecan core protein 2, YKL-40, complement factor D, 
tetranectin, cartilage acidic protein 1 and fibronectin (Mateos et al., 2012).  
Surgically induced OA with anterior cruciate ligament (ACL) transection 
caused alterations in the levels of several proteins in canine synovial fluid including 
those in the complement pathway (Gharbi et al., 2013). Application of 2D-DIGE 
compared proteins in healthy and OA knee synovial fluid (Ritter et al., 2013). Sixty-six 
proteins in the following pathways were affected: the complement, response signalling 
and coagulation pathways. Differential expression of clusterin, lumican and 3 other 
proteins were validated using selective reaction monitoring (Ritter et al., 2013).  
Changes in the complement pathway and proteins have been detected across 
several OA synovial fluid analyses, depicting a change in the inflammatory status of 
affected joints. 
1.6.7. Synovium/synoviocyte proteome 
Proteomic studies have also been completed on synovial membrane and the 
synoviocytes that maintain the synovium. A western blot array with 260 immobilised 
antibodies detected 58 proteins showing significant differences in expression between 
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RA and OA, including SOD2, cathepsin D and STAT1 (Lorenz et al., 2003). A 
comparison of protein profiles of OA synovium with RA and spondyloarthropathy 
synovium has also been completed (Tilleman et al., 2005). Significantly differential 
expression of 25 proteins in synovial fibroblasts was observed in a comparison 
between normal and RA or OA patients (Bo et al., 2009). Synoviocytes gave a very 
similar proteomic profile map to chondrocytes (Ruiz-Romero et al., 2010a), which is 
unsurprising given the function of both cell types is to maintain fibrous structures 
surrounding them. 
1.6.8. Urine and serum OA biomarker studies 
 The non-invasive collection of urine makes it an ideal biofluid for clinical 
analysis of biomarkers for early disease identification and monitoring of OA 
progression. Collagen type II neoepitopes have been investigated in urine and 
synovial fluid using immunoaffinity LC-MS/MS (Nemirovskiy et al., 2007). The most 
abundant neoepitope was identified as a 45 amino-acid peptide (uTIINE) and 
appeared to be an informative biomarker for MMP activity (Nemirovskiy et al., 2007, 
Nemirovskiy et al., 2010)  
 Analysis of serum has identified an autoantibody to triosephosphate 
isomerase as a potential diagnostic OA biomarker during a large population based 
study (Xiang et al., 2004). Differential protein levels of vitamin D-binding protein 
precursor along with apolipoprotein A-I and A-IV precursors were reported in a 2D 
electrophoresis based investigation comparing normal and OA serum (Jmeian and El 
Rassi, 2008). This study discovered that OA patients taking soy supplements, had 
serum alterations in kininogen, transthyretin, hemopexin precursor and vitamin D-
binding protein precursor (Jmeian and El Rassi, 2008). Analysis of OA serum 
compared to healthy individuals identified release of two biomarkers higher in OA: 
V65 vitronectin fragment and C3f peptide (de Seny et al., 2011). Quantitative 
iTRAQ analysis comparing serum from normal and OA patients produced a panel of 
potential biomarkers for early, moderate and severe OA (Fernandez-Puente et al., 
2011). Three glycoproteins were proposed as early biomarkers (lysosomal-associated 
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membrane protein (LAMP), galectin-3-binding protein (LG3BP) and 
glycosylphosphatidylinositol specific phospholipase D (PHLD)), whilst in severe OA: 
COMP, complement proteins and lumican were among biomarker candidates 
(Fernandez-Puente et al., 2011). In a glycoproteomic 2D-LC-MALDI MS analysis, four 
proteins were put forward as potential plasma biomarkers for OA progression: 
clusterin, macrophage stimulating protein, hemopexin and alpha-1 acid glycoprotein-2 
(Fukuda et al., 2012). A haptoglobin ȕ chain isoform was increased in OA serum 
compared to healthy individuals, which was one of fourteen differential proteins. This 
was discovered in a study utilizing DTT and acetonitrile depletion methods followed by 
2D-DIGE (Fernandez-Costa et al., 2012).  
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1.7. Treatments for OA 
 Conventional therapeutic treatments for OA are not effective at halting 
disease progression or repairing damage to cartilage (Goldring and Goldring, 2007). 
OA is commonly treated clinically with paracetamol in mild cases, or NSAIDs such as 
carprofen if paracetamol is inadequate. These conventional treatments only target the 
clinical symptoms associated with OA by reducing pain and inflammation (Goldring 
and Goldring, 2007). New disease modifying OA drugs (DMOADs) need to be 
developed to protect chondrocytes and reverse changes occurring in OA affected 
cartilage. Therapeutics targeting processes involved in cartilage degeneration such as 
MMPs, the cytokines IL-ȕDQG71)-ĮDQGL126PD\SURYHWREHHIIHFWLYH'02$'V
(Mobasheri, 2013). Supplements including GluN and CS are also popular alternatives 
taken by OA sufferers, while herbal medicines may also be prospective nutraceuticals 
(Cameron et al., 2009). 
1.7.1. Carprofen and other NSAIDs 
Pain and inflammation are relieved by NSAIDs, therefore allowing 
improvements in patient mobility. NSAIDs including phenylbutazone, flunixin, 
ketoprofen, naproxen and carprofen are available to treat equine OA (Goodrich and 
Nixon, 2006). The effects of the NSAID carprofen on explant cultures of equine 
articular cartilage were studied throughout this thesis. 
Prescription NSAIDs available for human use include: aspirin, ibuprofen, 
naproxen, diclofenac, celecoxib and etoricoxib (Zhang et al., 2008). The mechanism 
of action of NSAIDs is achieved via inhibition of cyclooxygenase enzymes (COX) 
(Vane and Botting, 1998). Production of bioactive lipids from the arachidonic acid 
pathway is controlled by the two isoforms: COX-1 and COX-2 (Vane and Botting, 
1998). Constitutive expression of COX-1 maintains healthy production of bioactive 
lipids for biological functions including prostacyclin release, which is cytoprotective to 
gastric mucosa of the stomach (Griffin, 1998). NSAIDs are associated with adverse 
side effects on gastrointestinal toxicity due to COX-1 inhibition (Griffin, 1998). COX-2 
is the inducible isoform that is up-regulated to during inflammatory processes (Vane et 
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al., 1994). Selective COX-2 inhibitors have therefore been developed to reduce 
inflammatory conditions in OA, whilst not causing gastrointestinal side-effects. 
Cardiovascular and renal side effects are reported with COX-2 specific NSAIDs 
celecoxib, parecoxib and valdecoxib (Caldwell et al., 2006, Aldington et al., 2005, 
Hooper et al., 2004), therefore NSAID treatment continues to have associated risks. 
Even with possible side-effects, OA treatment with NSAIDs continues to be 
recommended due to their proven analgesic effects (McAlindon et al., 2014). 
Carprofen (an NSAID marketed as Rimadyl® by Pfizer) was chosen for studies 
on IL-ȕ VWLPXODWHG FDUWLODJH H[SODQW VHFUHWRPH in this thesis. This NSAID is used 
clinically to treat OA associated inflammation and joint pain in horses and dogs 
(Goodrich and Nixon, 2006). Carprofen was voluntarily withdrawn from human use in 
1998 for commercial reasons, but continues to be applied to treat companion animals. 
It selectively inhibits COX-2 and blocks synthesis of PGE2 in the arachidonic acid 
signalling pathway therefore reducing inflammatory processes. Carprofen selectivity 
for COX-2 over COX-1 has been reported in an equine study (Beretta et al., 2005). 
Carprofen has been reported to improve clinical symptoms of OA in dogs (Sanderson 
et al., 2009). Changes in cartilage and subchondral bone that are associated with OA 
are inhibited by carprofen treatment in dogs (Pelletier 2000). In vitro studies on 
carprofen R and S enantiomers treatment of cartilage explants showed that 
proteoglycan synthesis was significantly increased by carprofen (Frean et al., 1999) 
The highest increase in proteoglycan synthesis was associated with the S enantiomer 
(Frean et al., 1999). PGE2 production and GAG release can also be reduced by 
carprofen in vitro during equine studies, which shows the potential therapeutic effects 
of this NSAID in OA treatment (Goodrich and Nixon, 2006).  
1.7.2. Intra-articular glucocorticoids and hyaluronate 
 Injection of glucocorticoids or hyaluronate into OA affected joints is another 
conventional approach to disease management. OARSI (Osteoarthritis Research 
Society International) recommends these injections if patients are not responding to 
NSAID therapy (McAlindon et al., 2014). Glucorticoids possess anti-inflammatory 
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actions asserted through interaction with cytoplasmic glucocorticoid receptors (van 
der Velden, 1998). The ability of glucocorticoids to alleviate symptoms of OA in the 
long-term continues to be debated. In vitro evidence from glucocorticoid treatment 
does not support disease modifying capabilities for OA. For example, IL-ȕVWLPXODWHG
GAG degradation and aggrecan cleavage are not decreased in cartilage explants by 
two glucocorticoids: dexamethasone and triamcinolone (Busschers et al., 2010). 
Hyaluronate is a large GAG component of cartilage ECM and synovial fluid. Injections 
of hyaluronate into OA affected joints are considered to provide symptomatic relief. 
Numerous studies have assessed therapeutic benefits of hyaluronate injections, and 
show that benefits are seen several weeks after injection (Zhang et al., 2008). A 
comparative study of glucocorticoids and hyaluronate reported that both treatments 
were equally effective against OA (Leopold et al., 2003). Both treatments provided 
higher WOMAC (Western Ontario and McMaster Universities Arthritis Index) scores, 
but clinical improvements were moderate (Leopold et al., 2003). Although modest 
alleviation of symptoms can be achieved with intra-articular injections, substantial OA 
recovery does not occur and new therapeutic approaches are needed. 
1.7.3. Alternative biological targets 
Fundamental OA disease processes including signalling mediators, 
inflammatory pathways and metabolic proteins can be targeted for developing new 
therapeutics. Inducible nitric oxide synthase can be inhibited, which may have positive 
applications in OA affected joints. An experimental dog model of OA showed iNOS 
inhibition lowered the levels of IL-ȕ &2;-2, MMP-1 and MMP-3 (Pelletier et al., 
1999). Inhibitors of pro-inflammatory cytokines have been investigated as a potential 
treatment for OA. Down-regulation of MMP-1, -3 and -13 along with decreases in 
collagen II cleavage and GAG release were observed in OA cartilage treated with IL-1 
and TNF-Į DQWDJRQLVWV (Kobayashi et al., 2005). Targeting catabolic proteases with 
anti-MMP therapies could lessen cartilage break down and loss occurring during OA. 
Pain behaviour, osteochondral vascularity and disease severity were reduced in a rat 
model of OA treated with an MMP inhibitor (Mapp et al., 2010). All these biological 
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targets have essential roles in healthy processes; therefore it is disadvantageous if 
normal processes are affected. Over-activity of catabolic proteins and inflammatory 
signals is characteristic of OA, therefore specifically targeting these processes could 
provide advances in OA therapeutics. 
1.7.4. Nutraceuticals 
The anti-inflammatory and chondroprotective effects of naturally derived 
compounds suggest nutraceuticals could be beneficial in OA treatment. Nutraceuticals 
may provide therapeutic effects without the adverse side-effects and lack of disease 
modifying properties associated with conventional medicine (Cameron et al., 2009). 
Popular equine nutritional supplements contain a range of potentially beneficial 
nutraceuticals to support joint health (Trumble, 2005). Nutraceutical alternatives may 
not totally replace, but could be taken in combination with existing therapeutics such 
as NSAIDs, to reduce dependence and consumption of traditional pharmaceuticals. 
Popular nutraceuticals include GluN and CS, while many herbal medicines also have 
potential valuable properties. Studies on GluN, CS and other potential nutraceuticals 
including curcumin, resveratrol, rosehips and boswellia have shown beneficial 
chondroprotective and anti-inflammatory properties that may be beneficial for OA 
treatment (Henrotin and Lambert, 2013, Clutterbuck et al., 2009, Csaki et al., 2009, 
Shakibaei et al., 2012, Sengupta et al., 2011). 
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1.8. Aims of this project using the equine inflammatory articular cartilage 
explant model 
OA is a common cause of joint disease in horses (Clegg and Booth, 2000), 
therefore enhancing understanding of OA and cartilage degradation in this species is 
of importance. Therefore studies on equine cartilage secretome were initiated aiming 
to study cartilage biology and degradation utilising tissue from this species. Studying a 
time course of the secretome aimed to determine dynamic changes in protein release 
over time, which has not previously been performed using proteomic approaches. The 
anti-inflammatory effects of the NSAID carprofen, on cytokine stimulated cartilage 
explants were studied by high-throughput MS. Catabolic MMPs and ECM proteins 
identified in the secretome were further investigated in response to IL-1ɴ and 
carprofen for the first time.  
A previous proteomic study on equine secretome reported various ECM, non-
ECM and intracellular proteins in the secretome (Clutterbuck et al., 2011). It did not 
offer a description of which proteins in each treatment group were identified by MS, 
although there is quantitative western blotting of five proteins. This thesis developed 
on high-throughput MS initially published (Clutterbuck et al., 2011), by identifying a 
greater range of proteins and associating proteins with treatment groups. This 
provided further insights into pro-inflammatory cytokine responses and investigated 
the capacity of this model as a screening tool for anti-inflammatory compounds. 
Compared to the previous work, additional protein identifications were made in equine 
cartilage secretome: MMP-13, collagen type II, secreted frizzled related protein 
(SFRP) and macrophage migration inhibitory factor (MIF). Inflammation and 
associated cartilage degradation are fundamental in OA progression, therefore 
stimulation with cytokines such as IL-ȕRU71)-Į during these in vitro assessments 
contributed towards understanding of this prevalent disease. While many complex 
features present in synovial joints and OA inflammation (immune cells, mechanical 
loading, hypoxia) were absent within the explant model, these studies aimed to 
improve a suitable alternative to in vivo models. These studies advanced biological 
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understanding of equine cartilage explant cultures, degradation and OA. Biomarkers 
to monitor IL-ȕVWLPXODWHGSURFHVVHV and for screening anti-inflammatory compounds 
in this model were also investigated.  
There are distinct advantages to utilizing cartilage explants in OA research 
over chondrocyte monolayers. Investigations with the explant model may therefore 
give a more accurate response to inflammatory stimulation and anti-inflammatory 
compound treatment. In explants, chondrocytes will be contained within their natural 
ECM environment. Chondrocytes within explants should therefore continue to act in a 
similar manner as they usually would in vivo. Chondrocytes in monolayer cultures 
dedifferentiate into fibroblast-like cells over time and with increasing passage numbers 
(Benya et al., 1978, Grundmann et al., 1980, Hamilton et al., 2005). Chondrocyte 
dedifferentiation causes loss of phenotype and a deficiency in the ability to express 
collagen type II (Benya et al., 1978). Within cartilage explants, chondrocytes are 
distributed alone or in pairs (Archer and Francis-West, 2003). It should also be taken 
into consideration that bioavailability of compounds to chondrocytes within explants 
may be reduced due to hindered diffusion of compounds through the ECM, while 
monolayers would have instant access to any treatments. Chondrocytes in 
monolayers are also more metabolically active therefore any responses to treatments 
would be more easily identifiable with monolayer studies compared to explant 
cultures. However, chondrocytes within the ECM are not rapidly dividing, highly 
metabolic or in a monolayer (Archer and Francis-West, 2003). There continues to be 
several limitations to the cartilage explant model employed in this thesis. The lack of 
surrounding synovial fluid, immune cells and underlying subchondral bone means that 
all influencing factors from inflammation and catabolic processes in associated tissues 
are not being assessed. Use of healthy cartilage stimulated by specific cytokines 
provides only a simplified picture of catabolic processes. The explant model is also 
static, and therefore does not introduce dynamic movement of the joint and synovial 
fluid that would be present in vivo. Taking into account these limitations, the explant 
model continues to provide the opportunity to study degradative processes on 
cartilage in response to cytokines and therapeutic treatments like carprofen. 
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In the first experimental chapter, release of cartilage proteins over a time 
course was investigated to discover if there were dynamic changes in types of 
proteins released as time passes (Chapter 3). Monitoring responses to IL-1ɴ 
stimulation and NSAID carprofen aimed to identify potential biomarkers of therapeutic 
efficacy in this cartilage model. High-throughput MS analysis had previously been 
used to identify proteins released from this culture model at only one time point 
(Clutterbuck et al., 2011), therefore the possibility of additional protein identifications 
being made at different points in the time course was investigated (Chapter 3). This 
would help determine an appropriate incubation time to proceed with in future 
proteomic applications. Alterations in release of a number of proteins were observed 
in response to IL-ȕVWLPXODWLRQ in chapter 3, but relevant low level proteins may have 
been masked by abundant ECM proteins within samples. Therefore, the next chapter 
attempted to gain additional protein identifications by preceding the high-throughput 
MS with approaches that attempted to remove or deplete the high abundance 
proteins. These approaches were CPC precipitation, Con A lectin chromatography 
DQG3URWHRPLQHUWHFKQLTXHV&KDSWHUThe high-throughput MS chapters 3 and 4 
identified candidate explant secretome biomarkers that were investigated further using 
western blotting in Chapter 5. Western blots of ECM components and secreted 
MMPs, validated responses in candidate biomarkers to IL-ȕ stimulation and the 
NSAID, carprofen (Chapter 5). The data obtained showed the explant model can be 
applied as a tool for assessing cytokine responses and screening potential anti-
inflammatory drugs or naturally occurring compounds.  
With proteomic studies, this work overall aimed to identify suitable biomarkers 
within the explant culture model to be used to study anti-catabolic and anti-
inflammatory effects of compounds. Deeper understanding at the molecular level of 
cartilage degradation and protection events will contribute towards research on OA, a 
prominent disease particularly in the elderly population and in companion animals. 
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The equine explant model studied here will help provide an alternative to in vivo 
models following the principles of the 3Rs (Replacement, Refinement and Reduction). 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. Animal tissues and statement of ethical approval 
 All animals used in these studies were sourced from two UK-based abattoirs. 
Animals were euthanized for non-research purposes having been stunned before 
slaughter for meat in accordance with Welfare of Animals (Slaughter or Killing) 
Regulations 1995. Approval for use of abattoir-derived animal tissues was obtained 
from the local Ethical Review Committee (Ethics Committee of the School of 
Veterinary Medicine and Science) with input from members of the University of 
1RWWLQJKDP¶V$QLPDO:HOIDUHDQG(WKLFDO5HYLHZ%RG\$:(5% 
2.2. Chemicals and Reagents 
Articular cartilage explants were cultured in culture media containing 
DuOEHFFR¶V Modified Eagles Medium (DMEM) low glucose (Hyclone) + 2% Pen/Strep 
(Penicillin/Streptomycin solution: (5000 units/ml penicillin, 5 mg/ml streptomycin) 
(Sigma). Sterile phosphate buffer solution (PBS) was prepared by dissolving 1 tablet 
(Gibco) in 500 ml reverse osmosis (RO) water before autoclaving. Carprofen 
(Rimadyl®) stocks were made by grinding down a tablet (containing 50 mg active 
compound = carprofen (Pfizer)) into a powder with a mortar and pestle. This powder 
was dissolved into 25 ml of culture media to provide a 2 mg/ml stock solution that was 
divided into single use aliquots. Protease inhibitor cocktail for general use was 
purchased from Sigma and contains 4-(2-aminoethyl)benzenesulfonyl fluoride 
hydrochloride, aprotinin, bestatin hydrochloride, N-(trans-Epoxysuccinyl)-L-leucine 4-
guanidinobutylamide, EDTA and leupeptin hemisulfate salt. 
2.3. Dissection and explant culture 
Cartilage harvested in the following studies was taken from animals 
euthanized for purposes other than scientific research. Equine metacarpophalangeal 
joints were utilized during this work and articular cartilage was obtained by the 
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following dissection protocol. The joints were first shaved to remove excess hair to 
improve the aseptic conditions for dissection. Joints were disinfected by washing with 
Hibiscrub and followed by Trigene, before being soaked in bleach for 1 hour. 
Afterwards, the skin and flexor tendon was carefully removed from the joint without 
breaking into the synovial structure. A sterile scalpel was used to open up the joint, 
which was then washed with sterile PBS (Gibco). Only healthy and macroscopically 
normal articular cartilage shavings of equal thickness were taken from the end surface 
of the third metacarpal and placed in 50 ml of DMEM (Thermo Scientific) + 4% 
Pen/Strep (Sigma) (Penicillin/Streptomycin solution: (5000 units/ml penicillin, 5 mg/ml 
streptomycin)) (pre-warmed to 37 °C). These cartilage shavings were transferred to a 
Falcon tube containing washing solution (Sterile PBS + 10% Pen/Strep) in which they 
were twice washed with rotation for 20 minutes.  
Cartilage explant discs were prepared using a 3 mm biopsy punch (Kai 
medical), with discs placed into wells (5 discs per 1 ml DMEM + 2% Pen/Strep) before 
incubation for 24 hours (37 °C, 5% CO2). After this equilibration period, the media was 
removed and replaced with treatment media required for the purposes of each 
different experiment. Once explants had been treated and incubated for the desired 
amount of time, the supernatant and cartilage discs were separately placed in labelled 
Eppendorf tubes and stored at -80 °C. Protease inhibitors (Sigma) were added to the 
supernatant samples at the time of removal and storage.  
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Figure 8. Schematic of dissection process to set up equine cartilage explant cultures 
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2.4. SDS-PAGE with Protean 3 mini-gels 
All polyacrylamide gels for SDS-PAGE were prepared within the laboratory 
using the recipe found in Table 2. When loading gels a volumetric system was used 
with the same volume of sample (10 µl) loaded in each lane so that relative protein 
levels between treatments could be distinguished. For each sample, 10 µl collected 
culture supernatant was added to 10 µl of Laemmli sample buffer (62.5 mM Tris-HCl, 
pH 6.8, 2% (w/v) SDS, 25% (w/v) glycerol, 0.01% (w/v) bromophenol blue) (Bio-Rad) 
containing dithiothreitol (DTT) (Bio-Rad) 0.15 M). Samples were boiled for 5 minutes 
at 95 °C before loading onto 10%T polyacrylamide gels. To reference protein 
molecular wHLJKWV3UHFLVLRQ3OXV3URWHLQ6WDQGDUGV%LR-Rad) were also loaded. A 
voltage of 120 V was applied until the dye front reached the bottom of the gel. 
Table 2. Recipes for two mini-gels with Protean 3  
 5% Stacking 10% Resolving 
Water (18 ohm) (Fisher) 4.1 ml 5.9 ml 
30% Acrylamide (Geneflow) 1.0 ml 5.0 ml 
1.5M Tris (pH 8.8) (Bio-Rad) - 3.8 ml 
0.5M Tris (pH 6.8) (Bio-Rad) 750 µl - 
10% (w/v) SDS (Bio-Rad) 60 µl 150 µl 
10% (w/v) APS (Bio-Rad) 60 µl 150 µl 
TEMED (Sigma) 5 µl 8 µl 
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2.5. Silver staining 
Silver staining was used to visualise the proteins once separation had been 
completed, with an Amersham processor (Amersham Pharmacia Hoefer processor 
plus) used to aid this process. The silver staining approach used was based on 
methods described by (Yan et al., 2000). Silver staining was chosen because it is 
highly sensitive and can detect proteins down in the 2-10 nanogram range (Rabilloud 
et al., 2009). Silver staining is advantageous because many secretome proteins are 
present at low levels. This provided detailed SDS-PAGE profiles with improved protein 
detection over Coomassie blue stains. The precise details of the steps and solution 
compositions can be found in Table 3. In brief, the gel was first fixed to stop diffusion 
of proteins in the gel. The gel was exposed to a sensitizer solution before an 
impregnating solution containing silver nitrate was added. Silver ions were reduced to 
metallic silver where proteins are present and therefore become deposited in a 
sensitive manner on the protein bands. A developing solution is added to visualize 
where silver has become deposited, and when optimal development has occurred a 
stop solution was added to end the process. 
 Stained gels were scanned using a densitometer (Bio-Rad GS-800 calibrated 
densitometer) linked with Quantity One (Bio-Rad) software to create digital images of 
gels. 
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Table 3. Silver staining method steps and solutions  
Based on method described by (Yan et al., 2000) 
Step Time 
(minutes) 
Solution Function Solution Composition 
(For 225 ml) 
1+2 2 x 15 Fixation 84.1 ml Methanol (Fisher) 
21.03 ml Acetic Acid 
(Fisher) 
Dilute to 225 ml with 18 
ohm water. 
3 30 Sensitizer 8.5 ml 5% Sodium 
thiosulphate (STS) 
(Fisher) 
14.3 g Sodium acetate 
(Sigma) 
Dilute to 225 ml with 18 
ohm water. 
4+5+6 3 x 5 Wash 18 ohm water 
7 20 Impregnate 0.477 g Silver nitrate 
(Fisher) 
8+9 2 x 1 Wash 18 ohm water 
10 2 (but 
variable. 
Time may 
need to be 
extended) 
Develop 5.31 g Sodium carbonate 
(Fisher) 
85 µl Formaldehyde 
(TAAB) 
11.9 µl STS (Fisher) 
Dilute to 225 ml with 18 
ohm water. 
11 10 Stop 3.1 g EDTA (Fisher) 
Dilute to 225 ml with 18 
ohm water. 
12+13+14 3 x 5 Wash 18 ohm water. 
5% (w/v) STS = 500 mg in 10 ml 18 ohm water 
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2.6. Western blotting 
 Samples were concentrated by lyophilisation (Heraeus-Christ) of 50 µl before 
resuspension in 20 µl Laemmli buffer (Bio-Rad) prior to completing SDS-PAGE (See 
SDS-PAGE method). Positive controls were prepared by crushing articular cartilage 
under liquid nitrogen with a mortar and pestle, and resuspended in Laemmli buffer. 
Proteins separated on gels were electroblotted onto low-fluorescence PVDF 
membrane (GE Healthcare) at 80 V for 2 hours. Washing steps with PBS-Tween 20 
(0.1% (v/v)) (3 x 5 minutes) were completed between each of the following 
incubations. Membranes were blocked for 1 hour with 3% (w/v) BSA (Sigma) in PBS-
Tween 20 (0.1%) (Fisher). Primary antibodies were diluted as required in blocking 
solution before overnight incubation at 4 °C. After the overnight primary incubation, 
membranes were incubated with secondary antibodies for 1 hour. Secondary 
antibodies in this study were all HRP conjugated and diluted to appropriate 
concentrations using 3% (w/v) BSA blocking solution.  
 $PSOLIOX5HG:HVWHUQ%ORW.LW6LJPDZDVXVHGWRVWDLQSURWHLQEDQGVZLWK
red fluorescence, which was detected on a FX-Imager (laser: 532 nm, filters: 555 nm 
LP, 1,064 blocking) (Bio-Rad) using Quantity One software (Bio-Rad). Densitometry 
was performed on the images obtained using ImageJ (NIH), with statistical analysis 
completed and results graphically displayed using GraphPad Prism 6. 
2.7. Band excision and tryptic digestion 
Protein bands were excised from silver stained SDS-PAGE gels using a 
scalpel, cut into 1 mm3 cubes and placed into wells of a microtitre plate each 
containing 60 µl HPLC grade water (Fisher Scientific). The microtitre plate was placed 
into the ProteomeWorks MassPREP robotic liquid handling station (Waters, U.K.) for 
the following procedures; destaining, reduction, alkylation and trypsin digestion. All 
LQFXEDWLRQV ZHUH SHUIRUPHG DW Û& XQOHVV RWKHUZLVH LQGLFDWHG $ GHVWDLQ VROXWLRQ
was freshly made containing a 1:1 mixture of 30 mM potassium ferricyanide (Sigma) 
and 100 mM sodium thiosulphate (Fisher Scientific). Destain solution was added to 
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the gel pieces for 3-15 minutes until the silver stain was removed and then the 
solution was removed. Gel pieces were washed for 20 minutes in 150 µl 200 mM 
ammonium bicarbonate (Sigma). Supernatant was removed before a further 15 
minutes wash in 150 µl HPLC water, before supernatant was again removed. 
Samples were dehydrated by incubation in 50 µl of acetonitrile (Fisher Scientific). 
After 5 minutes incubation, acetonitrile was removed and samples were incubated for 
10 minutes to allow evaporation.  
Proteins were reduced by incubation in 50 µl of a reducing solution containing 
10 mM dithiothreitol (Bio-Rad) in 100 mM ammonium bicarbonate. After 30 minutes 
incubation, reducing solution was replaced with 50 µl of alkylating solution (55 mM 
iodoacetamide (Bio-Rad) in 100 mM ammonium bicarbonate). Samples were 
incubated with alkylating solution for 20 minutes (room temperature), then washed for 
10 minutes with 50 µl of 100 mM ammonium bicarbonate followed by 50 µl of 
acetonitrile for 5 minutes, before a dehydrating wash with 50 µl acetonitrile followed by 
PLQXWHVHYDSRUDWLRQWLPH7KHPLFURWLWUHSODWHZDVFRROHGWRÛ&IRUPLQXWHV)RU
digestion, 25 µl of trypsin gold (Promega) at 10 ng/µl in 50 mM ammonium 
ELFDUERQDWHEXIIHUZDVDGGHGSHUZHOODQGLQFXEDWHGDWÛ&IRUPLQXWHVWRDOORZ
WU\SVLQHQWU\ LQWR WKHJHOZLWKPLQLPDODXWRFDWDO\VLVEHIRUH LQFXEDWLRQDWÛ& IRU
KRXUV6DPSOHVZHUHVWRUHGDWÛ&XQWLOPDVVVSHFWURPHWU\DQDO\VLVZDVSHUIRUPHG  
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2.8. High-throughput Mass Spectrometry 
2.8.1. Mass Spectrometry sample preparation 
To prepare proteins present in secretome samples for MS, reduction of di-
sulphide bonds was performed by addition of DTT (Bio-Rad) to a final concentration of 
10 mM, followed by vortexing and incubation at 37 °C for 30 minutes. Alkylation of 
thiol groups performed by addition of IAA (Bio-Rad) to a 55 mM concentration, then 
vortexed and incubated for 45 minutes at 37 °C (in the dark). Ice cold acetone (1.2 ml) 
(Fisher) added and incubated at -20 °C for 1 hour, then pelleted by centrifugation at 
15,000xg for 5 minutes and acetone was discarded. Proteins in the pellet were 
digested with 20 ng/µl trypsin gold (1:50 (w/w) ± protease: protein ratio) (Promega) at 
37 °C overnight (16 hours). The digestion was ended by addition of formic acid to give 
a 0.1% concentration. To desalt and ensure only soluble proteins were present, 
samples were ziptipped with C18 resin (Millipore) and eluted with 20 µl 50% methanol 
and 0.1% formic acid. Samples were heated to 65 °C to evaporate off excess 
methanol and reduce the volume to 10 µl. Samples were transferred to glass vials and 
transported to Bruker U.K. prior to being loaded onto the nanoLC column for MS 
analysis. 
2.8.2. Mass Spectrometry analysis on amaZon ETD 
High throughput MS analytical runs were made possible by the collaborative 
support of Dr Julia Smith at Bruker U.K, who performed the data acquisition on MS 
instruments, providing the raw data for the analysis performed and reported in this 
thesis. Samples were loaded onto a 15 cm Acclaim® Pepmap RSLC C18 column 
(Thermo) to be analysed by nanoLC-MS/MS on an amaZon ETD or amazon speed 
ETD (Bruker) (Figure 9 and Figure 10). A flow rate of 250 nl/minute was used to 
separate peptides. Solution A (100% H20 + 0.1% formic acid) and solution B (100% 
ACN + 0.1% formic acid) were set to create a gradient of 10% solution B to 30% 
solution B over the course of an hour (0.3% per minute). From each MS scan, the five 
most abundant peptides were selected for collision induced dissociation (CID) 
fragmentation. 
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2.8.3. Mass Spectrometry data processing 
 Once the raw data had been generated at Bruker U.K., Mascot Daemon 
software was used to search the NCBInr (All entries) and Swiss-Prot (mammalian 
entries) databases by submitting the .MGF files (Figure 11). The search parameters 
were as follows: Instrument: ESI-TRAP, peptide charge: 1+, 2+ and 3+ ions, peptide 
tolerance: 0.5 Da, 13C = 1, max missed cleavages = 1. Fixed modifications: 
carbamidomethyl (C) and variable modifications: oxidation (M).  
 Mascot scores were generated by comparing the peptide masses or fragment 
ion mass values of entries in the sequence databases with experimental data values. 
A probability based score is calculated for each peptide match. With increasing 
amounts of matched peaks, the likelihood of the identification being reliable is 
increased and this will be associated with a higher Mascot score. The threshold of 
significance (p<0.05) for scores has been selected as a cut-off to determine 
identification. The specific score for each search is detailed in each chapter because 
this significant threshold alters depending on the database searched and data 
submitted. 
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Figure 9. Example of two profiles of peptide elution throughout the mass spectrometry runs 
Displayed runs are from untreated control supernatant that has been processed with Con A lectin 
chromatography (above) and unprocessed (below). 
 
Figure 10. MS (above) and MS/MS (below). Example taken from run of untreated control supernatant 
The MS/MS of COMP peptide: ELQETNAALQDVR. 
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Figure 11. Example of Mascot database search results matching a COMP peptide  
Red indicates significant matches of observed with predicted fragment ion masses. 
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2.9. Dimethylmethylene blue (DMMB) assays (GAG assay) 
 Sulphated GAGs in cartilage cultures can be accurately measured by DMMB 
assays, therefore helping determine loss of GAGs in response to specific stimuli 
(Farndale et al., 1982). Solutions of 1, 9-dimethylmethylene blue (DMMB) and papain 
solution were prepared within the laboratory (detailed next page). Supernatant 
samples were diluted to be within the accurate range (0-75 µg/ml) of a chondroitin 
sulphate (Sigma) standard curve. On a 96 well plate, 40 µl per well of blank papain 
solution (duplicate), each standard (duplicate) or sample dilutions (triplicate) were 
added. Next, 200 µl of DMMB solution was added to each well, before absorbance 
was read at 540 nm (Labtech LT-4000 plate reader) within 10 minutes. To calculate 
total % GAG release, corresponding explant discs were digested overnight by 
incubating with papain solution at 60 °C, before their GAG content was also measured 
by DMMB assay. Total GAG release levels per well were calculated, before dividing 
the total GAG release by measurements for individual supernatant samples to provide 
the % GAG release due to treatments. GraphPad Prism 6 software was used to 
produce graphical images and complete statistical analysis with a one-way ANOVA 
XVLQJ7XNH\¶VPXOWLSOHFRPSDULVRQWHVW 
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DMMB assay solutions 
1, 9 ± dimethylmethylene (DMMB) blue solution 
x 5 ml 100% ethanol (0.5% (v/v)) (Fisher) 
x 2ml formic Acid (0.2% (v/v)) (Sigma) 
x Made up to 1 litre volume with distilled water 
x 16 mg 1, 9 ± dimethylmethylene blue (0.046 mM) (Sigma) 
x 2 g sodium formate (0.03 M) (Sigma) 
Papain Solution 
x 1.42 g dibasic sodium phosphate (Sigma) 
o In 90 ml distilled water 
x 79 mg cysteine hydrochloride (Sigma) 
x 186 mg EDTA (Fisher) 
x Adjusted to pH 6.5 using 1M hydrochloric acid (Fisher)  
x Volume made up to 100 ml with distilled water 
x 105.6 mg papain (Sigma) (1.06 mg/ml) 
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2.10. Protein assay 
To determine the concentration of protein present in supernatant samples, a 
modified Lowry based method was used (Lowry et al., 1951) (Bio-Rad DC protein 
assay). In brief, 5 µl of samples were loaded into a 96 well plate, along with 5 µl of 
blank, control media and BSA standards. To each well 25 µl of reagent A (alkaline 
copper tartrate) is added followed by 200 µl of reagent B (dilute Folin reagent), before 
mixing for 5 seconds on a shaker and incubation for 15 minutes at room temperature. 
The 96 well plate was placed in a Bio-Rad microplate plate reader and absorbance 
was read at 655 nm wavelength. A BSA standard curve ranging from 0-1.5 µg/µl was 
produced. Concentration of the protein in the unknown samples could therefore be 
established by comparison with the standard curve. 
2.11. PGE2 assay 
 To measure PGE2 content within culture supernatants a competitive 
immunoassay was purchased from R&D systems and performed following the 
PDQXIDFWXUHU¶VSURWRFRO$3*(2 standard curve was completed ranging from 39-2500 
pg/ml, along with zero standard and non-specific binding (NSB) wells. First, 150 µl of 
each sample was added to each well, followed by 150 µl primary antibody solution 
added (except for NSB wells) before incubation for 1 hour on a microplate shaker (500 
rpm) at room temperature. PGE2 conjugate (50 µl) was next added to all wells and 
incubated for 2 hours on the shaker. The plate was then washed with wash buffer four 
times, before 200 µl substrate solution was added and incubated for 30 minutes in the 
dark. Finally, 100 µl stop solution was added before optical density of the plate was 
read at 450 nm and 540 nm (LT-4000 plate reader). The 540 nm reading was 
subtracted from the 450 nm reading to correct for optical imperfections in the plate. 
The NSB value was subtracted from all experimental samples before a standard curve 
was created using GraphPad Prism 6 and PGE2 values interpolated. 
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CHAPTER 3 
TEMPORAL CHANGES IN THE SECRETOME OF 
ARTICULAR CARTILAGE EXPLANTS 
3.1. Introduction 
 7KHWHUP³VHFUHWRPH´UHIHUVWRSURWHLQV actively secreted from cells or 
tissues into the surrounding environment (Hathout, 2007). Once proteins are 
synthesised in eukaryotic cells, they can be secreted by classical endoplasmic 
reticulum (ER) mediated exocytosis or via non-classical secretion pathways (Nickel 
and Seedorf, 2008). In classical ER secretion pathways, proteins are folded and 
posttranslational modifications (e.g. glycosylation) occur in the Golgi apparatus. 
Proteins are then transferred into secretory vesicles that fuse with the cell membrane 
to release their contents. Several types of proteins are secreted including signalling 
proteins, hormones, enzymes and ECM components. Chondrocytes are the resident 
cells of articular cartilage that produce and secrete newly synthesised ECM proteins 
for incorporation into the matrix (Archer and Francis-West, 2003). They also express a 
unique set of metabolic proteins for controlling cartilage turnover (Archer and Francis-
West, 2003). Secreted catabolic proteins like ADAMTS and MMPs impact on cartilage 
maintenance, which can lead to ECM breakdown and OA development (Troeberg and 
Nagase, 2012). Proteins are secreted into the surrounding synovial fluid in OA 
diseased synovial joints in vivo (Sinz et al., 2002). Synovial fluid is consequently a 
source of OA biomarkers including various ECM components, as well as proteins 
associated with complement pathways or inflammation (Sinz et al., 2002, Yamagiwa 
et al., 2003, Drynda et al., 2004, Kamphorst et al., 2007, Gobezie et al., 2007, 
Chiaradia et al., 2012, Mateos et al., 2012, Gharbi et al., 2013, Ritter et al., 2013). 
Biomarkers entering systemic circulation are present in blood/serum/plasma or urine. 
For example, specific peptide breakdown fragments that are prospective biomarkers 
of OA in serum include: CTX-II, Coll2-1, Coll2-1NO2, Fib3-1 and Fib3-2 (Ishikawa et 
al., 2004, Henrotin et al., 2012b, Henrotin et al., 2012a).  
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3.1.1. Studying the cartilage explant secretome 
Cartilage explant cultures have advantages over high density cultured 
chondrocytes, primarily due to preservation of chondrocytes within their native ECM 
environment (Archer and Francis-West, 2003). Explant models provide opportunities 
to monitor cartilage turnover in response to pro-inflammatory cytokines, therapeutics 
or mechanical compression (Saklatvala, 1986, Morris et al., 1992, Sah et al., 1989). 
For example, IL-ȕ has been shown to contribute to catabolic processes by up-
regulating MMPs, and reducing the synthesis of proteoglycans and collagen type II 
needed to maintain the ECM (Chevalier, 1997).   
Although often referred to as cartilage secretome, not all proteins in explant 
conditioned media will be secreted. ECM present could be released by degradative 
processes or simply be leaking out of explants. Additionally, intracellular proteins 
identified are released during cell death and lysis, are not being truly secreted. 
Nevertheless, whilst assessing inflammatory or anti-inflammatory stimuli, analysis of 
FDUWLODJH ³VHFUHWRPH´has the capacity to show alterations in degradation of existing 
ECM proteins or effects on chondrocyte health (Clutterbuck et al., 2009, Clutterbuck 
et al., 2013). 
3.1.2. Gel based proteomic studies of the cartilage secretome 
Proteomics studies using 2DE have identified differential proteins between 
healthy and OA affected cartilage. Secreted metabolic and signalling proteins (CTGF, 
LQKLELQȕ$TIMP-1, PEDF, and TNF-R1) were all identified in OA cartilage secretome 
(Hermansson et al., 2004, De Ceuninck et al., 2005).  
OA relevant cytokine stimulation of healthy cartilage is also a popular 
approach to compare the responses of cartilage to stimuli. Release of ECM, metabolic 
and inflammatory associated proteins was significantly higher in cartilage stimulated 
with IL-ȕ71)-ĮRU5HW$ (Wilson et al., 2008, Stevens et al., 2008). Across these 
studies, IL-ȕ LQLWLDWHG LQFUHDVHV LQ 003-3, YKL-39, YKL-40, clusterin, haptoglobin 
and NGAL release (Wilson et al., 2008, Stevens et al., 2008).  
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3.1.3. High-throughput and quantitative studies on cartilage secretome 
Improvements in HPLC and MS technologies offer the potential to apply high-
throughput approaches. In high-throughput methods, digested protein samples are 
first separated by liquid chromatography which is directly coupled to a mass 
spectrometer instrument for tandem MS analysis. This allows faster sample analysis, 
without time consuming two dimensional gels and subsequent protein identification. 
Quantification strategies can be coupled with high-throughput MS analysis including 
spectral counting, SILAC, iTRAQ and QconCAT (Bantscheff et al., 2012). 
Proteins released from bovine cartilage explants treated with IL-ȕ71)-ĮRU
mechanical compression have been studied by quantitative iTRAQ labelling 
(Stevens et al., 2009). In that study, the cytokine stimulated increased release of 
aggrecan G2 and G3 domains, MMPs (-1, -3, -9 and -13), and decreased various 
collagen subunits (Stevens et al., 2009). Chemokines, cytokines and secreted 
signalling proteins were also raised in response to all treatments (Stevens et al., 
2009). Use of the SILAC technique showed that only 29% of the proteins present in 
cartilage conditioned media were newly synthesised, whilst most of the proteins 
identified (71%) were not synthesised during culture (Polacek et al., 2010). Proteins 
involved in ECM remodelling YKL-40 and TIMP-1 were newly synthesized and 
secreted (Polacek et al., 2010). A high-throughput analysis of equine cartilage explant 
secretome examined proteins in untreated, IL-ȕ DQG FDUSURIHQ WUHDWHG FXOWXUHV
(Clutterbuck et al., 2011). The proteins identified were mostly ECM components, 
along with secreted MMP-1, MMP-3 and clusterin, or intracellular proteins 
(Clutterbuck et al., 2011). MMP-1, MMP-3 and TSP were increased by IL-ȕ
stimulation compared to control explants (Clutterbuck et al., 2011). A QconCAT 
quantitative approach was applied to OA cartilage with or without IL-ȕVWLPXODWLRQ to 
compare secretome differences (Peffers et al., 2013). IL-ȕ VWLPXODWLRQ GLG QRW
significantly alter MMP-1, MMP-3, aggrecan, fibromodulin, COMP or plasminogen 
levels (Peffers et al., 2013). Differential release of TIMP-1 was the only significantly 
affected protein with IL-ȕstimulation of OA cartilage (Peffers et al., 2013).  
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One difficulty with high-throughput MS analysis of complex samples, including 
the cartilage explant secretome, is the dynamic range of proteins released. Cartilage 
ECM components such as COMP, fibronectin and small proteoglycans (biglycan, 
fibromodulin, decorin), are abundantly released during cartilage degradation (Wilson 
et al., 2008). Proteins secreted at lower levels such as MMPs and pro-inflammatory 
signalling molecules (IL-ȕ 71)-Į ,/-6) have vital functional roles in cartilage 
degradation, inflammation and progression of OA (Troeberg and Nagase, 2012). 
Detection of these lower level proteins can be prevented by the presence of abundant 
proteins. 
3.1.4. Hypothesis and aims 
The objective of the studies in this chapter was to expand knowledge on the 
secretome of an equine cartilage explant model and determine potential biomarkers to 
monitor efficacy of treatment. The NSAID carprofen was used to evaluate the 
capability of the IL-1ɴ stimulated model to screen for anti-inflammatory effects, 
therefore determining proteins as potential biomarkers of treatment efficacy. A 
previous high-throughput MS study on equine cartilage secretome reported protein 
identifications over six days of culture (Clutterbuck et al., 2011). It was hypothesised 
that extending incubation over a time course would result in the identification of 
additional relevant low abundance proteins, since the release of abundant ECM 
components from cartilage may be reduced by later time points.  
In the first study described in this chapter, a time course up to 27 days (time 
course A) assessed changes in cartilage secretome. After initial analysis, the time 
course was altered to collect samples every 6 days over a 24 day time course (time 
course B), providing samples suitable for downstream processing. Sample quality 
control was verified using SDS-PAGE, which provided a visual profile of protein 
release throughout the time courses, before high-throughput MS analysis of the 
cartilage secretome. Release of proteoglycans and GAGs in response to IL-ȕ DQG
carprofen was assessed using DMMB assays. Data from high-throughput MS and 
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DMMB assays taken together provided enhanced insights into cartilage metabolism 
degradation during IL-ȕDQGFDUSrofen treatment. 
In summary, high-throughput MS and conventional protein biochemistry were 
employed to study the secretome of articular cartilage explants, thereby identifying 
candidate biomarkers to monitor responses to IL-1ɴ stimulation and efficacy of 
carprofen treatment. The secretome was also examined throughout time courses to 
assist selection of a suitable incubation time point for future studies.  
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3.2. Materials & Methods 
3.2.1. Time course A (Initial 27 day time course)  
During the first stages of this study, time course experiments were completed 
up to 27 days (Figure 12). The following experimental design was completed three 
times. Articular cartilage was harvested from healthy equine metacarpophalangeal 
joints from separate individual horses on each occasion, with only normal cartilage 
collected. The dissection and explant culture protocol (Chapter 2.3.) was followed with 
differences detailed below. Culture media (3 ml) and 15 articular cartilage explants per 
well, were placed into 6 wells in a 6 well plate and incubated (37 °C, 5% CO2). 
Explants were equilibrated for 24 hours in culture media (no treatment) before the 
treatment phases began. Following equilibration, 3 ml of culture media containing six 
different treatments was added and incubated (37 °C, 5% CO2). Supernatant was 
removed and stored every 24 hours for the first 3 days of this study. The supernatant 
was replaced with fresh corresponding treatment media each time it was removed. 
After the first three day sampling had been completed, the media was replaced every 
3 days up to 27 days (Figure 12).  
Treatments were: untreated control, IL-ȕ 5	'V\VWHPV71)-Į5RFKH
IL-ȕFDUSURIHQ3IL]HUFDUSURIHQ,/-ȕDQGFDUSURIHQ71)-Į,/-ȕ%RWK,/-ȕ
and TNF-ĮZHUHDWDFRQFHQWUDWLRQRIQJPODQGFDUSURIHQZDVDWJPO 
3.2.2. Time course B (24 day time course) 
 After preliminary experiments had been assessed the secretome over time 
course A, it was concluded that samples collected with this experimental layout were 
very dilute and would need additional concentration steps for most downstream 
processes. Therefore a revised 24 day time course (time course B) was planned to 
develop analysis of the secretome and provide suitably concentrated samples that 
could be prepared for high-throughput MS. Each experiment was set up with cartilage 
from two healthy metacarpophalangeal joints from an individual horse. This was 
repeated three times with tissue from three separate horses, with collection of only 
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macroscopically normal cartilage. For time course B, dissection and explant culture 
protocols were followed (Chapter 2.3.) with three replicate wells (5 explants discs with 
1 ml culture media per well) for each treatment. Treatment cultures were incubated 
(37 °C, 5% CO2) for 6 days until removal and storage of supernatant, before fresh 
treatment media was added. This process was repeated to provide a time course with 
four time points: 0-6 days, 6-12 days, 12-18 days and 18-24 days (Figure 12). 
Treatments for the time course B were: untreated control, IL-ȕQJPOFDUSURIHQ
(100 µg/ml) or carprofen (100 µg/ml) + IL-ȕQJPO 
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Figure 12. Layout of explant culture time courses described in Chapter 3 
Culture supernatants removed after each time point, and treatment media replenished 
Time course A treatments: Untreated (control), IL-1ȕ (10 ng/ml), IL-1ȕ (10 ng/ml) + 
TNF-Į (10 ng/ml), carprofen (100 µg/ml), carprofen (100 µg/ml) + IL-1ȕ (10 ng/ml), 
carprofen (100 µg/ml) + IL-1ȕ (10 ng/ml) + TNF-Į (10 ng/ml). 
Time course B treatments: Untreated (control), IL-1ȕ (10 ng/ml), carprofen (100 
µg/ml), carprofen (100 µg/ml) + IL-1ȕ (10 ng/ml). 
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3.2.3. SDS-PAGE with Protean 3 mini-gels 
See Materials and Methods (Chapter 2.4.) 
3.2.4. SDS-PAGE with Protean xi 
To provide appropriate protein levels for band excision and analysis by mass 
spectrometry, electrophoresis was performed using larger gel formats. The recipe for 
the Protean II xi gels (16 cm x 20 cm) is included in Table 4. Molecular weight 
markers used with Protean xi gels were pre-stained markers from New England Bio-
labs. Samples were loaded into wells and a current of 32 mA (for two gels) was 
applied until the dye front reached the end of the stacking gel. The current was 
increased to 42 mA (for two gels) for separation through the resolving gel. 
Table 4. Recipe for Protean xi gels 
 5% Stacking 10% Resolving 
Water (18 ohm) (Fisher) 8.2 ml 8.04 ml 
30% Acrylamide (Geneflow) 2.0 ml 6.66 ml 
1.5M TRIS (8.8) (Bio-Rad) - 5 ml 
0.5M TRIS (6.8) (Bio-Rad) 1.5 ml - 
10% SDS (Bio-Rad) 120 µl 200 µl 
10% APS (Bio-Rad) 120 µl 200 µl 
TEMED (Sigma) 10 µl 6.7 µl 
3.2.5. Silver staining 
See General Materials and Methods (Chapter 2.5.)
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3.2.6. Mass Spectrometry 
 High-throughput MS procedures were described in detail in Chapter 2.8. Figure 13 summarises the identification process. 
 
Figure 13. Schematic diagram of high-throughput MS approach to identify secretome proteins 
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3.2.6.1. MS of time course B - IL-ȕand Carprofen + IL-ȕDWdays 6 and 18 
 All three replicates from one time course B experiment for IL-ȕDQGFDUSURIHQ
+ IL-ȕWUHDWPHQWVDWWLPHSRLQWVGD\DQGGay 18, were analysed to assess protein 
release at an early and late time point. Volumes corresponding to 50 µg protein were 
processed according to the MS sample preparation protocol (chapter 2.7.1.). After 
ziptipping, samples were heated at 60 °C to remove excess solvent and reduce the 
volume down to 2 µl, before 20 µl of 0.1% formic acid was added to increase the 
volume. For these runs, 2 µl of sample was injected into the HPLC column for analysis 
by an amaZon speed ETD and XtremeScan settings were used, which reduces the 
MS/MS cycle time. Individual ion scores > 37 (Swiss-Prot Mammals) indicated identity 
or extensive homology (p<0.05). 
3.2.6.2. MS of untreated and IL-ȕstimulated explant conditioned media 
MS analysis was carried out on culture supernatants after 6 days of 
incubation, from a single horse (untreated control and IL-ȕ WUHDWHG and a pool of 
supernatants from three animals (untreated control and IL-ȕ WUHDWHG $OO VDPSOH
preparation was completed as described in Chapter 2.8 on 90 µl of each sample. 
Excess solvent was evaporated by heating at 70 °C down to 10 µl and then 
transferred to glass vials. These samples were analysed on an amaZon speed ETD 
with 5 µl of each sample loaded onto the column. Individual ion scores > 42 (Swiss-
Prot Mammals) or > 65 (NCBInr) indicate identity or extensive homology (p<0.05). 
3.2.7. Dimethylmethylene blue (DMMB) Assays (GAG assay) 
 The % GAG release was measured in all time course B samples using DMMB 
assays as described in chapter 2.9. 
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3.3. Results 
3.3.1. Time course A 
3.3.1.1. The profile of proteins released into cartilage explant cultures 
throughout time course A 
 Time course A was undertaken to study cartilage explant secretome 
progression over 27 days. Representative images after protein separation by SDS-
PAGE and silver staining are displayed in Figure 14. The profiles contained proteins 
across a wide molecular weight range, which were present at different levels. 
Cytokine stimulation of cultures showed a greater number of proteins in the 
associated profiles. The images also showed carprofen alone did not cause visible 
effects on overall protein release compared to untreated controls.  
This investigation showed that chondrocytes within cartilage explants still 
respond to pro-inflammatory cytokines up to 27 days. Specific bands induced by 
cytokines are visible in SDS-PAGE protein profiles when compared to untreated 
samples. These cytokine induced bands continue to be present even at the later time 
points), providing evidence of continued cell viability up to 27 days. Cultures on 
explants frozen to cause chondrocyte death no longer showed any response to IL-ȕ
(data not shown), therefore as responses continue to be associated with this cytokine 
stimulation, viable cells must remain at the later time points. 
Visually comparing the profiles from IL-ȕDQG,L-ȕ71)-ĮWUHDWPHQWVGLG
not reveal additional bands that could be attributed to TNF-Į RQO\ However, some 
cytokine induced bands appeared to be slightly more intense when both cytokines 
were present, most obviously at ~60-70 kDa. Although certain proteins continue to be 
released at high levels, some fainter bands lose intensity as the time course 
progresses. One particular protein band (highlighted in red in Figure 14) was 
stimulated by IL-ȕ$VWKHWLPHFRXUVH progressed, there was a reduction in this band 
intensity due to carprofen presence. After 15 days, this band could no longer be 
visualised showing carprofen had a significant effect on the underlying protein over 
time. The high-throughput MS analysis would discover if proteins released later in the 
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time course were ECM components, indicators of cell death or other secreted 
metabolic proteins able to provide insights into cartilage inflammation and 
degradation.  
The 24 hour equilibration supernatant was also collected and examined 
during this first experiment as a control to determine any differences between wells 
before treatment commenced. All of the equilibration supernatants showed similar 
protein release, which was similar to untreated control wells throughout the rest of the 
time course. 
 To provide sufficient protein for reliable MS based identification of particular 
protein bands, the SDS-PAGE was scaled up onto larger format gels (16 cm x 20 cm). 
The silver stained image (Figure 15) show the identities of proteins present in selected 
bands. These include the ECM proteins: COMP, hyaluronan and proteoglycan link 
protein 1 (HAPLN1) and collagen type II, which were detected across all treatments. 
One band of note contained MMP-3. Cytokine stimulation of explants provided a 
substantial increase in the level of this protein. It was notably decreased in amount in 
cytokine stimulated cultures when the NSAID carprofen was also present. Another 
band identified as BSA, was introduced as a carrier protein in cytokine reagents. 
Double the amount of BSA will have been added with TNF-Į DQG ,/-ȕ WUHDWPHQW
compared to IL-ȕDORQH 
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Figure 14. Time course A shows protein release in response to cytokine and carprofen 
treatments 
Silver stained SDS-PAGE profiles of proteins released from articular cartilage explant cultures 
from a single horse, over 27 days of culture. The band highlighted in the red box was 
decreased by carprofen treatment contained MMP-3, Unt = untreated Control, IL = IL-1ȕ (10 
ng/ml), TIL = TNF-Į (10 ng/ml) + IL-1ȕ, C = carprofen (100 µg/ml), CIL = carprofen + IL-1ȕ, 
CTIL = carprofen + TNF-Į + IL-1ȕ. M = molecular weight markers. 
kDa 
kDa 
kDa kDa 
kDa 
kDa 
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Figure 15. MS of excised bands identified COMP, BSA, MMP-3, alpha-enolase, HAPLN1 
and a fragment of collagen type II  
Day 6 samples of time course A were separated by SDS-PAGE before bands were excised 
to identify proteins by MS. Treatment concentrations: IL-ȕQJPO71)-ĮQJPO
carprofen (100 µg/ml). Selected bands were manually excised and trypsin digested before 
nanoLC-ESI-MS/MS analysis. M = molecular weight markers. 
kDa 
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3.3.2. Time course B 
3.3.2.1. SDS-PAGE and silver staining of time course B presents higher yields of 
proteins in secretome 
 Previously, time course A provided initial insights into the continual release of 
cartilage proteins as shown in SDS-PAGE profiles in Figure 14, although later time 
points provided very dilute samples requiring concentration for most analytical 
approaches. To allow increased protein yields for downstream processes, a revised 
24 day time course B with sample collection every 6 days was therefore undertaken.  
 Representative SDS-PAGE images of time course B are shown in Figure 16. 
Incubation for 6 days allowed higher protein concentrations to accumulate. Silver 
stained visualization of protein profiles was enhanced with elevated secretome 
content, helping differences between treatments to be more easily distinguished. 
Greater concentrations of proteins were also beneficial for accurate measurement 
during downstream assays and high-throughput MS analysis. High-throughput MS 
analysis of time course A (data not shown) provided some protein identifications, but 
the amount of proteins identified was considerably less than the eventual MS analysis 
of time course B. Therefore incubation time points of 6 days can be deemed more 
suitable to provide samples for high-throughput MS analysis in the search for 
biomarkers. 
 The four different treatment groups provided profiles that were consistent 
across replicates. Untreated control and carprofen alone explants had similar profiles, 
although certain bands around 30 and 40 kDa may be slightly reduced by carprofen. 
Later in time course B at days 18 and 24, a band greater than 250 kDa was more 
intense in untreated and carprofen alone treated samples. This could correspond to 
an ECM protein being degraded during the early culture stages by IL-ȕLQIODPmatory 
processes, therefore its intact form remains only in untreated samples. Pro-
inflammatory IL-ȕFDXVHVGLVWLQFWFKDQJHs with considerably more bands visible due 
to the cytokines presence. Additional stronger bands in lower molecular weight 
regions due to IL-ȕPD\ VXJJHVW LQFUHDVHV LQGHJUDGHGSURWHLQV ,/-ȕVWLPXODWHG
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the 60 kDa band containing MMP-3, which was visibly decreased when combined with 
carprofen. Day 6 IL-ȕ DQG carprofen + IL-ȕ VKRZV VHYHUDO EDQGV DSSHDU PRUH
intensely when only the cytokine is present. The effects of carprofen on IL-ȕ
stimulated processes showed that changes in release of catabolic proteins can be 
seen in this model. One main objective of this study was to see if anti-inflammatories 
effects on relevant proteins could be screened using high-throughput MS. Therefore 
IL-ȕ DQG FDUSURIHQ  ,/-ȕ WUHDWHG H[SODQW VXSHUQDWDQWV ZHUH VWXGLHG E\ KLJK-
throughput MS in the next section. 
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Figure 16. Representative protein profiles of time course B displaying effects of IL-ȕDQG
carprofen over 24 days 
Images of SDS-PAGE that were silver stained, with each gel corresponding to a specific 
time point of collection: day 6, 12, 18 or 24. Treatments: untreated control, IL-ȕQJPO
carprofen (100 µg/ml) + IL-ȕRUFDUSURIHQ 
kDa kDa 
kDa kDa 
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3.3.2.2. Differences in high-throughput MS identifications after 6 day versus 18 
days in time course B shows temporal effect on protein identifications  
 The previous sections of this results chapter determined that differences in 
the progression of IL-ȕLQGXFHGLQIODPPDWLRQFRXOGEHGHWHFWHGRYHUWKHWLPHFRXUVH
Therefore the following high-throughput MS study assessed if the explant model could 
provide high quality longitudinal data with repeat sampling from the same cartilage 
culture. A major aim of the work in this thesis was to apply the model to provide a 
screening tool to assess the effects of anti-inflammatory drugs or natural compounds. 
Thus, the next objective was to use MS analysis to compare the proteins released 
during time course B into explant supernatants from IL-ȕ stimulation at day 6 and 
day 18 (Table 5), and NSAID carprofen + IL-ȕ treatment at day 6 and day 18 (Table 
6). 
 Many abundant ECM proteins were released at both early and later time 
points (Table 5). With IL-ȕstimulation, little distinction could be made between time 
points. Tenascin was an additional ECM protein found after IL-ȕ LQFXEDWLRQ IRU 
days. The same ECM proteins were identified in carprofen + IL-ȕ samples (Table 6).  
These data could be considered to be semi-quantitative. Increased levels of a 
protein will increase the probability of its peptides being detected during MS. Thus, a 
higher Mascot score will be associated with that specific protein. This effect could also 
be caused by decreases in other secretome proteins, as the relative amount of 
proteins compared to all the other proteins will affect the likelihood of it being 
detected. In the comparison of day 6 and day 18 MS analysis, carprofen reduced the 
Mascot scores of some proteins at day 18 therefore it could be considered that the 
amount of these proteins was reduced. For example, fibronectin attained scores of 
1881, 821 and 1191 at day 6, while these were decreased to 253, 277 and 280 at day 
18. Also, cartilage intermediate layer protein 1 (CILP-1) was not detected at day 18 
with carprofen + IL-ȕZKLOHLWZDVLGHQWLILHGLQDOOWKUHHFRUUHVSRQGLng replicates after 
6 days. 
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 In terms of non-ECM secreted proteins; nine were identified at IL-ȕ'D\ 
and eleven for IL-ȕDWGD\Table 5). Carprofen + IL-ȕDQDO\VLVLGHQWLILHGWHQQRQ-
ECM proteins at day 6 and only six at day 18 (Table 6). Certain non-ECM secreted 
proteins were identified at specific time points (e.g. YKL-40 & Procollagen C-
endopeptidase enhancer 2 (PCOC-2) in early and C-C motif chemokine 20 (CCL20) in 
late time points).  
A wide range of intracellular proteins were released from cartilage explants in 
response to IL-ȕ 7KH PDMRULW\ RI LQWUDFHOOXODU SURWHLQV ZHUH LGHQWLILHG LQ ,/-ȕ
samples at day 6, with considerably less intracellular proteins identified in IL-ȕGD\
18 samples (Table 5). A number of DNA associated histone proteins were identified at 
the IL-ȕ GD\  &RPSDULVRQ RI IL-ȕ VWLPXODWLRQ DORQH YHUVXV IL-ȕ  FDUSURIHQ 
treatments at day 18, showed higher amounts of intracellular protein identifications 
with IL-ȕ DORQH Differences in amounts of intracellular proteins present between 
treatment groups is demonstrated by identification of twenty-nine intracellular proteins 
in IL-ȕVDPSOHV Table 5), with only six identified with carprofen + IL-ȕ Table 6). 
Presence of intracellular proteins suggests cell death and therefore the release of 
proteins usually contained within chondrocytes. These findings that carprofen reduces 
intracellular protein identifications is consistent with its ability to decrease 
inflammation and therefore associated cell death.  
Certain proteins identified did not originate from cartilage explants but were 
added during sample processing or introduced by contamination. Firstly, bovine 
serum albumin (BSA) is included as a carrier protein for IL-1ɴ. Pancreatic trypsin 
inhibitor (BPT1_BOVIN) is a component of the protease inhibitor cocktail that was 
added during sample collection to reduce protein degradation. Trypsin is introduced to 
digest proteins into peptides prior to MS analysis, therefore autocatalysis fragments of 
trypsin are expected to be found. Although every attempt was made to reduce 
exposure during proteomics work, keratin is a source of contamination from dust, skin 
or hair during sample processing. 
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Table 5. Proteins identified using high-throughput MS in IL-ȕVDPSOHVat day 6 and day 18 of time course B 
Mascot scores are shown for proteins detected in each of three replicates at each time point after searches of Swiss-Prot 2013_01 (all mammalian entries) 
database. Only Mascot scores >37 indicating identity/extensive homology are included. Identifications organised into ECM proteins, Non-ECM Secreted 
Proteins and Intracellular Proteins. Proteins in order of highest Mascot score in IL-ȕ day 6. * indicates proteins where highest homology/Mascot scores 
corresponded to different species or isoforms therefore only the top scoring Swiss-Prot entry name is mentioned. 
  IL-ȕ'D\ (3 replicates) IL-ȕ'D\ (3 replicates) 
Protein Name Accession 1 2 3 1 2 3 
 
 Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
ECM proteins              
COMP COMP_BOVIN 8118 14 20793 16 9026 17 8253 16 18586 19 11318 16 
Fibronectin FINC_HUMAN 1037 15 1964 22 1042 20 1161 27 926 22 789 21 
Aggrecan core protein PGCA_HUMAN 1117 12 1744 15 1648 13 917 12 975 10 1015 11 
Chondroadherin CHAD_HUMAN 210 4 1610 7 1554 6 1570 11 2064 10 3157 12 
Fibromodulin FMOD_HUMAN 333 5 1444 6 918 7 1324 7 1454 6 1290 8 
Biglycan* PGS1_BOVIN 965 5 1571 7 1045 6 1828 10 4199 12 4247 11 
Decorin PGS2_HORSE 1428 5 1021 5 895 5 906 10 865 6 1445 9 
Thrombospondin-1 (TSP-1) TSP1_HUMAN 773 13 808 12 835 7 571 14 61 6 741 15 
CILP-1* CILP1_MOUSE 69 4 474 7 220 6 156 4 236 8 110 5 
Prolargin PRELP_MOUSE 43 2 88 4 123 2 245 5 405 4 406 4 
Proteoglycan 4 (lubricin) PRG4_HUMAN     86 6       
Asporin ASPN_BOVIN   46 3   113 3 49 2   
Collagen alpha-1(II) chain CO2A1_RAT       94 6     
Tenascin TENA_HUMAN       89 9     
Collagen alpha-2(I) chain CO1A2_HUMAN       47 4     
 
             
Non-ECM Secreted Proteins              
MMP-3 MMP3_HORSE 4280 15 5116 13 4486 12 2459 18 3378 14 1340 11 
Clusterin CLUS_HORSE 1800 6 1347 8 1435 8 481 5 317 6 163 3 
MMP-1 MMP1_HORSE 545 5 334 5 235 3 1176 20 712 11 67 4 
Serum Amyloid A protein* SAA_HORSE 285 4 108 4 176 5 177 4 65 4 85 2 
TNF receptor 11B* TR11B_MOUSE   173 1 153 3 94 2     
Chitinase-3-like protein (YKL-40) CH3L1_BOVIN   40 3 81 2       
Lysozyme C* LYSC2_HORSE   38 2 80 5 56 2 40 1 116 2 
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MMP-13 MMP13_HORSE   58 4   1339 13 828 10 254 4 
Procollagen C-endopeptidase enhancer 2 PCOC2_HUMAN     44 3       
Annexin A5 ANXA5_HUMAN       93 3 62 1 98 6 
C-x-C motif chemokine 6 CXCL6_BOVIN       63 1 40 1   
Coagulation factor XIII A chain F13A_MOUSE       61 2     
C-C motif chemokine 20 CCL20_BOVIN       44 2     
 
             
Intracellular Proteins              
Vimentin* VIME_MOUSE 574 10 1525 9 1796 16 628 13 248 6 405 9 
Enolase* ENOA_BOVIN     211 5       
Pyruvate kinase isoform M1/M2 KPYM_FELCA   61 5 248 9       
Phosphatidylenolamine-binding protein 1* PEBP1_BOVIN   122 2 163 1       
Thioredoxin THIO_HORSE 80 1   133 1       
POTE ankyrin domain family member F POTEF_HUMAN     115 8       
Phosphoglycerate Kinase 1 PGK1_HORSE     94 6       
L-lactate dehydrogenase A chain LDHA_BOSMU     81 3       
Transcription termination factor 1 TTF1_HUMAN 67 3 44 6 43 4 37 7 39 5   
Transaldolase TALDO_HUMAN     49 2       
Glutathione S-transferase P GSTP1_MACMU     47 2       
Putative polycomb group protein ASXL3 ASXL3_HUMAN     45 4       
Rho guanine nucleotide exchange factor 40 ARH40_MOUSE   44 3         
Sodium/hydrogen exchanger 2 SL9A2_RABIT   41 3 39 2 42 2 59 3 37 2 
POTE ankyrin domain family member E POTEE_HUMAN   39 4         
Phosphoglycerate mutase 1 PGAM1_BOVIN     39 1       
Sperm equatorial segment protein 1 SPESP_MOUSE 39 2           
Inositol 1, 4, 5-trisphosphate receptor type 2 ITPR3_RAT   38 9         
Adenomatous polyposis coli protein 2 APC2_MOUSE   37 13         
Purine nucleoside phosphorylase PNPH_HUMAN     37 3       
Triosephphosphate isomerase TPIS_BOVIN     37 2       
Histone H4* H4_BOVIN       363 7 250 5 459 5 
Transmembrane protein 104 TM104_PONAB       45 2     
Metallothionine 1-A MT1A-BOVIN       44 1     
Rho guanine nucleotide exchange factor 10-
like protein 
ARGAL_MOUSE        
39 
     
MMP-25 MMP25_MOUSE       38 5     
Solute carrier family 28 member 3 S28A3_MOUSE           38 3 
Transmembrane protein 87A TM87A_HUMAN       37 3     
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Other proteins              
Pancreatic trypsin inhibitor BPT1_BOVIN 192 2 57 3 194 2 316 2 318 2 417 2 
BSA ALBU_BOVIN   49 4 43  1046 26 913 17 1075 17 
Trypsin TRYP_PIG         37 4 78 2 
  
8
7
 
Table 6. Proteins identified using high-throughput MS in IL-ȕFDUSURIHQVDPSOHVat day 6 and day 18 of time course B 
Mascot scores are shown for proteins detected in each of three replicates at each time point after searches of Swiss-Prot 2013_01 (all mammalian entries) 
database. Only Mascot scores >37 indicating identity/extensive homology are included. Identifications organised into ECM proteins, Non-ECM Secreted 
Proteins and Intracellular Proteins. Proteins in order of highest Mascot score in IL-ȕ + carprofen day 6. * indicates proteins where highest homology/Mascot 
scores corresponded to different species or isoforms therefore only the top scoring Swiss-Prot entry name is mentioned. 
  IL-ȕFarprofen Day 6 (3 replicates) IL-ȕFarprofen Day 18 (3 replicates) 
Protein Name Accession 1 2 3 1 2 3 
  Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
ECM Proteins              
COMP COMP_BOVIN 8477 17 9934 18 8950 14 12626 16 10080 13 7244 14 
Aggrecan core protein PGCA_HUMAN 2012 12 1946 10 1578 11 2856 10 1592 8 1091 9 
Fibronectin FINC_HUMAN 1881 23 821 22 1191 18 253 19 277 11 280 15 
Chondroadherin* CHAD_HUMAN 1560 7 640 6 1334 5 93 4 48 5   
Fibromodulin FMOD_HUMAN 1455 6 974 6 646 5 103 4 170 5 52 4 
Decorin PGS2_HORSE 1241 9 1168 8 1382 5 618 6 880 7 661 7 
Thrombospondin-1 (TSP-1) TSP1_HUMAN 1381 17 266 10 1297 13 309 9 61 5 184 10 
Biglycan PGS1_BOVIN 1275 8 861 4 1201 6 206 4 101 4 95 3 
CILP-1 CILP1_PIG 275 6 141 6 101 3       
Prolargin PRELP_MOUSE 199 5 181 3   72 5 79 4 122 3 
Collagen alpha-2(VI) chain CO6A2_HUMAN 56 3           
Collagen alpha-1(II) chain CO2A1_RAT       72 4   47 5 
              
Non-ECM Secreted Proteins              
MMP-3 MMP3_HORSE 2596 13 1189 11 1552 10 362 9 431 7 343 8 
Clusterin CLUS_HORSE 810 8 646 5 1035 6 53 3 65 2 48 3 
TNF receptor 11B TR11B_RAT 234 4 227 2 83 1 39 1     
TIMP-1 TIMP1_HORSE 91 2           
MMP-13 MMP13_HORSE 57 4 75 1         
Serum Amyloid A protein* SAA_HORSE   51 2   61 2 57 2 40 2 
Chitinase-3-like protein (YKL-40) CH3L1_BOVIN 39 10 49 1 39 1       
Lysozyme C LYSCK_SHEEP   48 2         
MMP-1 MMP1_HORSE 47 2     53 2     
Procollagen C-endopeptidase PCOC2_HUMAN   39 2         
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enhancer 2 
C3 and PZP-like alpha-2-
macroglobulin domain containing 
protein 8 (Complement C4-A) 
(CPAMD8) 
 
CPMD8_HUMAN 
        52 6 45 4 
              
Intracellular Proteins              
Vimentin VIME_MOUSE 451 5   221 3     64 4 
Enolase ENOA_BOVIN 45 1           
Transcription termination factor 1 TTF1_HUMAN 39 5 44 3   62 5     
Transmembrane protein 87A TM87A_HUMAN     39 2       
Rho guanine nucleotide exchange 
factor 40 
ARH40_MOUSE 38 6           
              
Other proteins              
Pancreatic trypsin inhibitor BPT1_BOVIN 294 3 304 2         
BSA ALBU_BOVIN 102 5 37 2 52 3 39 1     
Trypsin TRYP_PIG   38 1 50 1   81 2 55 1 
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3.3.3. Comparison of proteins detected in untreated control and IL-ȕstimulated 
explant secretomes 
 Working towards the aim of applying the explant model for screening of anti-
inflammatory compounds, it was important to gather information on proteins affected 
by IL-ȕReversal of IL-ȕVWLPXODWHGSURFHVVHVZRXOGDllow assessment of an anti-
inflammatories ability to halt degradation. After time course B evaluation, it was 
concluded that supernatants collected after 6 days would provide the most 
appropriate incubation time for secretome studies. An incubation time of 6 days 
showed increased protein bands visible in SDS-PAGE profiles (Figure 16) and 
achieved highest quality MS data in the previous section.  
In this study, untreated control and IL-ȕ H[SODQW VXSHUQDWDQWV IURP DQ
individual horse and a pool of three horses was analysed by high-throughput MS, and 
organized into groups of ECM, secreted and intracellular proteins (Figure 17 and 
Table 7). These semi-quantitative data indicates altered levels of release some 
proteins. For example, MMP-3 was identified in all samples (untreated and IL-ȕEXW
Mascot scores for IL-ȕsamples were higher (5441, 4580) than for untreated controls 
(653, 956). This observation is supported by quantitative western blotting reported in 
Chapter 5. 
Fifteen ECM proteins were identified across all samples (Table 7). The only 
distinct difference in ECM proteins between treatments was the presence of collagen 
types VI and X, and SPARC (secreted protein acidic and rich in cysteine) in untreated 
controls. Collagen type II was present in both treatments. Twenty-one non-ECM 
proteins were detected in untreated supernatant, while seventeen were identified with 
IL-ȕ 0any non-ECM proteins were associated with one treatment group. TIMP-2, 
extracellular superoxide dismutase (SODE), PCOC-2, SFRP-3, connective tissue 
growth factor (CTGF), augurin, ceruloplasmin, integrin beta-like protein 1, melanoma-
derived growth regulatory protein (MIA) and insulin-like growth factor-binding protein 7 
(IGFBP7) were identified only in untreated control samples. MMP-1, MMP-13, heat 
shock 70kDa protein 1-like (HSP70), S-100 protein-A1, MIF, semaphorin-3C and C-X-
C motif chemokine 6 (CXCL6) were detected only after IL-ȕVWLPXODWLRQ. Intracellular 
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proteins were also identified in both untreated control (8 proteins) and IL-ȕ  
proteins) MS analysis, therefore IL-ȕVWLPXODWLRQ LQFUHDVHGQXPEHUVRI LQWUDFHOOXODU
proteins detected (Figure 17). These intracellular proteins should be contained within 
chondrocyte cytoplasm and organelles, therefore their detection is indicative of cell 
death. 
Separate databases contain differences in protein entries, therefore the 
choice of database may affect proteins identified by Mascot searches. Some 
additional identifications of released explant proteins were made when searching the 
NCBInr database (Table 8) rather than Swiss-Prot. Glia derived nexin is a serpin, 
while matrix Gla protein-like is involved with calcium binding. Osteopontin is found in 
the mineralized matrix, and CILP-2 forms interactions within the cartilage matrix. Beta-
defensins are secreted proteins with anti-bacterial functions. Although these extra 
identifications were made, many more relevant proteins were reliably identified in the 
Swiss-Prot database searches that were not identified in NCBInr searches. Therefore, 
the decision was made to concentrate on reporting MS identifications from Swiss-Prot 
throughout this thesis. 
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Table 7. Swiss-Prot protein identifications in untreated control and IL-ȕcultures with high-throughput MS 
Only Mascot scores >38 indicating identity/extensive homology are listed. Proteins identified are grouped into ECM, Non-ECM and Intracellular, and ordered 
by the highest Mascot scores in untreated samples. Database searched: Swiss-Prot 2013_01 (all mammalian entries). 
Protein Accession  Individual 
Untreated 
 
Pool  
Untreated 
 
Individual 
IL-ȕ 
Pool  
IL-ȕ 
 
  Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
ECM Proteins          
Cartilage oligomeric matrix protein COMP_BOVIN 4090 18 4763 17 7555 20 10590 21 
Fibronectin FINC_BOVIN 4422 41 6222 42 3786 40 3492 34 
Aggrecan core protein PGCA_HUMAN 1815 15 3389 16 2258 13 6412 14 
Fibromodulin FMOD_HUMAN 1307 9 3200 7 1381 6 1930 8 
Chondroadherin CHAD_HUMAN 1022 8 3069 6 1978 8 3689 8 
Thrombospondin 1 (TSP-1) TSP1_BOVIN 741 20 1256 13 3456 28 2782 21 
Biglycan PGS1_HORSE 1099 12 1062 10 2047 11 1720 9 
Decorin PGS2_HORSE 665 13 802 10 513 9 1130 8 
Cartilage intermediate layer protein 1 (CILP-1) CILP1_MOUSE 201 10 789 10 423 19 264 11 
Collagen alpha-2(VI)chain CO6A2_HUMAN 190 8 79 2     
Prolargin PRELP_MOUSE 124 5 147 5 311 6 301 2 
Proteoglycan 4 (Lubricin) PRG4_HUMAN 139 7 49 6   59 6 
Collagen alpha-1(II) chain CO2A1_BOVIN 137 15 59 10 139 9 82 8 
SPARC (secreted protein acidic, cysteine rich) (osteonectin) SPRC_PIG 108 4 96 5     
Collagen alpha-1(X) chain COAA1_MOUSE 77 2 102 4     
          
Non-ECM Secreted Proteins          
Clusterin CLUS_HORSE 2767 16 4723 16 1785 13 4876 14 
Chitinase-3-like protein 1 (YKL-40) CH3L1_BOVIN 574 6 1178 5 414 6 2018 5 
MMP-3 MMP3_HORSE 653 11 956 10 5441 20 4580 17 
Alpha-1-antiproteinase 2 A1AT2_HORSE 99 7 342 3 50 3   
TNF-R superfamily, member 11b (Osteoprotegerin) TR11B_RAT 252 4 319 3 388 6 638 4 
Metalloproteinase inhibitor 1 TIMP1_HORSE 83 5 312 4 457 4 146 3 
Procollagen C-endopeptidase enhancer 2 (PCOC-2) PCOC2_HUMAN 163 8 171 4     
Lysozyme C LYSM_BOVIN 72 1 168 2 179 3 148 2 
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Secreted frizzled-related protein 3 (SFRP) SFRP3_BOVIN 74 6 98 8     
Lactadherin MFGM_PIG 83 1 63 2   54 3 
Ceruloplasmin CERU_RAT   75 6     
Extracellular superoxide dismutase [Cu-Zn] (SODE) SODE_HUMAN 67 3 72 2     
Integrin beta-like protein 1 ITGBL_MOUSE 56 4       
Serum amyloid A protein SAA_HORSE   55 2 219 4 436 44 
 SAA_CANFA 43 2       
Connective tissue growth factor (CTGF) CTGF_MOUSE   55 3     
Augurin AUGN_HUMAN 54 1       
Ribonuclease 4 RNAS4_HUMAN   48 2 46 1 59 2 
Metalloproteinase inhibitor 2 TIMP2_CANFA   47 5     
Melanoma-derived growth regulatory protein (MIA) MIA_HUMAN 47 2       
Insulin-like growth factor-binding protein 7 IBP7_HUMAN 46 5       
MMP-13 MMP13_HORSE     1700 20 699 12 
MMP-1 MMP1_HORSE     1678 23 1586 20 
S-100 protein-A1 S10A1_BOVIN     383 1   
Macrophage migration inhibitory factor (MIF) MIF_HUMAN     91 2 86 2 
Heat shock 70kDa protein 1-like HS71L_MOUSE     62 8 74 4 
Semaphorin-3C SEM3C_HUMAN     47 6   
C-X-C motif chemokine 6 CXCL6_HORSE     44 2   
          
Intracellular proteins          
L-lactate dehydrogenase A chain LDHA_BOSMU     176 7 134 6 
Vimentin VIME_PIG     2361 24 3837 31 
 VIME_PANTR   84 4     
Transcription factor E3 TFE3_HUMAN 47 2       
DnaJ homolog subfamily C member 14 DJC14_BOVIN   43 3     
Sodium/hydrogen exchanger 2 SL9A2_RABIT 42 3   71 4   
Serine-protein kinase ATM ATM_PIG   42 9     
Alcohol dehydrogenase [NADP(+)] fragment AK1A1_CRIGR   42 3 72 5   
Phosphoglycerate kinase 1 PGK1_HORSE     792 15 651 8 
Alpha-enolase ENOA_BOVIN     506 13 686 11 
Pyruvate kinase isoforms M1/M2 KPYM_HUMAN     488 10 245 8 
Phosphatidylethanolamine-binding protein 1 PEBP1_HUMAN     423 4 229 5 
Triosephosphate isomerase TPIS_CANFA     246 5   
14-3-3 protein epsilon 1433E_BOVIN     211 4   
Glyceraldehyde 3-phosphate dehydrogenase  G3P_PIG     208 5 115 3 
Purine nucleoside phosphorylase PNPH_HUMAN     175 6 134 5 
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Phosphoglycerate mutase 1 PGAM1_MOUSE     170 7 104 7 
Thioredoxin THIO_HORSE     145 2 143 1 
Glutathione S-transferase GSTP1_PIG     119 3   
Superoxide dismutase [Mn], mitochondrial SODM_HORSE     102 1   
Fructose-bisphosphate aldolase A ALDOA_RABIT     101 8   
Actin, alpha skeletal muscle ACTS_BOVIN       88 6 
Metallothionein-1A MT1A_BOVIN       86 2 
Metallothionein-1E MT1E_PIG     85 3   
Gelsolin GELS_BOVIN     83 4   
Glycogen phosphorylase, brain form PYGB_PONAB     60 7   
Tripartite motif containing protein 46 TRI46_HUMAN       59 1 
Peptidyl-prolyl cis-trans isomerase A PPIA_AOTTR       51 3 
Transmembrane protein PVRIG_HUMAN     45 2   
Transaldolase TALDO_CRIGR     43 5   
Ras GTPase-activating protein 4 RASL2_MOUSE       43 4 
          
 Other          
Pancreatic trypsin inhibitor BPT1_BOVIN 283 2 477 2 281 2 703 2 
Keratin, type II cytoskeletal 3 K2C3_RABIT 151 4 277 2 110 4 82 6 
Trypsin TRYP_PIG 111 3   106 2 746 3 
Serum Albumin ALBU_BOVIN     283 11 86 8 
Uncharacterised protein C12orf55 homolog CL055_MOUSE       44 3 
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Table 8. Searching NCBInr database provides certain additional protein identifications in untreated control and IL-ȕFXOWXUHs with high-throughput MS 
Mascot scores >65 indicating identity/extensive homology. 
Protein Accession  Individual 
Untreated 
Pool  
Untreated 
Individual 
IL-ȕ 
Pool  
IL-ȕ 
  Mascot score Mascot score Mascot score Mascot score 
Osteopontin-like isoform 1 gi|149701529 544 394 131 323 
Matrix Gla protein-like gi|149713779 173 326 - 74 
Cartilage intermediate layer protein 2 gi|194223805 195 144 302 - 
Glia-derived nexin isoform 2 gi|149711173 81 104 81 - 
Beta-defensin-1 precursor gi|126352458 64 57 44 94 
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Figure 17. Classification of proteins identified from MS analysis of untreated and IL-ȕ
explant cultures 
Protein classifications based on information within the UniProt database 
(http://uniprot.org). Precise details of protein identifications displayed in Table 7. Numbers 
represent amount of proteins in each classification group. 
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3.3.4. IL-1ɴ stimulated GAG release is delayed by carprofen 
 GAGs are important ECM components that contribute towards cartilage¶s 
compressible properties. Release of GAGs from cartilage explants in response to 
treatment conditions can be measured by DMMB assays. Measurements of % GAG 
release are displayed for time course B days 0-6 and 6-12 in Figure 18. The majority 
of inducible GAG release occurred over the first 12 days incubation with subsequently 
very low levels of GAG release and no significant differences between treatments 
(data not shown) at the two later time points: day 18 and day 24.  
Studies in this chapter showed significant increases in GAG release attributed 
to IL-ȕstimulation (40%) by comparison with untreated controls (13%). There was no 
effect on % GAG release due to carprofen treatment alone (11%), as parallel levels 
were recorded compared to untreated cultures (13%). During the first 6 days of 
incubation, carprofen significantly decreased IL-ȕVWLPXODWHG*$*UHlease from 40% 
down to 26%. At day 12, IL-ȕ*$*UHOHDVHZDVEXWZDVVLJQLILFDQWO\KLJKHUZLWK
carprofen + IL-ȕDW 27%. GAG release during this time point will have been affected 
by the amount of GAG already released from explant cultures during the first 6 days of 
incubation. Carprofen therefore delayed IL-ȕstimulated GAG release. Over the time 
course similar levels of GAGs were eventually discharged by IL-ȕ stimulation, 
whether carprofen is present or not. 
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Figure 18. Percentage GAG release at days 6 and 12 from time course B with IL-1ȕ 
stimulation and NSAID carprofen treatment 
The following treatments were applied: untreated control, IL-1E only (10 ng/ml), IL-1E (10 
ng/ml) + carprofen (100 µg/ml) or carprofen only (100 µg/ml). The % GAG release was 
measured at 6 day intervals during time course B, with results up to day 6 and day 12 
displayed. Explant culture time courses were completed in 3 separate animals, with 3 
treatment replicates for each study. ** = P < 0.001, *** = P < 0.0001. Error bars indicate 
Standard Deviation. 
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3.4. Discussion 
The aim of this chapter was to provide new insights into the secretome of 
equine articular cartilage to identify potential biomarkers for efficacy of treatment. 
Silver stained SDS-PAGE monitored changes in the secretome over time. Proteins 
released from untreated control explants and in response to pro-inflammatory cytokine 
IL-ȕ DQG 16$,' FDUSURIHQ were assessed by high-throughput MS. Insights into 
equine cartilage explant secretome were achieved throughout studies described. 
Protein identifications made that were not reported by Clutterbuck et al., 2011 
included MMP-13, collagen type II, SFRP and MIF. Contributing factors for additional 
identifications could include biological variation, improvements in technical 
instruments and updates in the sequence databases. All ECM or non-ECM secreted 
proteins identified by Clutterbuck et al., 2011 were also identified in studies in this 
thesis. Identified proteins were organised into corresponding specific treatment groups 
(e.g. untreated, IL-ȕ RU FDUSURIHQ  ,/-ȕ ZKLFK was not detailed in previous MS 
data (Clutterbuck et al., 2011).  
3.4.1. The search for biomarkers of treatment efficacy 
Proteins identified within the secretome could be investigated as candidate 
biomarkers of treatment efficacy to study anti-catabolic and anti-inflammatory effects. 
Potential efficacy biomarkers to highlight include biglycan, fibromodulin, 
chondroadherin and CILP-1, as release of these ECM proteins was reduced by 
carprofen treatment (when in combination with IL-1ɴ) compared to IL-1ɴ stimulation 
alone. IL-1ɴ stimulated non-ECM proteins reduced by carprofen included MMP-1, 
MMP-3 and MMP-13. These proteins therefore also hold potential as biomarkers and 
were further investigated by western blotting in chapter 5.  
Potential biomarkers require further verification and validation to determine 
their application as new biomarkers of efficacy according to recognised guidelines 
(Lee, 2009). The biomarkers highlighted in this thesis may only be relevant to 
screening in this specific equine model, or may be able to be characterised in the 
wider OA disease population and clinically relevant. For example, a neoepitope 
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collagen TIINE was first identified as released from human cartilage in vitro in 
response to cytokine stimulation and MMP activity (Nemirovskiy et al., 2007). An 
immunoaffinity LC-MS/MS assay was clinically validated to measure levels of collagen 
TIINE in urine to investigate this neoepitope as an OA biomarker (Li et al., 2007). 
Biomarkers originating in synovial joints can enter systemic circulation and therefore 
be detected in serum, plasma or urine (Firestein, 2008). After initial discovery of 
candidate biomarkers in vitro, a targeted approach should be applied to verify and 
quantify the biomarker in a designed cohort of individuals using an appropriate assay 
method, such as LC-MS/MS or ELISA. Clinical validation across higher numbers of 
the population can then be completed to confirm a biomarkers value. 
In this chapter, cytokine stimulation of explants was examined over 24 days in 
time course B using IL-ȕZKLFKLVDVVRFLDWHGZLWK(&0EUHDNGRZQLQ2$(Goldring 
and Goldring, 2007). High-throughput MS analysis showed changes in release of 
various proteins in response to IL-ȕVWLPXODWLRQ The NSAID carprofen was selected 
as an anti-inflammatory treatment throughout the time course because it is used to 
treat horses and dogs suffering from OA and other painful joint diseases. Synthesis of 
bioactive lipid PGE2 is inhibited by carprofen, because it specifically blocks COX-2. 
The treatments were selected to investigate high-throughput MS to identify 
biomarkers of anti-inflammatory treatment efficacy. Proteins identified showing semi-
quantitative differences based on Mascot scores using MS analysis, were selected for 
further analysis by western blotting, allowing a quantitative measurement of release 
described in chapter 5. 
3.4.2. ECM proteins identified 
3.4.2.1. Non-collagenous ECM proteins 
High-throughput MS analysis of explant cultures consistently identified many 
abundant ECM proteins released into supernatant. The non-collagenous proteins 
COMP, fibronectin, thrombospondin-1 (TSP-1), CILP-1, chondroadherin and tenascin 
found in this study, were identified in previous secretome studies, indicating that this 
model is consistent with similar models from other species (Hermansson et al., 2004, 
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De Ceuninck et al., 2005, Polacek et al., 2010). Furthermore, these proteins are 
biologically relevant and vital components of the ECM that could be further studied.  
One abundantly released component was COMP, a pentamer protein from 
the thrombospondin family (Hedbom et al., 1992). COMP binds to collagen fibres and 
fibronectin within the ECM, directing organisation of the structural matrix (Rosenberg 
et al., 1998, Di Cesare et al., 2002). COMP fragmentation has been demonstrated in 
vitro by stimulation of cartilage explants with IL-1 (Ganu et al., 1998). It is a potential 
predictive urinary biomarker of OA in horses after carpal bone fracture (Arai et al., 
2008).  
During the search for biomarkers of OA, it should be taken into account that 
specific post-translational modifications may distinguish a protein as a biomarker. 
Deamidated COMP with native Asn64 (asparagine) converted to Asp64 (aspartic 
acid), is a biomarker for OA located in the hip (Catterall et al., 2012). To determine if 
post-translational modifications were required to identify responses to IL-ȕMascot 
searches were carried out for deamidated modifications on MS data collected here. 
None were found, possibly because the explant model utilises healthy cartilage often 
from younger horses, while deamidation of COMP is associated with accumulation of 
this non-enzymatic modification in aged human OA cartilage (Catterall et al., 2012).  
Fibronectin has the ability to bind collagens and other cell surface proteins (Di 
Cesare et al., 2002). During OA, fragments of fibronectin are released and induce 
catabolic signalling through interaction with receptors in synovial joint cells 
(Homandberg et al., 1998, Homandberg et al., 2006). Tenascin can bind to 
proteoglycans (Burg et al., 1996) and cell surface integrins (Sriramarao and Bourdon, 
1993), and is known to contain a fibronectin III domain (Leahy et al., 1992). CILP-1 is 
a monomeric glycoprotein that is cleaved into two polypeptides and is mostly found in 
the intermediate zone of cartilage (Lorenzo et al., 1998). Up-regulation of CILP is 
associated with both early and later stages of OA (Lorenzo et al., 2004). The IL-ȕ
stimulated explant model is therefore able to simulate certain aspects of OA 
progression, as it produces release of these important ECM proteins that are released 
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during OA. The NSAID carprofen was shown to reduce the Mascot scores of many 
ECM proteins at day 18 of incubation compared to IL-1ɴ stimulated cultures. These 
included CILP-1 that was not detected at day 18 with carprofen + IL-1ɴ. Fibronectin 
Mascot scores were also lower with carprofen treatment as described in chapter 
3.3.2.2 and Table 6. 
3.4.2.2. Collagens 
&ROODJHQV SULPDULO\ W\SH ,, DUH HVVHQWLDO IRU SURYLGLQJ FDUWLODJH¶V tensile 
strength and stiffness. Explant experiments have previously shown that IL-1Į initiated 
loss of collagen causes tensile weakness (Temple et al., 2006). Peptides originating 
from collagen fibres have been identified across several cartilage secretome studies 
using 2DE and MS (Hermansson et al., 2004, Stevens et al., 2009, Polacek et al., 
2010). Collagen types II, VI and X were identified in MS based proteomic experiments 
in this thesis.  
Collagen type II identification (Table 7) had not previously been reported by 
MS in equine cartilage explant supernatant (Clutterbuck et al., 2011). Collagen 
release is increased after longer incubation times of cartilage with pro-inflammatory 
stimuli, as assessed by collagen ELISA and hydroxyproline assays (Sztrolovics et al., 
1999, Gabriel et al., 2010). Collagen type II identification was also made in untreated 
healthy cartilage explant supernatant as shown in Table 7. The half-life of collagen in 
cartilage is reported to be around 117 years (Verzijl et al., 2000). Release of collagen 
fragments from the healthy cartilage explants described in this thesis may be a result 
of stresses occurring during the experimental culture process. Analysis of time course 
B day 18 did not show increased identification of collagen peptides (Table 5) 
compared to day 6 samples. Collagen types VI and X were only identified in untreated 
cultures (Table 7), indicating that IL-ȕ stimulation may affect the identification of 
these collagen fibres. This could be due to inhibition of synthesis of collagen types VI 
and X, or because they are only detected in the absence of abundant proteins 
released in response to IL-ȕ The pericellular matrix located around chondrocytes 
contains a high proportion of type VI collagen, helping to bind cells with the 
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surrounding ECM (Poole et al., 1988). Collagen type X is produced by chondrocytes 
and is usually found within the calcified zone of cartilage (Gannon et al., 1991). 
Synthesis of six fibrillar collagen types is reported to be decreased by IL-ȕDQG71)-
Į ZLWKLQ H[SODQW FXOWXUH (Stevens et al., 2009). Collagen consists mostly of proline, 
hydroxyproline and glycine, therefore Mascot searches with hydroxyproline as a 
modification were completed on some MS data (from time course A day 18 - data not 
shown). This identified increased Mascot scores and hits to collagen from many 
species including equine collagen type II,  
3.4.2.3. Proteoglycans 
Analysis of explant cultures shows a range of proteoglycans are released 
from cartilage (Steinberg et al., 1979), including small proteoglycans that are 
commonly detected (Polacek et al., 2010, Clutterbuck et al., 2011). In the studies 
described in this chapter, small leucine-rich proteoglycans like biglycan, decorin, 
fibromodulin, chondroadherin and prolargin were identified, as well as asporin which is 
not widely reported in secretome studies. Asporin inhibits TGF-ȕVLJQDOOLQJ in human 
articular cartilage, having consequences on expression of chondrogenesis and 
cartilage specific genes (Nakajima et al., 2007). Increased expression of an asporin 
polymorphism in cartilage is associated with OA (Kizawa et al., 2005). 
The effect on carprofen on IL-1ɴ stimulated explant cultures aided the search 
for potential ECM biomarkers of NSAID treatment efficacy such as proteoglycans 
biglycan, chondroadherin and fibromodulin. Decreased release of these proteoglycans 
was observed after MS analysis of carprofen + IL-1ɴ samples compared to IL-1ɴ 
alone after 6 days incubation, and more noticeably after 18 days of incubation. 
Proteoglycans including decorin, biglycan, fibromodulin, chondroadherin and 
prolargin, bind to collagen fibrils to support correct fibre formation and maintain the 
rate of assembly (Hedbom and Heinegard, 1989, Oldberg et al., 1989, Mansson et al., 
2001, Bengtsson et al., 1995). These small proteoglycans continue to bind collagen 
fibres after formation and play an important role in cross-linking to other ECM 
components (Heinegard, 2009).  
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Lubricin (also known as proteoglycan 4) is secreted at the superficial zone of 
cartilage, aiding maintenance of a smooth and lubricated surface for joint movement 
(Schmidt et al., 2004). The link proteins that are responsible for binding together large 
chains of glycosylated side chains in aggrecan were also identified, namely: aggrecan 
core protein and HAPLN1. The proteoglycan lumican, was not identified in this study, 
but has been in previous secretome studies using gel fractionation prior to MS 
(Polacek et al., 2010). High-throughput MS used in this thesis cannot identify all 
proteins present in the secretome, due to the complexity of samples and the presence 
of high abundance proteins. Attempts of increase additional MS identifications were 
therefore made in chapter 4, using abundant proteins depletion approaches. 
The proteoglycans identified in equine cartilage explant supernatant studies 
are consistent with previous cartilage secretome studies (Chapter 1, Table 1). Small 
proteoglycans have vital roles in the ECM constituent binding and organisation 
(Heinegard, 2009). Therefore it may be expected that IL-ȕVWLPulated catabolism of 
the ECM would increase release of these proteoglycans. This was not observed in 
these studies using MS proteomic analysis. Detectable levels of small proteoglycans 
were continually present in untreated control cultures therefore these may be leaking 
out of the ECM, or being secreted straight into the supernatant. 
3.4.2.4. ECM proteins modulated by stimuli 
Certain collagen proteins displayed differences between untreated and IL-ȕ
stimulated explants (Table 7). Collagen type II was identified across all explant 
cultures, but collagen types VI and X were only identified in untreated cultures. 
Chondrocytes control collagen synthesis, therefore IL-ȕDSSHDUVWRKDYHDQHJDWLYH
impact on their ability to synthesize and turnover these fibrous proteins. Another ECM 
protein only identified in untreated controls was SPARC. SPARC has roles in calcium 
mineralization, signalling during development and cellular processes, and binds with 
collagen (Motamed, 1999).  
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3.4.3. Non-ECM proteins 
Limited variation in ECM protein release was shown comparing untreated and 
IL-ȕ treatment, while there were more obvious alterations in secreted non-ECM 
proteins (Table 7). Additional insights into alterations of non-ECM secreted proteins 
may have been available if abundant ECM proteins did not hinder additional MS 
identifications. Approaches were taken in chapter 4 of this thesis to remove abundant 
ECM proteins in an attempt to increase secreted protein identifications.  
Decreases in a MMP-3 containing band due to carprofen were shown by 
SDS-PAGE and silver stained images from both time course studies. MMP-3 is a 
catabolic protease induced during inflammation by IL-ȕ ZLWK WKHDbility to degrade 
collagens and proteoglycans (Shiomi et al., 2010). Activation of procollagenases 
MMP-1 and MMP-13 is also initiated by MMP-3 activity (Nagase and Woessner, 
1999). 
Serum amyloid protein (SAA) has consistently been present in untreated and 
cytokine treated supernatants, and is an inflammatory related component (Sipe, 
1995). Studies have measured SAA in serum and synovial fluid as a diagnostic 
marker of inflammatory activity in degenerative joint diseases in dogs (Kjelgaard-
Hansen et al., 2007). Another identified protein, YKL-40 that was detected in several 
IL-1ȕ DVVRFLDWHG VDPSOHV LQ WKLV WKHVLV has been suggested as a biomarker in a 
range of different diseases (Prakash et al., 2013). This glycosylated protein is thought 
to be involved in tissue remodelling and signalling, although the precise mechanisms 
of its biological function require further research. Increased levels of YKL-40 in serum 
are associated with OA (Conrozier et al., 2000). Interestingly, increased expression of 
YKL-39 was recorded in OA cartilage while YKL-40 expression was not increased 
(Steck et al., 2002). Macrophages and synovial cells are the likely source of YKL-40, 
therefore providing rises of YKL-40 in OA serum (Steck et al., 2002). 
3.4.4. Untreated control secretome associated secreted proteins 
Proteins identified in untreated control supernatants, but not after IL-ȕ
stimulation included: TIMP-2, SODE, PCOC-2, SFRP, CTGF, augurin, ceruloplasmin, 
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integrin beta-like protein 1, MIA and insulin-like growth factor-binding protein 7 
(IGFBP7). Extracellular space is protected from reactive oxygen species by SODE, 
which catalyses breakdown of superoxide radicals into H2O2 and O2. A reduced ability 
of chondrocytes to protect themselves from radicals could increase cell death and 
have negative implications on maintenance of cartilage.  
PCOC-2 binds to procollagen C-terminal propeptide and aids its cleavage by 
bone morphogenetic protein-1 (BMP-1) into the mature collagen form, allowing 
incorporation into the ECM (Steiglitz et al., 2002). New cartilage is processed into its 
final fibrillar form to provide the ECM with strength and stability, therefore IL-ȕPD\
be interfering with collagen turnover.  
Another protein only identified in untreated controls was SFRP, a modulator of 
Wnt signalling pathways. SFRP inhibits Wnt activation through blockage of frizzled 
receptors, therefore stopping activation of this signalling pathway (Luyten et al., 2009). 
This has implications on cell development, migration and proliferation (Luyten et al., 
2009). IL-ȕ LQWHUUXSWLRQ RIRUGLQDU\ FHOOXODU VLJQDOOLQJ WKURXJK GHFUHDVHG UHOHDVHRI
SFRP and other signalling factors such as CTGF, MIA and IGFBP7 will affect 
chondrocytes ability to maintain healthy cartilage.  
3.4.5. IL-ȕVWLPXODWHGVHFUHWRPHDVVRFLDWHGVecreted proteins 
Certain important catabolic proteins in OA associated cartilage degradation 
including ADAMTS and cathepsin family members (Troeberg and Nagase, 2012) were 
not detected in the IL-ȕVWLPXODWHGH[SODQWVHFUHWRPH. However, release of several 
additional proteins was initiated by IL-ȕ VWLPXODWLRQ RI FDUWLODJH H[SODQWV &DWDEROLF
proteases MMP-1 and MMP-13 were only identified with IL-ȕ VWLPXODWLRQ ZKLOH
Mascot scores for MMP-3 were noticeably higher. Further in depth western blot 
analysis of MMP-1, MMP-3, and MMP-13 release in this explant model is detailed in 
chapter 5 of this thesis. Secretion of the pro-inflammatory cytokine MIF, was also 
detected with IL-ȕVWLPXODWLRQ. This cytokine can increase expression of MMP-1 and 
MMP-3 in synovial fibroblasts (Onodera et al., 2000). Increasingly higher levels of 
serum and synovial MIF are observed in OA knee patients compared to normal 
 106 
 
controls (Liu and Hu, 2012). The chaperone HSP70, calcium binding protein S-100 
protein A-1, semaphorin-3C and chemokine CXCL6 were identified in IL-ȕVWLPXODWHG
samples. The identifications of IL-ȕ DVVRFLDWHG LQIODPPDWRU\ SURWHLQV LQ WKHVH
studies, has demonstrated the utility of the cartilage explant model in combination with 
high-throughput MS. These approaches have identified inflammatory related proteins 
as potential biomarkers including MMP-1, MMP-3, MMP-13, MIF, HSP70 and CXCL6, 
which could be applied to monitor anti-inflammatory effects.  
3.4.6. Effects of carprofen on non-ECM secreted proteins 
Carprofen also affected release of several IL-ȕVWLPXODWHGQRQ-ECM 
proteins, which included reducing the Mascot scores of MMP-3 and clusterin at later 
stages of the time course. MMP-13, YKL-40 and lysozyme C were not observed after 
18 days when carprofen was present. Interestingly, CPAMD8 (C3 and PZP-like, 
alpha-2-macroglobulin domain containing 8) was only detected after 18 days of 
incubation with carprofen + IL-ȕ7KLVVHFUHWHGFRPSOHPHQWSURWHLQLVVKRZQWRELQG
heparin to become membrane associated (Li et al., 2004). CPAMD8 has likely 
functions in innate immunity like other complement family proteins (Li et al., 2004). 
Complement family proteins in synovial fluid have been associated with OA in a 
number of studies (chapter 1.6.6.), therefore further studies on CPAMD8 may provide 
insights into OA processes. 
3.4.7. Intracellular protein release from cartilage explants 
Identification of intracellular proteins increased with IL-ȕ stimulation, 
compared to untreated cultures. IL-ȕ LV NQRZQ WR FDXVH FHOO GHDWK WKHUHIRUH
increased death/lysis of chondrocytes will release proteins expected to be located in 
the nucleus and cytoplasm (Caramés et al., 2008). :HVWHUQ EORWWLQJ RI ȕ-actin was 
used as an indirect assessment of levels of chondrocyte lysis in these explant culture 
studies (data described in appendix 1). ȕ-actin release was only detected in cultures 
with treatments containing IL-ȕDIWHUGD\VRILQFXEDWLRQZKLOHFDUSURIHQWUHDWPHQW 
alone GLG QRW FDXVH DQ LQFUHDVH LQ ȕ-actin release. Release of another intracellular 
protein, lactate dehydrogenase (LDH) can also be used as a measure of cytotoxicity. 
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LDH measurements on explant cultures treated with IL-ȕ VKRZHG LQFUHDVHG /'+
release with cytokine stimulation, which was not significantly altered by carprofen 
treatment (data not shown). 
The cytoplasmic proteins vimentin and enolase are often observed during 
proteomic investigations and tend not to be specific to any particular disease or 
species (Wang et al., 2009b, Petrak et al., 2008). Enolase has diverse biological roles 
and is suggested to be a marker of pathological stress in several diseases (Diaz-
Ramos et al., 2012). Due to the high sensitivity of MS approaches, proteins released 
due to minor levels of cell death may be identified. Indeed, the presence of 
intracellular proteins has been reported in other proteomic studies of cartilage 
conditioned media (Wilson et al., 2008, Stevens et al., 2008, Polacek et al., 2010, 
Clutterbuck et al., 2011). Small amounts of cell lysis may release sufficient 
intracellular proteins to hinder MS identification of some low level secreted proteins. 
Commonly identified intracellular proteins include metabolic enzymes such as 
pyruvate kinase and phosphoglycerate kinase, which were identified in this chapter 
and the studies mentioned above. 
The MS analysis of the day 18 IL-ȕstimulated explant supernatant revealed 
the presence of histone proteins. Histone aids formation of nucleosomes that enable 
DNA to be compacted within chromosomes. Release of histones specifically at this 
time point could indicate that prolonged IL-ȕ H[SRVXUH FDXVHV UHOHDVH RI these 
proteins. Another nuclear protein found in the explant cultures was transcription 
termination factor 1. Comparison of the data in Table 5 and Table 6, shows IL-ȕDQG
carprofen + IL-ȕ VDPSOHV identified twenty-nine and six intracellular proteins 
respectively. Since carprofen decreased the amounts of cytoplasmic and nucleus 
associated proteins, it may have the effect of reducing IL-ȕVWLPXODWHGFHOOGHDWK 
3.4.8. Changes in protein release at different time points  
There were advantages to high-throughput analysis at both early and late 
time points. Only IL-ȕ treated cultures without the addition of carprofen showed the 
presence of YKL-40 and PCOC-2, and only at the day 6 in time course B. Both of 
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these proteins are of substantial interest to cartilage turnover and metabolism, 
therefore may represent key features to detect and monitor changes in the secretome 
under different experimental conditions.  
At day 18 of time course B with IL-ȕ stimulation, additional identifications 
were made of two chemokines: C-x-C motif chemokine 6 (CXCL6) and C-C motif 
chemokine 20 (CCL20), and two blood coagulation related proteins: Annexin A5 and 
coagulation factor XIII A chain.  
The CXCL6 protein was not identified at early time points during time course 
B comparison analysis, but was subsequently identified after 6 days of IL-ȕ
incubation in study 3.3.3. (Table 7). CXCL6 is a chemokine known to attract neutrophil 
granulocytes to sites of inflammation (Proost et al., 1993). CCL20 (also known as 
macrophage inhibitory protein-3A) is strongly chemotactic to lymphocytes. CCL20 has 
a weaker attraction for neutrophils (Hieshima et al., 1997). The presence of 
chemokines at this stage of the cultures may represent increased release of 
chemokines later in the time course as inflammatory processes progress, or an 
enhanced ability to identify these by MS at 18 days of culture. 
The release of proteoglycans (decorin, biglycan, lumican, fibromodulin) from 
IL-ȕVWLPXODWHGH[SODQWV over a 14 day time course has previously been assessed by 
western blotting (Sztrolovics et al., 1999). Only fibromodulin showed increased 
degradation product release as time progressed (Sztrolovics et al., 1999). Extended 
time courses may therefore not produce alterations in release of most ECM proteins. 
This is consistent with continued identification of proteoglycans and ECM components 
in high-throughput MS analysis at day 18 described in this chapter (Table 5 and 
Table 6). 
3.4.9. IL-ȕDQGFDUSURIHQDIIHFWVGAG release throughout the time course 
Stimulation with IL-ȕFDXVHs higher levels of MMPs and other proteases to 
be activated (Busschers et al., 2010). Subsequently this initiates increased release of 
GAGs and proteoglycans, which can be measured by DMMB assays (Figure 18). The 
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COX-2 specific inhibition by carprofen reduces bioactive lipid signalling of PGE2, 
thereby decreasing levels of catabolic MMPs, which has effects on cartilage 
degeneration (Goodrich and Nixon, 2006). In the present study, carprofen significantly 
reduced IL-ȕDVVRFLDWHG*$*UHlease up to six days (Figure 18). GAG release was 
not halted during the entire time course as seen at day 12, but carprofen did delay 
loss of GAGs. Measurements of GAG content in explant supernatant at 18 and 24 
days, showed that most of the inducible GAG loss occurred in the first 12 days. 
Another time course study of IL-ȕVWLPXODWHGH[SODQWVshowed the majority of GAG 
release occurred within 4 days over a 14 day experiment (Sztrolovics et al., 1999). 
Previous studies on equine cartilage stimulated with IL-ȕ indicated increased levels 
of GAG release over 5 days, compared to untreated control explants, whilst carprofen 
was reported to reduce IL-ȕ induced GAG release (Clutterbuck et al., 2009, 
Clutterbuck et al., 2013). Treatment of canine chondrocytes in 3D agarose culture with 
IL-ȕ DQG FDUSURIHQ GHPRQVWUDWHV ,/-ȕ stimulated GAG release was lower with 
carprofen up to 6 days (Dvorak et al., 2002), which agrees with findings in this thesis. 
However, a study investigating another NSAID meloxicam on OA affected canine 
explants, showed it did not cause a decrease in GAG or collagen release (Budsberg 
et al., 2013).  
Other aggrecanases not affected by carprofen also contribute towards GAG 
release. The ADAMTS enzymes are responsible for the majority of aggrecan, GAG 
and proteoglycan degradation (Sandy and Verscharen, 2001). Therefore while 
carprofen blocks one route of GAG breakdown via MMP inhibition, ADAMTS continue 
to degrade the ECM. A study has shown, inhibition of ADAMTS-4 and ADAMTS-5 
prevented aggrecan degradation in human OA cartilage explants (Malfait et al., 2002). 
ADAMTS presence was not detected within this explant model, therefore no 
assessment was made on its release due to IL-ȕ RU FDUSURIHQ The study in this 
chapter showed that although IL-ȕ VWLPXODWHG *$* UHOHDVH ZDV UHGXFHG E\
carprofen, it did not completely inhibit all mechanisms of GAG release. This is likely to 
be due to continued activity of ADAMTS that were not affected by carprofen. 
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3.4.10. Conclusions 
The studies in this chapter have developed understanding of this equine 
articular cartilage explant model and explored changes in protein release throughout a 
time course of incubation. It was hypothesised that high-throughput MS analysis 
would show differences in untreated control, IL-ȕ and carprofen treated explant 
cultures. This aimed to identify biomarkers of treatment efficacy that could be 
monitored in this model to screen anti-inflammatory compounds such as carprofen.  
This chapter has found that NSAID carprofen has various effects on the 
release of IL-1ɴ stimulated proteins. Carprofen decreased release of ECM proteins 
including biglycan, fibromodulin, chondroadherin, CILP and fibronectin. DMMB assays 
also showed that IL-1ɴ stimulated GAG release was decreased when carprofen was 
present. Inhibition of proteoglycan synthesis by carprofen could potentially account for 
the reduced release observed, although carprofen has been shown to be capable of 
increasing proteoglycan synthesis by measuring incorporation of 35SO4 into equine 
cartilage explants (Frean et al., 1999). A similar approach could be applied to assess 
proteoglycan synthesis in the experimental culture conditions utilised in this thesis. 
Various NSAIDs effect proteoglycan synthesis in different ways, either increasing 
proteoglycan synthesis, causing no change or inhibiting synthesis (Dingle, 1999, 
Mastbergen et al., 2006). Celecoxib, a COX-2 specific inhibitor (as is carprofen), 
increased proteoglycan synthesis in vitro (Mastbergen et al., 2006). Catabolic proteins 
stimulated by IL-1ɴ such as MMP-1, MMP-3 and MMP-13 were reduced by carprofen. 
The number of intracellular proteins identified by MS on cultures stimulated with IL-1ɴ 
were lowered due to carprofen treatment, suggesting this NSAID reduced 
chondrocyte death. 
A number of candidate biomarkers were released in response to IL-ȕ7KHVH
included MMP-1, MMP-3, MMP-13, MIF, HSP70 and CXCL6. As carprofen decreased 
release of the following matrix proteins, potential ECM biomarkers of treatment 
efficacy were identified including proteoglycans (biglycan, fibromodulin and 
chondroadherin) and CILP were identified by high-throughput MS. Selected candidate 
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proteins including MMPs, TSP and fibronectin, were further studied in chapter 5 to 
assess their capability to be biomarkers in this model. These may help in the 
screening of anti-inflammatory effects of novel treatments in the equine cartilage in 
vitro model.  
High-throughput MS analysis reported that few additional proteins were 
uncovered by MS analysis at 18 days of incubation as compared with 6 days, as the 
majority of identifications continued to be ECM constituents. The day 18 cultures were 
examined to determine whether extending the time of culture would produce samples 
with reduced levels of ECM proteins, since the leaking out of these proteins from cut 
cartilage discs may be expected to reduce over time. Cultures containing lower levels 
of the abundant ECM components would aid high-throughput MS identification of 
additional secreted proteins involved in cartilage degradation and inflammatory 
processes. Silver stained profiles of later time points and MS identification of excised 
bands showed proteins present were mostly still ECM proteins including COMP, 
fibronectin and aggrecan core protein. Additional protein identifications were 
insufficient in number to support modifying the culture model to include MS analysis of 
later incubation time points. In addition, only limited information was gained by DMMB 
assay analysis at later time points, since explant GAG measurements were influenced 
by release during earlier incubation. Incubating cartilage cultures over longer periods 
of time also required additional costs of resources and time that did not warrant this 
approach in subsequent secretome studies. An incubation time of 6 days was 
therefore chosen for the next studies in this thesis, which involved abundant protein 
depletion approaches prior to high-throughput MS analysis detailed in chapter 4. 
Overall, the series of studies described in this chapter identified 
physiologically relevant cartilage proteins released into untreated, IL-ȕDQG ,/-ȕ
carprofen treated explant cultures. Proteins identified provided insights into ECM 
components released during cartilage degradation and the secreted proteins involved 
in inflammatory related degradative diseases like OA.   
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CHAPTER 4 
UNCOVERING ADDITIONAL PROTEINS RELEASED 
FROM ARTICULAR CARTILAGE BY DEPLETION OF 
HIGH ABUNDANCE PROTEINS 
4.1. Introduction  
High-throughput MS analysis described in chapter 3 previously identified a 
range of abundantly released ECM and non-ECM secreted proteins in an equine 
cartilage explant model. It was hypothesised that depletion of the highly abundant 
cartilage proteins would allow additional identification of low level proteins and a 
further in depth analysis of the secretome. In chapter 3, non-ECM proteins including 
clusterin, MMP-1, MMP-3, MMP-13, SAA and MIF were released in response to IL-ȕ, 
which have been implicated in inflammatory processes and cartilage degradation in 
OA (Kjelgaard-Hansen et al., 2007, Fukuda et al., 2012, Liu and Hu, 2012, Troeberg 
and Nagase, 2012). Low abundance proteins previously unidentified in the cartilage 
secretome could be of interest in cartilage biology and also candidate biomarkers of 
treatment efficacy, allowing greater understanding of cartilage degradative processes 
and OA disease. The aim of this chapter was to identify additional secreted proteins 
associated with IL-1ɴ stimulation and inflammatory processes occurring in cartilage 
explant culture. 
Analysis of complex protein samples with a large dynamic range of protein 
levels by high throughput mass spectrometry approaches provides reliable 
identifications of high abundance components, but identification of low abundance 
proteins that could provide additional biological information is hindered by the high 
signal levels from the abundant proteins (Millioni et al., 2011). Therefore, depleting the 
secretome of high abundance proteins could provide additional protein identifications 
of lower abundance proteins by MS analysis. In this chapter, three different 
approaches to deplete the high abundance proteins present in cartilage explant 
culture fluids were investigated. In two of these, the characteristic of glycosylation of 
the abundant ECM proteins was exploited. Abundant ECM proteins are highly 
 113 
 
glycosylated therefore this property can be targeted by cetylpyridinium chloride (CPC) 
precipitation (Hermansson et al., 2007) and concanavalin A (Con A) lectin 
chromatography depletion methods. Another potential technique to deplete high 
abundance proteins for high-WKURXJKSXW SURWHRPLFV DSSURDFK LV 3URWHRPLQHU
protein enrichment technology (Fernandez et al., 2011). This approach involves 
application of samples to a diverse bead-based ligand library, which subsequently 
reduces the dynamic range of complex protein samples. 
4.1.1. GAG depletion with CPC precipitation 
CPC is a cationic detergent that interacts with negatively charged groups 
inherent in glycosylated ECM proteins and GAGs. This approach has previously been 
used to increase resolution during 2DE proteomics of cartilage tissues because GAGs 
and proteoglycans interfere with the separation and isoelectric focusing of other 
proteins in gels (Catterall et al., 2006, Ruiz-Romero et al., 2010a, Hermansson et al., 
2007, Hermansson et al., 2004). Indeed, a comparison of proteins released from 
healthy or OA cartilage found it necessary to remove proteoglycans with CPC to allow 
resolution by 2DE (Hermansson et al., 2004). The same study showed increases in 
FROODJHQW\SH,,DQGLQKLELQȕ$UHOHDVHIURP2$FDUWLODJH (Hermansson et al., 2004). 
In 2006, a study aimed to increase resolution of higher molecular weight proteins 
during 2DE used CPC precipitation, enzymatic digestion or anion exchange 
techniques on proteins secreted from human chondrocytes stimulated with IL-ȕDQG
oncostatin M (Catterall et al., 2006). On that occasion, only eight proteins were 
identified from 2DE gels without CPC precipitation including MMP-1, MMP-3, YKL-40 
and S100A11 (Catterall et al., 2006). Although CPC precipitation produced reduced 
protein smearing during 2DE, high losses of biologically relevant proteins and 
insufficient high molecular weight resolution was reported (Catterall et al., 2006). In 
another study, the ability to distinguish and identify individual spots with MS from 2DE 
based investigations on cartilage extracts was improved using CPC precipitation 
(Ruiz-Romero et al., 2010a). Proteins identified after CPC precipitation included 
collagen type VI, COMP, fibromodulin and ferritin light chain (Ruiz-Romero et al., 
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2010a). Application of CPC precipitation prior to high throughput MS analysis of 
cartilage explant secretome has not been reported in the literature. Therefore the 
investigations described in this chapter evaluated if this approach would uncover 
additional low abundance proteins with high-throughput MS. 
4.1.2. Glycoprotein depletion with concanavalin A lectin chromatography 
Lectin chromatography techniques are used to selectively bind glycosylated 
proteins. Specific lectins are chosen that bind specific types of carbohydrate 
structures for example, galactose, mannose, N-acetylglucosamine or fructose 
residues. A multi-lectin affinity chromatography (M-LAC) approach has been 
developed that can bind a wide range of side chains types. Plasma has often been 
processed with M-LAC to assist analysis of the plasma proteome (Plavina et al., 2007, 
Kullolli et al., 2010, Dayarathna et al., 2008), and in searches for biomarkers of 
diseases like RA (Zheng et al., 2009) and breast cancer (Zeng et al., 2011). In 2009, 
the RA human plasma peptidome and proteome were studied after M-LAC depletion 
via tryptic digestion and nanoLC-MS/MS (Zheng et al., 2009). Calgranulin A, B and C 
were identified only in M-LAC bound RA fractions, while C-reactive protein and actin 
were associated with RA plasma both with and without M-LAC depletion (Zheng et al., 
2009).  
The lectin Con A is derived from the jack bean (canavalia ensiformis). Con A 
has D KLJK DIILQLW\ IRU Į-D-PDQQRV\O DQG Į-D-glucosyl residues (Bryce et al., 2001) 
found throughout ECM GAGs and proteoglycans. In a model of chondrocyte 
maturation, early stage chondrogenesis differentiation markers have recently been 
reported after Con A chromatography and MS (Ishihara et al., 2013). In that study, 
glycoproteins were fractionated from lysate of mouse chondroprogenitor cells that had 
been matured by insulin presence (Ishihara et al., 2013). Selected glycoproteins from 
MS identification in glycosylated fractions were then subjected to gene expression 
analysis in human MSCs, to assess the relevance of applying chondroprogenitor cell 
markers to a human chondrogenesis model. Transcription of collagen type III, 
collagen type XI, aquaporin-1, netrin receptor unc-5 homolog B and ectonucleotide 
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pyrophosphatase/phosphodiesterase family member 1 were shown to be up-regulated 
during early chondrogenesis (Ishihara et al., 2013). In this chapter, Con A lectin 
chromatography was applied to deplete explant culture media of high abundance 
proteins and produce a glycoprotein depleted fraction for high-throughput MS 
analysis. 
4.1.3. Proteominer technology to reduce the dynamic range of secretome 
Proteominer protein enrichment kits (Bio-Rad) were developed to decrease 
the dynamic range of complex biological samples, thereby allowing improved 
analytical coverage of the proteome (Figure 19). The principle involves applying 
complex protein samples to a diverse bead-based combinatorial peptide ligand library. 
High abundance proteins will saturate their available binding ligands. Proteins of lower 
abundance are concentrated (relative to high abundance proteins) on their high 
affinity ligands. Excess proteins are washed away and therefore once proteins are 
eluted off the ligand beads, there will be a reduction in the dynamic range of all 
proteins. Proteominer technology has been reported to assist the proteomic 
analysis of whole OA cartilage (Ikeda et al., 2013), serum (Fernandez et al., 2011), 
cell lysates (Fonslow et al., 2011), urine (Candiano et al., 2012), egg white extract 
(D'Ambrosio et al., 2008) and beer (Fasoli et al., 2010). To discover new biomarkers 
for OA, Proteominer technology has been applied to healthy and OA serum before 
2DE, which showed OA serum to be associated with an altered haptoglobin 
(Fernandez-Costa et al., 2012). In another study searching for OA biomarkers in 
whole cartilage, the use of 3URWHRPLQHU depletion before iTRAQ quantification 
revealed three novel candidate OA biomarkers: leukocyte cell-derived chemotaxin-2 
(LETC2), BAALC (brain and acute leukaemia, cytoplasmic) and peroxiredoxin-6 
(PRDX6) (Ikeda et al., 2013). The Proteominer technology was assessed as an 
approach to deplete the cartilage explant secretome of high abundance proteins, and 
therefore potentially uncover additional protein identifications using high-throughput 
MS. 
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Figure 19. 3URWHRPLQHUSURWHLQHQULFKPHQWWHFKQRORJ\GHFUHDVHs the dynamic 
range of proteins in biological samples, allowing increased identification of low 
abundance proteins 
(http://www.bio-rad.com/en-uk/product/proteominer-protein-enrichment-kits) 
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4.1.4. Hypothesis and aims 
High-throughput MS on cartilage explant conditioned media was studied 
within Chapter 3. Released proteins were identified including ECM components, 
secreted metabolic and intracellular proteins. This data provided a comprehensive 
foundation to assess the capabilities of using the previously described high-
throughput MS approach (chapter 3), but extra steps need to be implemented into 
experimental procedures for analysis to aid identification of additional proteins in the 
explant model. The hypothesis addressed in the work of this chapter was that by 
depleting the cartilage explant supernatant of highly abundant ECM proteins, the 
detection of additional low-level proteins may be achieved. Therefore CPC 
precipitation, Con A lectin chromatography or Proteominer enrichment, were carried 
out before high-throughput MS techniques were applied with a view to expand the 
range of proteins identified within the explant culture secretome. This aimed to 
discover if any of these procedures prior to high-throughput MS would allow further 
identification of low abundance proteins. 
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Figure 20. Methods to deplete high-abundance proteins trialled in Chapter 4 
Three methods were applied to cartilage secretome prior to high-throughput MS: CPC 
precipitation, Con A chromatography or Proteominer enrichment. 
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4.2. Materials and Methods 
4.2.1. CPC precipitation 
 CPC precipitation was based on the approach developed by (Hermansson et 
al., 2007) for 2DE analysis of cartilage secretome. A stock solution of 5% CPC 
(Sigma) was prepared in HPLC grade water (Fisher), and appropriate volumes were 
added to samples to give a ratio of 3 mg CPC/mg GAG. Typically, samples contained 
between 100-400 µg/ml GAG as estimated by DMMB assays (Appendix 2, Figure 36). 
Samples with CPC were incubated at room temperature for 30 minutes to precipitate 
the GAG/CPC complex, before centrifugation at 13,000xg for 10 minutes. The GAG 
depleted supernatant was transferred to a fresh Eppendorf tube. To resuspend the 
proteins in the CPC pellet, it was first washed with 0.4 M sodium acetate (Sigma) in 
90% (v/v) ethanol (Fisher) and then washed with ethanol alone (to remove sodium 
acetate). It was then resuspended in Laemmli buffer for SDS-PAGE or AMBIC (+10% 
ACN) for MS analysis processing.  
4.2.1.1. Preliminary CPC precipitation mass spectrometry  
 During preliminary investigations, 1 ml of an untreated and an IL-ȕ WUHDWHG
explant culture supernatant sample (from time course A, day 21-24 (chapter 3)) were 
CPC precipitated. The CPC/GAG pellet was resuspended in 50 µl AMBIC (+10% 
ACN). The GAG depleted samples (350 µl of each supernatant) were taken for the 
next stages.  
A methanol/chloroform precipitation method was applied to remove salt and 
detergent. Per 100 µl of sample, 400 µl of methanol (Fisher), 200 µl chloroform 
(Fisher) and 300 µl of H20 were added. Samples were centrifuged for 1 minute at 
14,000xg, before the top aqueous layer was removed and an additional 300 µl 
methanol was added. Again, samples were centrifuged at 14,000xg for 5 minutes, 
before as much methanol as possible was removed without disturbing the pellet. 
Pellets were briefly allowed to air dry and then resuspended in 20 µl AMBIC (+10% 
ACN).  
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Samples were prepared for MS runs with reduction, alkylation and acetone 
precipitation as described in Chapter 2.8.1. Prior to loading onto the column, 10 µl of 
these samples were diluted 1:10 in 0.1% formic acid and was loaded and analysed by 
nanoLC-MS/MS on an amaZon ETD (Bruker).  
4.2.1.2. Final CPC precipitation mass spectrometry 
CPC/GAG depletion was carried out (chapter 4.2.1.) on IL-ȕ VWLPXODWHG
explant conditioned media that had been incubated for 6 days. This time, free CPC 
and salts were removed using dialysis overnight against 20 mM Tris-HCl (pH 7.4) 
(slide-A-Lyzer, 10 kDa cut off, Pierce). The GAG depleted sample and an 
unprocessed aliquot of the same culture supernatant (also dialysed) were reduced, 
alkylated, acetone precipitated and trypsin digested as previously described in 
Chapter 2.8.1. After digestion, the samples were desalted and concentrated using 
C18 resin ZipTips (Millipore) according to the PDQXIDFWXUHU¶V instructions and using 20 
µl 50% methanol and 0.1% formic acid to elute the bound peptides. Excess solvent 
was evaporated off by heating at 70 °C to leave 10 µl of samples, which was 
transferred to glass vials ready to be loaded onto the nanoLC column. During this 
analysis, 5 µl was loaded onto the column for nanoLC-MS/MS analysis on an amaZon 
speed ETD (Bruker).  
4.2.2. Con A lectin chromatography 
4.2.2.1. Con A column fractionation method 
Binding buffer was prepared with 20 mM Tris (Bio-Rad)-HCl pH 7.4 + 0.5 M 
NaCl (Sigma) + 1 mM MnCl2 (Sigma) + 1 mM CaCl2 (Sigma). Concanavalin A (Con A) 
(GE Healthcare) was prepared into a slurry by washing in 10 bed volumes of binding 
buffer to remove preservative. This was centrifuged for 2 minutes at 8000xg in a 50 ml 
falcon tube before excess buffer was removed. An equal amount of fresh binding 
buffer was added to the settled medium (i.e. 1 ml settled medium + 1 ml binding 
buffer), which was allowed to equilibrate to room temperature and degassed. 
Prepared Con A slurry was placed in Micro Bio-Spin® Chromatography Columns (Bio-
Rad) (0.5 ml of slurry per column), centrifuged at 1,000xg for 2 minutes and excess 
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binding buffer was removed. Samples (200 µl) were added to the centre of the column 
and centrifuged at 1000xg for 4 minutes. Bound proteins were recovered by 
introducing  0 PHWK\O Į-D-mannopyranoside (200 µl) to the column before 
centrifugation at 1000xg for 4 minutes. 
4.2.2.2. Con A MS analysis 
 To ascertain if the Con A approach would provide additional protein 
identifications, selected samples were analysed by MS before and after lectin 
chromatography. Untreated and IL-ȕ WUHDWHGH[SODQWFXOWXUHPHGLD DIWHUGD\VRI
incubation) from an individual horse and a pool of three separate horses went through 
the Con A column fractionation. Dialysis against 18 ohm water was performed 
overnight on samples using a Tube-O-Dialyzer MWCO 1000 Da (G-Biosciences). 
Corresponding unprocessed samples were also MS analysed for comparison with the 
Con A technique. Reduction, alkylation, acetone precipitation, trypsin digestion and 
C18 ZipTip desalting were carried out as previously described (chapter 2.8.1.), before 
nanoLC-MS/MS analysis on an amaZon speed ETD. 
4.2.3. Proteominer protein enrichment 
 Explant cultures were set up (chapter 2.3.) with 8 explant discs per 1 ml 
DMEM + 2% Pen/Strep, with the aim of collecting highly concentrated secretome 
supernatants. Explants were either left untreated (12 wells) or treated with 10 ng/ml 
IL-ȕ 12 wells). After 6 days incubation, supernatants for each treatment were 
concentrated from 12 ml down to ~0.5 ml using Centriplus YM-3 (Millipore) and 
Centricon-3 (Millipore) centrifugal filter units. The concentrated samples (500 µl) were 
processed with a 6PDOO &DSDFLW\ 3URWHRPLQHU 3URWHLQ (QULFKPHQW .LW %LR-Rad) 
IROORZLQJ WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV $IWHU HOXWLRQ  O ZDV UHFRYHUHG IURP
which 20 µl was protein assayed (DC Bio-Rad) to allow trypsin to be added at an 
appropriate amount during later digestion. The remaining 100 µl was reduced, 
alkylated, acetone precipitated and trypsin digested overnight, before digested 
peptides were applied to C18 spin columns (Pierce), followed by nanoLC-MS/MS 
analysis on an amaZon speed ETD (Bruker) (chapter 2.8). 
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4.2.4. MS data processing 
 MS data was processed as described in chapter 2.8.3. 
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4.3. Results 
4.3.1. CPC Precipitation 
Fractionation using CPC precipitation provided separation of components of 
the cartilage explant secretome which could be visualized by SDS-PAGE and silver 
staining (Figure 21). Some of the most strongly staining bands corresponding to 
abundant proteins were effectively located in the CPC pellets. These abundant 
proteins were depleted in both untreated control and IL-ȕ WUHDWHG explant 
supernatants. In untreated control supernatants, the majority of protein bands were 
removed by CPC precipitation, suggesting that most proteins released from untreated 
explants are ECM proteins containing negatively charged side groups. A greater 
number of proteins remained in IL-ȕ treatment supernatants after CPC precipitation 
compared to untreated control samples, including bands known to contain MMP-3 and 
COMP. Although some of the abundant proteins remain in IL-ȕ GAG depleted 
samples, it was anticipated that removal of the majority of abundant proteins would 
allow identification of additional proteins by nanoLC-MS/MS in the next phase of the 
assessment of the CPC precipitation technique. 
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Figure 21. One dimensional gel protein profiles of untreated control (A) and IL-ȕWUHDWHG%
cartilage explant supernatants showing the protein fractionation achieved by the CPC 
precipitation  
Unprocessed supernatant shows profile before CPC precipitation. The supernatant profiles 
after CPC precipitation (GAG depleted) are visible along with profiles of proteins contained 
within resuspended CPC pellets that had been extracted during the process. All samples 
were run in duplicate. 
(A) (B) 
kDa kDa 
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4.3.1.1. Predominantly ECM proteins are identified in resuspended CPC pellet 
Preliminary MS analysis of GAG depleted supernatant by CPC precipitation 
was unsuccessful, most likely because the protein amount recovered after trypsin 
digestion of samples was very low. Figure 22 and Table 9 show the proteins identified 
in the high-throughput MS of proteins present in the CPC pellets from untreated 
controls and IL-ȕ H[SODQW FXOWXUH supernatants. ECM proteins including COMP, 
fibronectin and small proteoglycans decorin and biglycan, were identified in the pellets 
from both treatment types. Aggrecan core protein and HAPLN1 which form links within 
large aggregating proteoglycans in the ECM were also detected in both treatment 
pellets. In addition, the predominant collagen type in articular cartilage (type II) was 
present in the IL-ȕSHOOHW. Identification of extra ECM proteins in the IL-ȕsamples 
could be due to increased release of these proteins after cytokine stimulated catabolic 
processes, as the protease MMP-3 was also found. Almost all the proteins in the 
pellets were ECM constituents that are released at high levels during cartilage explant 
culture. This suggested that CPC precipitation could be an effective method to deplete 
high abundance proteins from explant culture supernatants. 
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Figure 22. Venn diagram showing proteins identified in CPC precipitated pellets from untreated 
control and IL-1ɴ cartilage explant supernatant  
Details of protein identifications made by high-throughput MS are displayed in Table 9. 
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Table 9. Protein identifications from CPC precipitated pellets from untreated control 
and IL-ȕFDUWLODJHH[SODQWVXSHUQDWDQWV 
Pellets were resuspended after CPC precipitation and prepared for MS analysis. 
Swiss-Prot 2013_01 (all mammalian entries) database search performed using 
Mascot search engine. Only Mascot scores >39 indicating identity/extensive 
homology are reported. 
Protein Accession  Mascot Score Unique 
Peptides 
Sequence 
Coverage (%) 
Untreated     
Fibronectin FINC_BOVIN 1467 26 12 
HAPLN1 HPLN1_HORSE 495 12 30 
COMP COMP_MOUSE 233 6 10 
Decorin PGS2_HORSE 224 15 43 
Thrombospondin TSP1_BOVIN 199 18 17 
Tenascin TENA_HUMAN 79 4 6 
Biglycan PGS1_HORSE 70 7 19 
Aggrecan core protein PGCA_CANFA 65 8 3 
Collagen type II COA1_BOVIN 62 12 9 
Lactadherin MFGM_PIG 48 3 8 
     
IL-ȕ     
Fibronectin FINC_BOVIN 1408 29 4 
Biglycan PGS1_HORSE 516 7 20 
HAPLN1 HPLN1_HORSE 374 13  
Decorin PGS2_HORSE 118 14 26 
MMP-3 MMP3_HORSE 246 7 4 
Tenascin TENA_HUMAN 108 16 9 
COMP COMP_BOVIN 105 6 7 
Collagen type II COA1_BOVIN 92 9 8 
Fibromodulin FMOD_HUMAN 76 2 6 
Lactadherin MFGM_PIG 60 4 10 
Aggrecan core protein PGCA_PIG 56 8 11 
Perlecan PGBM_HUMAN 46 12 3 
Rho-associated protein kinase 2 ROCK2_MOUSE 41 6 5 
Sorting nexin 2 SNX2_BOVIN 41 5 12 
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4.3.1.2. Depletion of GAG from the secretome by CPC precipitation 
A further CPC precipitation experiment was attempted on IL-ȕ VWLPXODWHG
supernatant after alterations to technical aspects of the preparation methods and in 
selection of appropriate samples. High-throughput MS analysis was completed on IL-
ȕWUHDWHGH[SODQWVXSHUQDWDQWIURPDQLQGLYLGXDOKRUVHEHIRUHXQSURcessed) and on 
the supernatant fraction from the CPC precipitation (GAG depleted), with the 
identifications shown in Table 10. Overall, 39 proteins were identified in the 
unprocessed sample and 36 unbound proteins were detected in the GAG depleted 
sample. Although not truly quantitative, clear differences in Mascot scores can give 
indications on proteins affected by CPC precipitation. Small proteoglycans decorin 
and fibromodulin were not identified after CPC precipitation, while biglycan gave a 
considerably lower score, suggesting these were successfully removed. 
Thrombospondin-1 and aggrecan core protein also gave higher scores before the 
depletion step was applied. Two ECM proteins appeared to be enriched after the 
process: HAPLN1 and CILP-1.  
 It was hypothesised that removal of abundant ECM proteins with CPC 
precipitation would facilitate identification of additional secreted proteins involved in 
cartilage turnover and maintenance in the unbound fraction, but large numbers of 
additional proteins were not found. Proteins with roles in cartilage breakdown and 
inflammation were lost: MMP-13 and macrophage migration inhibitory factor (MIF), 
while MMP-10 and HAPLN1 were detected in unbound samples after CPC 
precipitation. The overlap of ECM and secreted protein detected in unprocessed 
samples or unbound fractions after CPC precipitation are displayed in Figure 23.  
 The intracellular proteins that were detected are consistent with chondrocyte 
cell death caused by IL-ȕF\WRNLQH (Table 10). A number of these proteins were only 
identified in either the unprocessed sample or in the GAG depleted sample after CPC 
precipitation. The mitochondrial form of SOD and ferritin heavy chain protein detection 
was aided by precipitation, while scores for alpha-enolase and triosephosphate 
isomerase were considerably higher. Phosphoglycerate kinase 1, L-lactate 
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dehydrogenase A chain and sodium/hydrogen exchanger 2 were identified only in 
unprocessed supernatants. 
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Table 10. Proteins detected in IL-1ȕ treated explant supernatants with or without CPC precipitation 
Identifications included in the table only if the protein was found above identity cut-off in either unprocessed or CPC precipitated sample. Swiss-Prot 2013_01 
database (all mammalian entries) searched with Mascot Daemon software. Identification cut-off determined by Mascot scores >42 indicates identity/extensive 
homology. 
Protein Accession  Unprocessed Supernatant Supernatant after CPC 
Precipitation 
 
 Mascot score Unique 
peptides 
Mascot score Unique 
peptides 
ECM Proteins 
     
COMP COMP_BOVIN 18133 17 13737 18 
Aggrecan core protein PGCA_HUMAN 5791 14 785 9 
Fibronectin FINC_HUMAN 2810 32 4474 34 
Decorin PGS2_HORSE 2063 8   
Biglycan PGS1_HORSE 5766 12 689 3 
Chondroadherin CHAD_HUMAN 4834 9 5273 8 
Fibromodulin FMOD_HUMAN 2439 6   
Thrombospondin 1 TSP1_BOVIN 1197 20 168 11 
Collagen alpha-1(II) chain CO2A1_BOVIN 99 7 140 7 
Cartilage intermediate layer protein 1 (CILP-1) CILP1_MOUSE 78 4 506 6 
Cartilage intermediate layer protein 2 (CILP-2) CILP2_HUMAN 55 8   
Tenascin TENA_HUMAN 522 13 51 10 
Proteoglycan 4 (lubricin) PRG4_HUMAN 75 5 101 11 
Hyaluronan and proteoglycan link protein 1 (HAPLN1) HPLN1_HORSE   48 5 
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Secreted Proteins 
     
Clusterin CLUS_HORSE 3130 12 120 3 
Chitinase-3-like protein CH3L1_BOVIN 2344 6 2732 5 
Serum amyloid protein A SAA_HORSE 400 4   
Lysozyme C LYSM_BOVIN 367 2 450 4 
Metalloproteinase inhibitor 1 TIMP1_HORSE 213 2 1358 5 
MMP-1 MMP1_HORSE 1481 17 3074 23 
MMP-3 MMP3_HORSE 5480 19 5159 17 
MMP-10 MMP10_HUMAN   710 1 
MMP-13 MMP13_HORSE 96 6   
Macrophage migration inhibitory factor MIF_HUMAN 69 2   
Lactadherin MFGM_PIG 69 3 54 1 
Ribonuclease 4 RNAS4_HUMAN 63 1   
Intracellular proteins 
     
Vimentin VIME_MOUSE   427 12 
 VIME_PIG 1899 21   
Alpha-enolase ENOA_BOVIN 179 3 2152 12 
L-lactate dehydrogenase A chain LDHA_MOUSE 68 4   
Phosphoglycerate kinase 1 PGK1_HORSE 57 5   
Superoxide dismutase [Cu-Zn] SODC_HORSE 63 7 64 5 
Superoxide dismutase [Mn], mitochondrial SODM_HORSE   175 3 
Metallothionein-1G MT1G_HUMAN 66 2   
Metallothionein-1A MT1A_BOVIN   119 2 
Ferritin heavy chain FRIH_HORSE   118 3 
Triosephosphate isomerase TPIS_BOVIN   825 3 
Ras GTPase-activating protein 4 RASL2_MOUSE   64 5 
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Tripartite motif containing protein 46 TRI46_HUMAN   72 1 
Sodium/hydrogen exchanger 2 SL9A2_RABIT 151 3   
Zinc finger protein 643 ZN643_HUMAN 48 2   
Cytoplasmic dynein 1 heavy chain 1 DYHC1_HUMAN 44 12   
Class E basic helix-loop-helix protein 23 BHE23_MOUSE 42 1   
Tetratricopeptide repeat protein 19, mitochondrial TTC19_MOUSE   50 1 
Solute carrier family 28 member 3 S28A3_RAT   50 5 
Putative malate dehydrogenase 1B MDH1B_BOVIN   43 2 
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Figure 23. Venn diagram showing the number of ECM and secreted proteins detected 
in unprocessed samples and unbound fractions  
nanoLC-MS/MS analysis was completed on IL-1ȕ stimulated explant supernatant. 
Details on specific proteins are provided in Table 7. 
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4.3.2. Concanavalin A Lectin Chromatography 
4.3.2.1. Depletion of proteins with Con A shown on SDS-PAGE 
In a second approach to produce a glycoprotein depleted fraction of the 
cartilage explant secretome, Con A lectin chromatography was investigated. Silver 
stained SDS-PAGE displayed distinct bands after supernatant was centrifuged 
through Con A spin columns (Figure 24). A strong band was introduced to samples at 
30 kDa corresponding to Con A itself. Additional elution steps were completed in an 
attempt to reduce the presence of this band, but this did not alter the amount of Con A 
present in the samples (data not shown). Introducing high levels of Con A to samples 
will cause high signal detection from this abundant protein that will hinder the ability of 
MS to identify additional proteins. 
 The unprocessed SDS-PAGE profiles were similar to previous explant 
supernatant profiles (Figure 24). The Con A lectin has high affinity for glycosylating 
carbohydrate groups, therefore only non-glycosylated proteins should pass through 
the column and appear in the unbound fraction. Attempts were made to elute bound 
proteins from the lectin ZLWKPHWK\OĮ-D-mannopyranoside. Figure 24 shows that the 
proteins were not eluted and remained directly or indirectly bound to Con A. 
 The majority of proteins were bound to Con A within the spin column, 
especially in untreated controls fractions. This suggests most proteins in untreated 
secretome are ECM proteins that tend to be highly glycosylated. Higher numbers of 
unbound proteins are visible in the IL-ȕ stimulated fractions. To provide protein 
identities, bands were excised and analysed by trypsin digestion and nanoLC-MS/MS. 
An intense band in both untreated and IL-ȕ XQERXQG IUDFWLRQV at ~50 kDa was 
identified as HAPLN1 (Figure 24). Some of the lower intensity bands excised from 
unbound IL-ȕIUDFWLRQVZHUH003-3 and BSA, which were proteins already reliably 
identified with high-throughput MS in Chapter 3. A higher molecular weight band ~250 
kDa contained two ECM constituents: fibronectin and aggrecan core protein. 
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Figure 24. SDS-PAGE and silver staining of untreated and IL-1ɴ stimulated 
supernatants from explant cultures with two different horses show the protein band 
profiles before and after Con A chromatography 
Excised bands identified using nanoLC-MS/MS and NCBInr database searches. 
Unprocessed supernatant shows profile before Con A chromatography. The profiles of 
supernatant after Con A chromatography (unbound) are shown along with a lane 
containing eluted proteins from the Con A lectin spin column. 
kDa 
kDa 
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4.3.2.2. High-throughput analysis of Con A chromatography glycoprotein 
depleted secretome 
A comparison of proteins identified by nanoLC-MS/MS was completed on 
unprocessed explant supernatants and Con A unbound fraction supernatants from the 
same experimental culture. Both untreated and IL-ȕ VDPSOHV ZHUH DQDO\VHG WR
ascertain any differences between treatment types. Protein identifications in untreated 
explant cultures before or after Con A processing are shown in Table 11, and IL-ȕ
stimulated culture identifications are shown in Table 12. The classification of the 
proteins identified are summarised in Figure 25. 
 
  
Figure 25. Bar graph summarizing the number and classification of proteins 
identified by MS during the Con A lectin chromatography study  
Classification of the proteins described in detail in Table 11. A reduction in the 
number of proteins identified after Con A chromatography is observed, particularly 
secreted non-ECM proteins. Information on protein classification was from protein 
entries in the UniProt database (www.uniprot.org). 
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There was a decrease in the number of ECM proteins found in both untreated 
and IL-ȕVXSHUQDWDQWV (unbound) after Con A techniques had been applied, and a 
substantial decrease in Mascot scores of some of those proteins that remained. MS 
analysis on untreated cultures identified 14 ECM proteins without Con A processing, 
and only 8 ECM proteins afterwards in unbound supernatants. IL-ȕ sample MS 
analysis followed a similar pattern, with 12 unprocessed and 8 unbound ECM protein 
identifications. It is noticeable that HAPLN1 appeared to be highly enriched by Con A, 
as it achieved high Mascot scores for each sample after Con A. This protein was 
already known to be released into explant cultures, but was below the set 
identification threshold in these runs on unprocessed samples. HAPLN1 remained 
unbound during chromatography, therefore making up a high proportion of the 
depleted fraction. This allowed HAPLN1 to be consistently and reliably identified with 
less interference from other previously abundant proteins.  
Detection of non-ECM secreted proteins was reduced after Con A 
approaches. In untreated cultures only 3 non-ECM proteins were identified in Con A 
unbound supernatant, while 21 were detected in unprocessed supernatant (Table 11). 
Therefore Con A chromatography appears to be detrimental to an in depth analysis of 
the explant model. Interleukin-9 (IL-9) was identified only in unbound supernatants 
and was the only non-ECM secreted protein uncovered.  
A range of intracellular proteins were found both in unprocessed and Con A 
unbound supernatants, especially in IL-ȕVDPSOHVonce again indicating an increase 
in cell death (Table 12). Proteins involved in metal binding and storage such as ferritin 
heavy and light chains, metallothionine and selenium binding protein were identified 
after Con A, but not in unprocessed samples. Although numerous intracellular 
proteins were identified, these are of limited interest because they are unlikely to yield 
any insights on cartilage biology or inflammatory processes. Con A of untreated 
cultures also showed higher scores for many contaminating keratin proteins. These 
could have been introduced during the additional sample processing involved with the 
Con A procedure, or the process may have been selective for this type of protein. 
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 The number of ECM and secreted proteins associated with Con A processing 
are shown for untreated and IL-ȕ VWLPXODWHG FXOWXUHV in Figure 26. In both cases, 
introducing Con A chromatography prior to MS contributed limited additional or novel 
protein identifications. 
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Table 11. Proteins identified in untreated explant supernatants, unprocessed (no Con A) or unbound after Con A lectin chromatography 
Identifications provided searching MS data within the Swiss-Prot 2013_01 (all mammalian entries) database. Mascot scores >38 indicate identity/extensive 
homology. 
Protein Accession 
Number 
Unprocessed 
Individual  
Unprocessed 
Pool  
Con A Unbound 
Individual 
Con A Unbound 
 Pool 
 
 Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
ECM Proteins          
Cartilage oligomeric matrix protein COMP_BOVIN 4090 18 4763 17 274 7 399 6 
Thrombospondin 1 TSP1_BOVIN 741 20 1256 13     
Fibronectin FINC_BOVIN 4422 41 6222 42   137 8 
Chondroadherin CHAD_HUMAN 1022 8 3069 6 306 7 2728 7 
Aggrecan core protein PGCA_HUMAN 1815 15 3389 16 4846 13 11335 15 
Proteoglycan 4 (Lubricin) PRG4_HUMAN 139 7 49 6     
Decorin PGS2_HORSE 665 13 802 10   44 3 
Biglycan PGS1_HORSE 1099 14 1062 10   82 4 
Fibromodulin FMOD_HUMAN 1307 9 3200 7     
Collagen alpha-1(II) chain CO2A1_BOVIN 137 15 59 10     
Collagen alpha-2(VI)chain CO6A2_HUMAN 190 8 79 6     
Collagen alpha-1(X) chain COAA1_MOUSE 77 2 102 4     
Prolargin PRELP_MOUSE 124 5 147 5     
Cartilage intermediate layer protein 1 (CILP-1) CILP1_MOUSE 201 10 789 10     
 CILP1_PIG     1501 9 3451 7 
Hyaluronan and proteoglycan link protein 1 
(HAPLN1) 
HPLN1_HORSE     2110 20 4968 21 
Secreted Proteins          
Clusterin CLUS_HORSE 2767 16 4723 16 53 5 261 3 
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Serum amyloid A protein SAA_CANFA 43 2       
 SAA_HORSE   55 2     
Chitinase-3-like protein 1 (YKL-40) CH3L1_BOVIN 574 6 1178 5   134 1 
Metalloproteinase inhibitor 1 TIMP1_HORSE 83 5 312 4     
Metalloproteinase inhibitor 2 TIMP2_CANFA   47 5     
Alpha-1-antiproteinase 2 A1AT2_HORSE 99 7 342 3     
Extracellular superoxide dismutase [Cu-Zn] SODE_HUMAN 67 3 72 2     
MMP-3 MMP3_HORSE 653 11 956 10     
Procollagen C-endopeptidase enhancer 2 PCOC2_HUMAN 163 8 171 4     
TNF-R superfamily, member 11b (Osteoprotegerin) TR11B_RAT 252 4 319 3     
SPARC (secreted protein acidic, cysteine rich) SPRC_PIG 108 4 96 5     
Secreted frizzled-related protein 3 SFRP3_BOVIN 74 6 98 8     
Lysozyme C LYSM_BOVIN 72 1 168 2     
Lactadherin MFGM_PIG 83 1 63 2     
Connective tissue growth factor CTGF_MOUSE   55 3     
Augurin AUGN_HUMAN 54 1       
Ceruloplasmin CERU_RAT   75 6     
Interleukin-9 IL9_HUMAN     49 1 71 1 
Ribonuclease 4 RNAS4_HUMAN   48 2     
Insulin-like growth factor-binding protein 7 (IGFBP7) IBP7_HUMAN 46 5       
Integrin beta-like protein 1 ITGBL_MOUSE 56 4       
Melanoma-derived growth regulatory protein MIA_HUMAN 47 2       
          
Intracellular proteins ± Overall number  3 proteins 5 proteins 4 proteins 3 proteins 
Other ± Overall number  3 proteins 2 proteins 6 proteins 5 proteins 
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Table 12. Proteins identified in IL-ȕWUHDWHGH[SODQWsupernatants, unprocessed (no Con A) or unbound after Con A lectin chromatography 
Identifications provided searching MS data within the Swiss-Prot 2013_01 (all mammalian entries) database. Mascot scores >38 indicate identity/extensive 
homology. 
Protein Accession  Unprocessed 
Individual 
Unprocessed 
Pool  
Con A Unbound 
Individual 
Con A Unbound 
 Pool  
  Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
Mascot 
score 
Unique 
peptides 
ECM Proteins          
Cartilage oligomeric matrix protein COMP_BOVIN 7555 20 10590 21   254 8 
 COMP_RAT     839 9   
Thrombospondin 1 TSP1_BOVIN 3456 28 2782 21 115 2   
Fibronectin FINC_BOVIN 3786 40 3492 34     
 FINC_HUMAN     893 14   
Chondroadherin CHAD_HUMAN 1978 8 3689 8 1683 6 3518 6 
Aggrecan core protein PGCA_HUMAN 2258 13 6412 14 4521 16 17599 14 
Proteoglycan 4 (Lubricin) PRG4_HUMAN   59 6     
Decorin PGS2_HORSE 513 9 1130 8     
Biglycan PGS1_HORSE 2047 11 1720 9 169 5   
Fibromodulin FMOD_HUMAN 1381 6 1930 8     
Collagen alpha-1(II) chain CO2A1_BOVIN 139 9 82 8     
Prolargin PRELP_MOUSE 311 6 301 2     
Cartilage intermediate layer protein 1 (CILP-1) CILP1_MOUSE 423 19 264 11 2320 7 4235 6 
Hyaluronan and proteoglycan link protein 1 
(HAPLN1) 
HPLN1_HORSE     2204 20 2915 18 
Secreted Proteins          
Clusterin CLUS_HORSE 1785 13 4876 14 200 7   
Serum amyloid A protein SAA_HORSE 219 4 436 6     
Chitinase-3-like protein 1 (YKL-40) CH3L1_BOVIN 414 6 2018 5 127 3   
Metalloproteinase inhibitor 1 TIMP1_HORSE 457 4 146 3     
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Alpha-1-antiproteinase 2 A1AT2_HORSE 50 3       
MMP-1 MMP1_HORSE 1678 23 1586 20 89 8 52 3 
MMP-3 MMP3_HORSE 5441 20 4580 17 421 7 118 8 
MMP-13 MMP13_HORSE 1700 20 699 12     
Interleukin-9 IL9_HUMAN       51 1 
TNF-R superfamily, member 11b 
(Osteoprotegerin) 
TR11B_RAT 388 6 638 4     
Heat shock 70kDa protein 1-like HS71L_MOUSE 62 8 74 4     
Macrophage migration inhibitory factor MIF_HUMAN 91 2 86 2 60 2   
Lysozyme C LYSM_BOVIN 179 3 148 2     
 LYSCK_SHEEP     42 2   
Lactadherin MFGM_PIG   54 3     
Ribonuclease 4 RNAS4_HUMAN 46 1 59 2     
Semaphorin-3C SEM3C_HUMAN 47 6       
C-X-C motif chemokine 6 CXCL6_HORSE 44 2       
          
Intracellular proteins ± Overall number  22 proteins 15 proteins 22 proteins 18 proteins 
Other ± Overall number  4 proteins 5 proteins 5 proteins 2 proteins 
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Figure 26. Venn diagram displaying the number of ECM and secreted protein 
identifications associated with unprocessed and Con A chromatography on 
untreated and IL-1ɴ stimulated cartilage secretome 
nanoLC-MS/MS analysis was completed on untreated and IL-1ɴ cartilage explant 
conditioned media. Details on specific proteins provided in Table 8 and Table 9. 
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4.3.4. Proteominer enrichment technology 
 The final approach which was assessed for reducing the dynamic range of 
proteins present in the cartilage explant culture secretome was the Proteominer 
enrichment technology. Proteins identified after Proteominer processing are 
recorded in Table 13 for untreated cultures and Table 14 for IL-ȕVWLPXODWHGH[SODQW
cultures. Only 10 proteins were identified in untreated supernatant after 
3URWHRPLQHU enrichment, with 3 of these being trypsin or protease inhibitor cocktail 
components. These included high abundance ECM proteins like COMP, fibronectin, 
fibromodulin and chondroadherin. A secreted component of the complement pathway, 
complement C4-A was also identified here.  
In IL-ȕ VWLPXODWHG FXOWXUHV  SURWHLQV ZHUH LGHQWLILHG RYHUDOO after 
3URWHRPLQHU enrichment. These included several inflammatory related proteins 
usually observed like clusterin, SAA, HSP70 and MIF, but unfortunately many of the 
expected identifications (i.e. MMP-1, -3 and -13) were not made. Four highly abundant 
ECM proteins continued to be identified and 6 intracellular proteins were present. 
Intracellular proteins found in these samples that were not already mentioned in this 
thesis were actin, nestin (intermediate filament, neural development) and erlin-2 
(endoplasmic reticulum associated protein). 
One limitation to Proteominer analysis was the presence of CHAPS within 
the elution buffer (8M urea, 2% (w/v) CHAPS). This interfered with peptide 
identification from about half way through MS runs, at which point CHAPS came off 
the column and produced a strong signal that overwhelmed the signal of any peptides. 
Attempts were made to reduce the concentration of this detergent with the acetone 
precipitation and C18 spin columns, but this did not deplete CHAPS significantly 
enough. Time constraints did not allow further development of the method to explore 
alternative elution buffers or complementary clean up attempts, during which CHAPS 
concentrations may have been reduced to improve MS analysis. 
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Table 13. Protein identifications in untreated explant cultures after Proteominer enrichment 
Database searches were performed with Mascot Daemon on the Swiss-Prot 2013_01 database (all mammalian entries). Mascot scores >38 indicate 
identity/extensive homology. 
Protein Accession  Mascot 
Score 
Unique 
Peptides 
Sequence 
Coverage (%) 
Biological Function 
Clusterin CLUS_HORSE 300 9 12.50 Implicated in various functions, primarily an 
extracellular chaperone 
COMP COMP_BOVIN 141 4 4.50 Extracellular matrix protein 
Trypsin TRYP_PIG 121 3 16.50 Introduced by trypsin digestion of proteins 
Pancreatic trypsin inhibitor BPT1_BOVIN 103 2 22.00 Introduced in protease inhibitor cocktail 
Fibromodulin FMOD_BOVIN 82 2 6.90 Small proteoglycan in extracellular matrix 
Fibronectin FINC_RAT 73 2 1.00 Extracellular matrix protein 
Chondroadherin CHAD_BOVIN 68 2 4.40 Extracellular matrix protein 
Fibronectin (Fragment) FINC_CANFA 61 2 6.10 Extracellular matrix protein 
Eukaryotic translation initiation factor 
2-alpha kinase 4 
E2AK4_HUMAN 50 1 0.50 Cytosolic ± promotes phosphorylation of 
eukaryotic translation initiation factor 
Complement C4-A CO4A_HUMAN 50 1 0.60 Secreted component of complement pathway 
Spleen trypsin inhibitor I BPT2_BOVIN 48 1 9.00 Introduced in protease inhibitor cocktail 
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Table 14. Protein identifications in IL-ȕWUHDWHGH[SODQWFXOWXUHV after Proteominer enrichment 
Database searches were performed with Mascot Daemon on the Swiss-Prot 2013_01 database (all mammalian entries). Mascot scores >38 indicate 
identity/extensive homology. 
Protein Accession  Mascot 
Score 
Unique 
Peptides 
Sequence 
Coverage (%) 
Biological Function 
Vimentin  VIME_HUMAN 278 6 10.10 Cytoplasmic intermediate filament protein 
Clusterin  CLUS_HORSE 263 6 9.60 Implicated in various functions, primarily an 
extracellular chaperone 
Serum amyloid A protein  SAA_HORSE 145 3 30.90 Major inflammation acute phase reactant, 
induced by cytokines 
Serum amyloid A protein  SAA_BOVIN 143 2 20.80 Major inflammation acute phase reactant, 
induced by cytokines 
Actin, aortic smooth muscle  ACTA_BOVIN 108 2 5.60 Cytoskeletal protein, aids cell mobility 
Macrophage migration inhibitory 
factor  
MIF_BOVIN 81 1 9.60 Pro-inflammatory cytokine 
Pyruvate kinase isozymes M1/M2  KPYM_HUMAN 69 2 5.50 Glycolytic enzyme 
COMP COMP_RAT 68 2 4.10 Extracellular matrix protein 
Fibromodulin  FMOD_BOVIN 63 2 6.90 Small proteoglycan in extracellular matrix 
Trypsin  TRYP_PIG 58 1 3.50 Introduced by trypsin digestion of proteins 
Heat shock 70 kDa protein 1-like  HS71L_BOVIN 54 1 2.30 Stress induced chaperone 
Nestin  NEST_MOUSE 51 1 0.50 Neural development protein, intermediate 
filament 
Alpha-enolase  ENOA_HUMAN 50 2 3.90 Multifunctional enzyme, glycolysis 
Thrombospondin-1  TSP1_HUMAN 46 1 1.20 Extracellular matrix protein 
Erlin-2  ERLN2_HUMAN 41 1 2.70 Endoplasmic-reticulum associated protein, IP3R 
degradation 
Fibronectin  FINC_MOUSE 40 1 0.70 Extracellular matrix protein 
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4.4. Discussion 
 The previous chapter covered a time course of proteins released from 
cartilage explant cultures with high-throughput nanoLC-MS/MS. This identified 
proteins that could be utilized to study aspects of cartilage biology. Coverage of the 
explant secretome could be expanded with further in depth studies to identify 
additional biologically relevant proteins. Knowledge of additional proteins will provide 
biomarkers for monitoring responses to inflammatory mediators and potential anti-
inflammatory compounds. In complex samples, highly abundant proteins are known to 
³PDVN´ LGHQWLILFDWLRQV RI ORZ-level proteins (Millioni et al., 2011). In the MS analysis 
described in this thesis, only the 5 most abundant peptides from each MS survey scan 
are selected for fragmentation, therefore low abundance peptides will generally fail to 
be analysed. Three different approaches, CPC precipitation, Con A chromatography 
and Proteominer were assessed for their ability to deplete high abundance proteins 
prior to MS. For both CPC precipitation and Con A approaches, SDS-PAGE and silver 
staining were used as an additional assessment of the depletion of samples. After it 
was confirmed abundant proteins were being removed, the depleted supernatants 
were analysed by high-throughput MS. 
4.4.1. CPC precipitation in cartilage proteomics  
CPC was effective at precipitating highly abundant ECM components 
including proteoglycans, as certain small proteoglycans like decorin and fibromodulin 
were no longer detected after CPC precipitation, but were present in the CPC pellet 
(Table 9). Unexpectedly, two ECM proteins HAPLN1 and CILP-1 appeared to be 
enriched by the CPC processing. It is possible that degraded fragments of these 
proteins may not interact with CPC. While YKL-40 and MMP-13 identifications were 
lost, MMP-10 was identified after this approach. Of the three depletion processes 
described in this chapter, CPC precipitation was least detrimental with respects to 
reduction of the overall number of proteins detected by MS.  
One protein that was found only in the glycoprotein depleted secretome after 
CPC precipitation was MMP-10 (stromelysin-2), which is a member of the stromelysin 
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group of MMPs as is MMP-3 (stromelysin-1). MMP-10 can activate other 
procollagenases like MMP-1 (Nakamura et al., 1998) and has a weak degradative 
action on collagens type III, IV and V (Nicholson et al., 1989). Presence of MMP-10 
was detected in synovial fluid and cartilage from RA and OA patients (Barksby et al., 
2006). That study also demonstrated MMP-¶VUROHLQSUR003DFWLYDWLRQVSHFLILFDOO\
MMP-1, MMP-8 and MMP-13 (Barksby et al., 2006). Synoviocytes expressing MMP-
10, -1 and -3, display significantly more invasive characteristics contributing to RA and 
OA progression (Tolboom et al., 2002). A Wnt-1-inducible signalling pathway protein 3 
(WISP3/CCN6) gene mutation associated with OA and cartilage breakdown can 
increase MMP-10 expression in chondrocytes (Baker et al., 2012). Stimulation with 
OA related cytokines can also affect MMP-10 secretion, including increased release 
from IL-1 stimulated OA cartilage detected by protein antibody arrays (Jarvinen et al., 
2008). Chondrocytes and synovial fibroblasts can be induced to express MMP-10 by 
the pro-inflammatory cytokines IL-1, TNF-Į DQG RQFostatin (Barksby et al., 2006). 
Confirmation of the presence of MMP-10 in the secretome of IL-ȕ WUHDWHG HTXLQH
cartilage could allow this OA associated protease to be studied within this explant 
model. 
4.4.2. Con A and M-LAC aided analysis in cartilage proteomics 
The highly glycosylated status that attracts water molecules and swells the 
ECM is an important characteristic of cartilage (Buckwalter and Mankin, 1998b). Con 
A lectin chromatography was chosen to target glycosylated residues on abundant 
ECM components to provide depleted fractions for MS analysis. One limitation to this 
approach was introduction of Con A leaching out into elution material, observed in the 
SDS-PAGE image in Figure 24. A band at 30 kDa corresponding to Con A after 
sample processing, is not present in unprocessed supernatants. Introducing an 
additional abundant protein will be detrimental to detection of low level proteins. 
Attempts to reduce Con A release with wash steps before processing were made, but 
these did not decrease levels of Con A leakage. Mascot searches of the Con A 
processed samples against all taxonomic entries in the NCBInr database revealed 
  
149 
 
Con A to be the top protein hit (data not shown). Con A presence at such high levels 
will have hampered identification of additional low level proteins in these experiments. 
 Lectin chromatography techniques have not yet been widely used for OA 
research. No reports have been published on Con A fractionation of proteins from 
cartilage conditioned media 3XE0HG VHDUFK WHUPV ³SURWHRPLFV´ ³FDUWLODJH´ RU
³RVWHRDUWKULWLV´ 'HF . The plasma peptidome and proteome of RA have been 
studied with M-LAC fractionation being used prior to high-throughput MS analysis 
(Zheng et al., 2009). Actin and C-reactive protein were associated with RA plasma, 
and calgranulin A, B and C were detected only in M-LAC bound fractions (Zheng et 
al., 2009). The glycoproteome of early chondrogenesis and accompanying differential 
markers has been investigated with Con A (Ishihara et al., 2013). Lysate of 
differentiating mouse chondroprogenitor cells was fractionated to identify the 
glycoproteome, before gene expression of selected proteins in human MSCs (Ishihara 
et al., 2013). Collagens type III and XI, aquaporin-1, netrin receptor unc-5 homolog B 
and ectonucleotide pyrophosphatase/phosphodiesterase family member 1 all showed 
potential as early chondrogenesis markers (Ishihara et al., 2013). The types of 
proteins found in cell lysate will be fundamentally different to those found in cartilage 
secretome, which may explain why Ishihara et al achieved successful application of 
Con A methods. In this chapter, Con A processing did increase detection of metal 
binding proteins like ferritin heavy/light chains, metallothionine and selenium binding 
proteins, which are all involved in intracellular metal storage (Proulx-Curry and 
Chasteen, 1995). The presence of intracellular proteins in the cartilage explant 
secretome suggests that there is some chondrocyte cell death during culture. 
However, detecting such proteins in greater numbers after depleting the levels of 
abundant ECM proteins demonstrates that using Con A for glycoprotein depletion has 
facilitated the MS detection of proteins present at lower levels.  
Excised bands from SDS-PAGE provided MS identifications of high 
abundance ECM proteins such as fibronectin and aggrecan core protein, and 
catabolic MMP-3 in Con A unbound samples (Figure 24). Therefore targeted removal 
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of glycosylated proteins was not totally effective at removal of abundant ECM 
proteins. HAPLN1 achieved higher Mascot scores after this Con A processing, 
indicating it was comparatively enriched compared to the other proteins present. Con 
A did not bind this ECM protein, therefore it remained in the unbound fraction as 
observed in Figure 24. This link protein is responsible for attachment of hyaluronic 
acid chains with proteoglycan aggregates (Poole et al., 1982), which help to form a 
highly hydrated ECM. A high proportion of HAPLN1 must be unbound from the 
aggregating proteoglycans to not interact and be depleted by Con A chromatography. 
This could be newly synthesised HAPLN1 that has not been incorporated into the 
ECM. 
 The cytokine IL-9 was identified in the secretome of untreated and IL-ȕ
stimulated explants, only in unbound supernatants after Con A processing. IL-9 
stimulates expression of IL-22 in T lymphoma cells, which in turn will contribute 
towards release of pro-inflammatory factors (Ikeuchi et al., 2005, Dumoutier et al., 
2000). STAT1, STAT3 and STAT5 transcription factors are activated by IL-9 leading 
to gene expression that inhibits apoptosis (Demoulin et al., 1999). The potential role of 
IL-9 in OA has not been extensively studied and therefore the implications of this 
identification are unclear and warrant further research. Further proteomic and other 
studies will assess the reliability of IL-9 identification because sample numbers were 
limited, and only one significant peptide was repeatedly detected to contribute towards 
reported Mascot scores. Con A chromatography has aided identification of IL-9 in the 
explant model, but additional work is needed to determine effects of cytokines or anti-
inflammatory factors on this protein. 
4.4.3. Applications of Proteominer in proteomics and OA 
Proteominer technology is designed to enrich low abundance proteins and 
decrease the dynamic range of complex samples. This technique has been applied 
analysis of serum for a range of diverse diseases to discover potential biomarkers. 
Proteominer analysis of serum from lung cancer patients aided identification of 
SAA1 (Milan et al., 2012). Gelsolin association with hepatitis B-associated liver 
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cirrhosis was also found with Proteominer enrichment of serum (D'Amici et al., 
2012). In the search for novel biomarkers for osteoarthritis, serum analysis with 
Proteominer technology has also been completed (Fernandez et al., 2011, 
Fernandez-Costa et al., 2012). An altered haptoglobin profile in serum showed this 
protein to be increased in OA patients by 2DE (Fernandez-Costa et al., 2012).  
In chapter 3 of this thesis, coverage of the secretome was limited by the 
presence of highly abundant proteins, therefore a trial study using Proteominer 
before MS was completed. The high-throughput MS analysis of cartilage explant 
secretome after Proteominer application did not prove beneficial to low abundance 
protein identification. Optimisation of this kit by the manufacturers focused on plasma 
and serum therefore it was not guaranteed to work for cartilage explant conditioned 
PHGLDDOWKRXJKZKROH2$FDUWLODJHKDVEHHQDQDO\VHGZLWK3URWHRPLQHUZLWKWKUHH
novel OA biomarkers proposed: LECT2, BAALC and PRDX6 (Ikeda et al., 2013). 
While many proteins may be found both in whole cartilage or cartilage supernatant, 
there are fundamental differences in composition of these samples. Throughout the 
literature, many other sample types have been aided by Proteominer including urine 
(Candiano et al., 2012), egg white extract (D'Ambrosio et al., 2008), cell lysates 
(Fonslow et al., 2011) and beer (Fasoli et al., 2010). 
Proteominer kit instructions stated best results would be achieved with 10 
mg protein being processed by the procedure. With knowledge that suitable volumes 
and concentrations from cartilage explant culture supernatant would provide 
considerably lesser amounts of proteins, two changes were introduced to previous 
explant culture methods. Firstly, the number of explants was increased from 5 to 8 
discs per 1 ml media. Secondly, centrifugal filter units were utilised to concentrate 12 
ml of secretome samples down to ~0.5 ml. Protein assays confirmed that 
concentrated samples contained protein amounts that would be more suitable for 
starting this procedure. Although these steps were introduced to concentrate material, 
it is possible that cartilage explant supernatants still provided sample material that 
was not ideal for Proteominer techniques. Analysis of whole cartilage benefited from 
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3URWHRPLQHU DSSOLFDWLRQ (Ikeda et al., 2013), but achieving suitably higher 
concentrations of protein would be possible with whole cartilage samples. Another 
limitation to this trial was the presence of CHAPS in elution buffer. Sample preparation 
with acetone precipitation and C18 spin columns did not decrease this detergent 
sufficiently, and therefore high levels were present in the MS runs. The first half of 
runs provided peptide peaks within the mass spectrum, but once CHAPS began to 
come off the column, signals from it obscured the peptide signals. The protein 
identifications that were made with data before the peptide signals were lost, indicated 
that known high abundance ECM proteins continued to achieve the highest Mascot 
scores and limited additional low-level proteins were found (Table 13, Table 14). 
Alternative elution buffers (not containing CHAPS) could be investigated to separate 
bound proteins from the hexapeptide bead library, but this was not followed up due to 
time constraints. Identifications from data received also gave no indication of effective 
depletion of abundant proteins. The majority of Proteominer studies used 2DE 
afterwards to assess improvements in proteomic coverage, in which CHAPS did not 
disrupt the process. One study on cell lysate from HeLa cells did show improvements 
in enrichment of low abundance proteins using an alternative elution buffer before 
high-throughput MS (Fonslow et al., 2011). Therefore high-throughput MS 
applications can be achieved via this technology with further method optimisation. 
4.4.4. Challenges of abundant protein depletion in cartilage explant culture 
proteomics 
There are several possible explanations for the minimal yield of additional low 
abundance proteins identified in high-throughput MS using depletion methods 
reported in this chapter. The functional roles of many cartilage related proteins 
involves binding to other proteins within the ECM (Heinegard, 2009). Therefore ECM 
constituents contain a variety of binding sites for smaller proteins, growth factors and 
cytokines. It is possible that binding interactions remained during the 
depletion/enrichment procedures therefore low abundance proteins were co-extracted 
along with the selectively-removed ECM components. Therefore the depleted sample 
remaining was also depleted of low abundance proteins, hence the lack of additional 
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identifications reported. This effect could be influential on the current results because 
there are excess abundant ECM proteins to bind with lower level proteins. Secreted 
low abundance proteins may also be glycosylated themselves so would interact and 
be removed by the Con A lectin or CPC precipitation. Further refinement of these or 
alternative high abundant protein depletion approaches may aid additional proteins 
identifications in cartilage secretome. Enzymatic treatment of samples prior to CPC 
precipitation/Con A chromatography could aid analysis with the techniques. For 
example, trypsin digestion before Con A chromatography and MS was completed on 
ATDC5 cells (Ishihara et al., 2013). Enzymatically digesting proteins or reducing 
proteins with DTT may interrupt the binding abilities of abundant proteins and 
therefore develop effective depletion methods. Unfortunately due to time constraints 
of this project, no further improvements were made to report in this thesis. 
4.4.5. Conclusion 
The hypothesis of this chapter was that by depletion of highly abundant ECM 
proteins, coverage of low level proteins in explant secretome could be achieved. 
Three different methods were trialled on explant conditioned media before nanoLC-
MS/MS. CPC precipitation targeted negatively charged groups inherent in 
proteoglycans and GAGs. Con A lectin chromatography specifically binds to 
glycosylation groups, allowing abundant ECM components to be bound, leaving 
behind a glycoprotein depleted fraction. Proteominer enrichment aimed to equalise 
the dynamic range of secretome, thereby enriching low level proteins and decreasing 
abundant proteins. MMP-10 and IL-9 identification was aided by CPC precipitation 
and Con A chromatography respectively. Uncovering these low level proteins that are 
relevant to the cartilage explant model and OA, demonstrates the potential of applying 
these depletion approaches prior to high-throughput MS. The most effective depletion 
method was CPC precipitation due to effective removal of certain proteoglycans and 
ECM proteins, whilst being least detrimental to numbers of secreted proteins 
identified, including MMP-1, MMP-3, MMP-10 and TIMP-1. Although, the data 
achieved in this thesis showed high-throughput MS analysis on unprocessed cartilage 
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supernatant (without any depletion methods as reported in chapter 3) provided the 
most definitive coverage of the secretome. Whilst these current studies only revealed 
a few additional low abundance proteins, further optimisation of the experimental 
approaches described here may allow increased identifications. Once an appropriate 
depletion technique is developed, larger scale studies will allow greater coverage of 
the cartilage secretome to be achieved. 
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CHAPTER 5 
APPLYING AN IL-ȕSTIMULATED CARTILAGE 
EXPLANT MODEL TO ASSESS ANTI-INFLAMMATORY 
EFFECTS OF CARPROFEN 
5.1. Introduction 
 Progression of OA is a complex process, leading to loss of cartilage ECM 
facilitated by inflammatory mediators and metabolic processes (Goldring et al., 2008). 
Excess release of catabolic proteins within synovial joints affected by OA contributes 
towards cartilage breakdown and loss (Abramson and Attur, 2009). Degradative 
fragments of ECM proteins such as fibronectin, are released into surrounding synovial 
fluid where they initiate further inflammatory signalling (Homandberg et al., 1998). 
These degradative products are also released into culture supernatant whilst 
incubating cartilage explants. In Chapter 3, released ECM components and catabolic 
MMPs were identified in cartilage secretome by high-throughput MS. These candidate 
proteins identified in the secretome were chosen for quantitative western blotting. 
These proteins can act as biomarkers within this model for assessment of cartilage 
breakdown and metabolism in response to selected treatments. This chapter 
describes the ability of the cartilage explant model to monitor selected candidate 
proteins MMP-1, MMP-3, MMP-13, TSP, COMP, fibronectin and clusterin. 
5.1.1. IL-ȕDQGFDUSURIHQWUHDWPHQWVZLWKLQH[SODQWFXOWXUH 
The pro-inflammatory cytokine IL-ȕ was chosen to stimulate cartilage 
explants. IL-ȕ is implicated in OA cartilage inflammation and progression of the 
disease, and is found at significantly higher levels in early OA stages (Benito et al., 
2005). In chondrocytes it stimulates release of cytokines, chemokines and catabolic 
proteins, and inhibits synthesis of collagen type II and IX (David et al., 2007, 
Busschers et al., 2010, Goldring et al., 1988). Injection of IL-ȕLQWRV\QRYLDOMRLQWVRI
horses demonstrates comparable responses in vivo (Ross et al., 2012). Stimulation of 
cartilage explants with IL-ȕ also caused changes in SDS-PAGE profiles and MS 
analysis identifications throughout previous thesis chapters.  
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The NSAID, carprofen (marketed as Rimadyl® by Pfizer) was chosen to 
evaluate the potential for screening anti-inflammatory effects on IL-ȕ VWLPXODWHG
cartilage explant secretome. Joint pain and inflammation associated with OA in dogs 
and horses are treated clinically using this NSAID (Goodrich and Nixon, 2006). 
Carprofen was available as a prescription medication for humans from 1988 to 1998 
but was voluntarily withdrawn for commercial reasons. It is a selective COX-2 inhibitor 
that blocks synthesis of PGE2 in the arachidonic acid signalling pathway. Selectivity 
for COX-2 (over COX-1) at IC50 has been confirmed in horses (Beretta et al., 2005). 
Carprofen has been reported to hold back progression of OA related changes in 
cartilage and subchondral bone in dogs (Pelletier 2000). Beneficial effects include 
decreased PGE2 production and GAG release, and increased proteoglycan synthesis 
in equine in vitro studies (Goodrich and Nixon, 2006). Carprofen was selected to study 
the explant models ability to screen anti-inflammatory compound effects on ECM 
degradation and secretion of proteases. 
5.1.2. Candidate protein biomarkers monitored in the explant model - MMPs, 
ECM proteins and clusterin  
MMPs -1, -3 and -13 were all identified in IL-ȕVWLPXODWHGFDUWLODJHH[SODQW
secretome and showed semi-quantitative differences in release (Chapter 3). These 
three MMPs have all been implicated in progression of OA. Collagenases (MMP-1 
and MMP-13) will degrade collagen fibres along with other non-collagenous ECM 
proteins. MMP-1 is known as interstitial collagenase, which efficiently cleaves 
collagen types I, II and III (Chung et al., 2004). MMP-1 has the vital ability to unwind 
triple-helical collagen fibres to facilitate collagen enzymatic degradation (Manka et al., 
2012). The C-terminal hemopexin domain enables this unwinding, whilst a separate 
N-terminal catalytic domain cleaves the collagen chain (Manka et al., 2012). IL-ȕ
treatment causes significant increases in MMP-1 secretion from chondrocytes in vitro 
shown by quantitative SILAC analysis (Calamia et al., 2011). IL-ȕ DQG /36 LQWUD-
articular injections up-regulate gene expression of MMP-1 in equine articular cartilage 
in vivo (Ross et al., 2012). 
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MMP-13 has an important role in collagen type II degradation, which is the 
most abundant collagen type found in cartilage (Knauper et al., 1996, Reboul et al., 
1996). Collagens types VI and IX, aggrecan and other proteoglycans can also be 
degraded by MMP-13 (Shiomi et al., 2010). Transgenic mice have shown that 
constitutive active MMP-13 causes OA in vivo (Neuhold et al., 2001). Delayed 
development of OA occurs with deletion of the MMP-13 gene from a meniscal-
ligamentous injury (MLI)-induced mouse model (Wang et al., 2013). Proteomic 
investigations have also identified MMP-13 as a differentially up-regulated protein in 
OA cartilage (Iliopoulos et al., 2008).  
MMP-3 (stromelysin-1) can degrade fibronectin, collagens including types I, 
IV and IX, and proteoglycans (Chin et al., 1985, Okada et al., 1989). MMP-3 has a 
vital role in producing collagen degradation by cleavage of pro-peptide domains to 
activate collagenases including MMP-1 and MMP-13. The secretome of OA cartilage 
contains higher levels of MMP-3 compared to healthy tissue (Hermansson et al., 
2004, De Ceuninck et al., 2005). Its release is also stimulated by pro-inflammatory 
cytokine treatment of chondrocytes and cartilage (Stevens et al., 2008, Calamia et al., 
2011, Catterall et al., 2006). Treatment with an MMP inhibitor on a rat meniscal 
transection model of OA, showed a reduction in perceived pain, joint damage and 
osteochondral vascularisation (Mapp et al., 2010). Semi-quantitative differences in 
MMP-1, -3 and -13 were consistently reported in the secretome. The physiological 
relevance of these MMPs in cartilage degradative and OA make these proteins 
suitable candidates for western blotting analysis.  
ECM proteins made up a large proportion of the cartilage secretome 
identifications after MS analysis (Chapter 3). Pro-inflammatory cytokines increase 
release of catabolic enzymes including ADAMTS and MMPs, which leads to 
degradation of the ECM (Goldring, 1999). Here, western blots of ECM constituents 
COMP, TSP and fibronectin assessed if pro-inflammatory or anti-inflammatory stimuli 
caused differential release of degraded fragments. This helped determine if changes 
in ECM proteins correlated with alterations occurring in MMP secretion levels. 
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COMP is a non-collagenous pentameric protein made up of 5 glycosylated 
subunits around 100 kDa (Hedbom et al., 1992). It binds to collagen fibres and is 
important in organisation of the cartilage ECM (Rosenberg et al., 1998). COMP has 
been studied as a diagnostic and prognostic biomarker of OA, and a deamidated 
epitope of COMP in serum is associated with hip OA specifically (Catterall et al., 
2012). TSP is an adhesive glycoprotein that helps mediate cell to matrix interactions 
in cartilage, interacting with integrins in the plasma membrane (Frazier et al., 1999). 
Fibronectin is a dimeric glycoprotein (440 kDa) found in cartilage ECM, which 
interacts with collagens and cell surface proteins (Potts and Campbell, 1996). Its main 
roles involve contributing to cell adhesion in the ECM and motility (Potts and 
Campbell, 1996). Fragments of fibronectin released during osteoarthritis contribute 
towards cartilage degradation by up-regulating catabolic signaling (Homandberg et al., 
1998). These degradation fragments are produced by MMP-1, MMP-3 and MMP-13 
enzymatic actions (Zhang et al., 2012a). 
Clusterin consistently achieved high Mascot scores in chapter 3. Clusterin is a 
secreted chaperone that takes part in a variety of different functions including 
inflammation and apoptosis, which could contribute to diseases like OA (Wilson and 
Easterbrook-Smith, 2000). One study has shown that clusterin mRNA was expressed 
at higher levels in early OA compared to healthy cartilage (Connor et al., 2001). Whilst 
in late OA, clusterin mRNA expression was reduced (Connor et al., 2001). In early 
stages of OA there could have been an increased attempt to protect cartilage from 
damage, while in advanced disease stages there is a loss of ability to express 
clusterin (Connor et al., 2001).  
Synovial fluid and synoviocyte expression of clusterin from RA and OA 
patients has revealed differences in expression levels (Devauchelle et al., 2006). The 
full-length and spliced isoform of clusterin mRNA were lower in RA samples compared 
to both OA and normal synovial tissues (Devauchelle et al., 2006). Clusterin was 
proposed as a marker to distinguish between RA and OA (Devauchelle et al., 2006). 
Intracellular studies showed siRNA targeting clusterin caused an increase in IL-6 and 
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IL-8 synthesis, and that clusterin can affect NF-ț% VLJQDOOLQJ ZLWKLQ V\QRYLRF\WHV
(Devauchelle et al., 2006). A comparison of serum and synovial fluid from healthy 
individuals and patients suffering from knee or hip OA reported elevated levels of 
secreted clusterin (Fandridis et al., 2011). In 2012, clusterin was identified as a 
candidate plasma biomarker for OA progression after 2D-LC-MALDI glycoprotein 
analysis (Fukuda et al., 2012). Unfortunately, validation of clusterin as a biomarker for 
OA progression was not supported by ELISA or western blot data completed (Fukuda 
et al., 2012). This chapter monitored clusterin release from cartilage explants in 
response to IL-ȕ DQG FDUSURIHQ WUHDWPHQWV GXH WR FOXsterin abundance in the 
secretome and potential association with OA. 
5.1.3. Nitric Oxide (NO) measurement 
OA cartilage explants produce increased levels of NO release associated with 
cartilage inflammation (Amin et al., 1995). Cytokine stimulation increases iNOS 
release, which synthesises NO and leads to higher NO levels in inflammatory 
conditions (Taskiran et al., 1994). NO has a variety of functional roles related to OA 
including pain perception, catabolic signalling and apoptosis (Abramson, 2008). NO 
released into cartilage conditioned media will eventually be converted to nitrite, which 
can be measured by Griess assays. This allowed comparison of NO released from 
untreated cartilage in response to IL-ȕand carprofen stimulation.  
5.1.4. Hypothesis and aims 
In previous chapters, high-throughput MS analysis on cartilage secretome 
identified released ECM proteins, along with secreted chemokines, metabolic proteins 
and inflammatory stress related proteins. Studies in this chapter describe assessment 
of the effects of IL-ȕDQGFDUSURIHQ WUHDWPHQWVRQquantitative release levels of the 
proteases MMP-1, -3 and -13, clusterin, selected ECM constituents and NO. It was 
hypothesised that carprofen would decrease IL-ȕ VWLPXODWHG release of catabolic 
MMPs and inflammatory related products, due to its inhibition of COX-2 and PGE2 
production. Decreases in MMPs could therefore cause reduced release of degradative 
ECM components monitored by western blotting. Examining effects of carprofen on 
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IL-ȕWUHDWHGH[SODQWFXOWXUHVVKRZed this approach can be used to screen other anti-
inflammatory compounds. 
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5.2. Methods 
5.2.1. Dissection and explant culture 
 See Materials & Methods for dissection and explant culture protocols 
(Chapter 2.3.). All articular cartilage explant cultures in this chapter were incubated for 
6 days at 37 °C, 5% CO2. 
5.2.2. Western blotting 
 Western blotting protocol was described in Chapter 2.6. Primary antibody 
dilutions were made up as follows in 3% (w/v) BSA: MMP-1 (1:800 dilution, Aviva), 
MMP-3 (1:1000 dilution, Aviva), MMP-13 (1:1000 dilution, Aviva), TSP (1:1000, 
Abcam), fibronectin 1 (1:1000 dilution, Aviva), clusterin (1:1000 dilution, Aviva), 
COMP (1:500 dilution, kindly donated from the Misumi laboratory). 
 Secondary antibodies were diluted in 3% (w/v) BSA to the following 
concentrations: 1:100,000 anti-rabbit (Bio-Rad) for MMP-1, MMP-3, MMP-13, 
fibronectin and clusterin or 1:40,000 anti-mouse (Bio-Rad) for COMP. All secondary 
antibodies were HRP FRQMXJDWHGWREHFRPSDWLEOHZLWK$PSOLIOX5HGGHWHFWLRQ 
5.2.3. Griess assay 
 Measurement of nitrite concentration was achieved using a Griess Reagent 
System (Promega) (Griess, 1879). A reference curve was prepared for each assay, 
starting with a 100 µM nitrite concentration before 6 serial two-fold dilutions were 
completed. This provided nitrite concentrations of 100, 50, 25, 12.5, 6.25, 3.13, 1.56 
and 0 µM, all diluted in DMEM + 2% Pen/Strep. Each experimental sample was 
assayed in triplicate with 50 µl added into a 96 well plate. Sulfanilamide solution (50 
µl) was added to all wells and incubated for 5 minutes protected from light. Next, 
naphthylethylenediamine dihydrochloride (NED) solution (50 µl) was added and 
incubated for 5 minutes protected from light. Phenol red in culture media interferes 
with the ability to measure quantitative nitrite levels. Thus, interpolated levels of 
untreated and carprofen samples reported negative values, therefore optical density 
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(540 nm) values were recorded to compare treatments. Absorbance at 540 nm was 
measured within 30 minutes on a LT-4000 plate reader using Manta software 
/DEWHFK *UDSKLFDO DQG VWDWLVWLFDO DQDO\VLV 7XNH\¶V PXOWLSOH FRPSDULVRQV ZDV
completed with GraphPad Prism 6. 
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5.3. Results 
5.3.1. Carprofen reduces IL-1ɴ stimulated MMP-1 release  
 Qualitative differences in MMP-1 identifications between untreated and IL-ȕ
supernatants analysed by MS were reported in Chapter 3, with Mascot scores up to 
1678 reported in IL-1ɴ samples after 6 days, while no score was associated with 
untreated samples (Table 7). To quantify MMP-1 release, western blotting and 
densitometry were completed as displayed in Figure 27. Release of MMP-1 was not 
detected in cartilage conditioned media from untreated or carprofen only treated 
extracts. In IL-ȕDQGcarprofen + IL-ȕWUHDWHGVXSHUQDWDQWVEands visible at around 
53 kDa corresponded to the expected molecular weight of MMP-1. The positive 
control provided an additional band at a slightly lower molecular weight, as well as the 
53kDa band observed in secretome samples. Intense MMP-1 bands were initiated by 
IL-ȕWUHDWPHQW. A decrease in IL-ȕVWLPXODWHG003-1 release was observed when 
carprofen is present alongside the cytokine. Densitometry reveals this decrease to be 
statistically significant, therefore carprofen is able to reduce release of this catabolic 
protein. This may indicate beneficial effects of carprofen treatment to lessen cartilage 
breakdown catalysed by MMP-1 during OA. 
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Figure 27. IL-ȕVWLPXODWHGUHOease of MMP-1 is significantly decreased with carprofen 
treatment 
(A) Representative image of western blot against MMP-1 on cartilage explant supernatant after 
6 days of incubation. Treatments were as follows: untreated, IL-1beta (10 ng/ml), carprofen 
(100 µg/ml) + IL-1beta (10 ng/ml) or carprofen (100 µg/ml). 50µl of each cartilage supernatant 
sample was lyophilised, then resuspended in 20 µl Laemmli buffer and loaded onto gels. (B) 
Densitometry analysis on western blots (ImageJ, GraphPad Prism 6) from three horses, each 
with three treatment replicates (n=9). Error bars indicate standard deviation. M = molecular 
weight markers (Bio-Rad), + = positive control prepared by crushing articular cartilage with a 
mortar and pestle in liquid nitrogen and resuspending in Laemmli buffer, before being 5-fold 
diluted for loading. 
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5.3.2. Carprofen decreases IL-1ɴ stimulated MMP-3 release 
 In previous chapters, MMP-3 was identified by nanoLC-MS/MS across all 
explant treatments. An increase in MMP-3 release was suggested by higher Mascot 
scores with IL-ȕVWLPXODWLRQ (956 in untreated samples, 5441 in IL-1ɴ samples (Table 
7)). To accurately quantify MMP-3 release across treatments, this chapter set out to 
western blot this protein in response to IL-ȕDQGFDUSURIHQ$WN'D003-3 bands 
are visible across all treatments studied (Figure 28). An additional band is stimulated 
in samples where IL-ȕ LV SUHVHQW 003-3 is synthesized in a non-active zymogen 
form where cleavage of pro-peptide domain activates the enzyme (Woessner, 1991, 
Grossetete et al., 2009). The lower band therefore should correspond to the active 
form of MMP-3, which is activated by IL-ȕ VLJQDOOLQJ Carprofen significantly 
decreased the cytokine stimulated MMP-3 when densitometry on western blots was 
completed. As MMP-3 has roles in ECM breakdown and activation of related 
procollagenases, carprofen treatment could affect MMP mediated degradation in OA. 
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Figure 28. IL-ȕVWLPXODWHGUHOHDVHRI003-3 is significantly reduced by carprofen 
(A) Representative image of western blot against MMP-3 on cartilage explant supernatant 
after 6 days of incubation. Treatments were as follows: Untreated, IL-1beta (10 ng/ml), 
carprofen (100 µg/ml) + IL-1beta (10 ng/ml) or carprofen (100 µg/ml). 50µl of each 
cartilage supernatant sample was lyophilised, then resuspended in 20 µl Laemmli buffer 
and loaded onto gels. (B) Densitometry analysis on western blots (ImageJ, GraphPad 
Prism 6) from three horses with three technical replicates (n=9). Error bars indicate 
standard deviation. M = molecular weight markers (Bio-Rad). 
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5.3.3. IL-1ɴ stimulated MMP-13 release is decreased by carprofen 
MMP-13 was selected as a candidate protein to western blot after 
identification by MS of the cartilage secretome (Chapter 3) and its known roles in 
ECM degradation and OA (Knauper et al., 1996, Shiomi et al., 2010). In chapter 3, 
Mascot scores up to 1700 were reported with IL-1ɴ stimulated samples, while 
untreated samples did not provide MMP-13 identification (Table 7). Throughout 
western blotting analysis in the current chapter, MMP-13 was not detected in 
untreated or carprofen only samples (Figure 29). When IL-ȕZDVSUHVHQW LWFDXVHG
MMP-13 bands to be observed at 54 kDa (Figure 29). Fainter bands are visible with 
carprofen + IL-ȕ WUHDWPHQW FRPSDUHG WR LQWHQVH EDQGV ZLWK ,/-ȕ DORQH
Densitometry confirmed statistically higher levels of MMP-13 for IL-ȕ DQG ORZHU
levels with carprofen + IL-ȕ 
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Figure 29. Carprofen decreases IL-ȕVWLPXODWHG003-13 release from cartilage 
explants  
(A) Representative image of western blot against MMP-13 on cartilage explant 
supernatant after 6 days of incubation. Treatments were as follows: Untreated, IL-1beta 
(10 ng/ml), carprofen (100 µg/ml) + IL-1beta (10 ng/ml) or carprofen (100 µg/ml). 50µl of 
each cartilage supernatant sample was lyophilised, then resuspended in 20 µl Laemmli 
buffer and loaded onto gels. (B) Densitometry analysis on western blots (ImageJ, 
GraphPad Prism 6) from three horses with three replicates per treatment (n=9). Error 
bars indicate standard deviation. M = molecular weight markers. 
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5.3.4. Thrombospondin release stimulated by IL-1ɴ is not affected by carprofen 
Western blotting against TSP was completed on selected MMP-3 blotted 
membranes. MMP-3 along with other MMPs is known to target ECM substrates 
(Troeberg and Nagase, 2012), therefore TSP release was assessed by western 
blotting. TSP bands were detected around the expected 125 kDa in IL-ȕ DQG
carprofen + IL-ȕFRQGLWLRQHGmedia (Figure 30). No TSP was detected in untreated 
and carprofen only samples. In Chapter 3, TSP was reliably identified across all 
treatments with high Mascot scores, but only IL-ȕwas capable of releasing TSP to 
detectable levels in western blots. Although IL-ȕLQGXFHGVHFUHWLRQDQGDFWLYDWLRQRI
MMPs can be decreased by carprofen, this does not have an impact on levels of TSP 
released from the ECM. 
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Figure 30. Thrombospondin release stimulated by IL-ȕLVQRWVLJQLILFDQWO\GHFUHDVHG
following carprofen + IL-ȕWUHDWPHQW 
Thrombospondin western blots produced a band at 125 kDa only observed when IL-ȕ
stimulation was present. An unpaired t-test comparing IL-ȕDQGFDUSURIHQ,/-ȕEDQGV
reported no significant difference (p>0.05). Explant cultures were completed for 6 days 
with 3 treatment replicates from the same individual animals (n=3). Explant treatment: 
untreated control, IL-1beta (10 ng/ml), carprofen (100 µg/ml) + IL-1ɴ (10 ng/ml) or 
carprofen (100 µg/ml). 50µl of each cartilage supernatant sample was lyophilised, then 
resuspended in 20 µl Laemmli buffer and loaded onto gels. 
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5.3.5. IL-ȕVWLPXODWLRQRIH[SODQWFXOWXUHLQLWLDWHVGHJUDGDWLRQRI&203 
 One of the most abundant proteins in the cartilage explant secretome is 
COMP, which achieved high Mascot scores across all sample types in MS analysis 
(Chapter 3). Western blotting provided insights into COMP degradation occurring 
during cytokine stimulation of cartilage explants (Figure 31). The highest band (120 
kDa) was released into supernatant in all treatments, and was the definitive band in 
the cartilage positive control. Cultures with IL-ȕDQGFDUSURIHQ,/-ȕFRQWDLQHGDQ
intense band slightly below (at 110 kDa). A fainter band is seen at 90 kDa across all 
samples, while another band around 10 kDa smaller (at 80 kDa) is observed in 
samples associated with IL-ȕ%DQGVDWN'DDQGN'Dwere only visible after 
explants are IL-ȕVWLPXODWHGZKLFKVXJJHVWVWKHVHEDQGVFRUUHVSRQGWRGHJUDGDWLRQ
products. It was not possible to complete densitomeric quantification for COMP due to 
streaking and the close proximity of bands. Application of an ECL detection approach 
during future western blotting could allow development times to be altered, which 
could improve the ability to accurately quantify specific bands. 
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Figure 31. IL-ȕVWLPXODWLRQRIH[SODQWFXOWXUHVLQLWLDWHVUHOHDVHDQGGHJUDGDWLRQRI&203 
Western blot image against COMP shows four main bands corresponding to glycosylated 
COMP monomer (120 kDa) and lower COMP products (110, 90, 80 kDa). Explant culture 
was completed for 6 days with 3 replicates per treatment (n=3). Explant treatments: 
untreated control, IL-1E (10 ng/ml), carprofen (100 µg/ml), or carprofen (100 µg/ml) + IL-1E  
(10 ng/ml). M = molecular weight markers (Bio-Rad), + = positive control prepared by 
crushing articular cartilage with a mortar and pestle in liquid nitrogen and resuspending in 
Laemmli buffer. A 10-fold dilution of positive control stock was performed and 20µl was 
loaded. 50µl of each cartilage supernatant sample was lyophilised, then resuspended in 
20µl Laemmli buffer and loaded onto gels. 
 
kDa 
kDa 
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5.3.6. Release of a fibronectin 60 kDa degradation product stimulated by IL-ȕLV
reduced by carprofen 
 High-throughput MS identified fibronectin released into the cartilage 
secretome in chapter 3, reporting Mascot scores up to 6222 in untreated and 3786 in 
IL-1ɴ samples (Table 7). Therefore it was selected as a candidate protein to assess 
differential release in response to IL-ȕ DQG FDUSURIHQ )LEURQHFWLQ ZHVWHUQ EORWWLQJ
showed bands at 230 kDa, 60 kDa and 30 kDa. The glycosylated monomer of 
fibronectin corresponds to the highest molecular weight band at 230 kDa, the intensity 
of which was lower when IL-ȕLVSUHVHQW7KLVSUR-inflammatory cytokine caused an 
intense band at 60 kDa to be detected, which is probably a degradation product 
released due to cytokine stimulation of catabolic enzymes. Carprofen caused a 
significant reduction in intensity of this IL-ȕ LQGXFHG N'D EDQG VXJJHVWLQJ WKLV
NSAID could potentially reduce certain mechanisms of ECM degradation.  
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Figure 32. Fibronectin degradation induced by IL-ȕZDVGHFUHDVHGE\FDUSURIHQ 
(A) Representative image of fibronectin western blot. The band at 230 kDa corresponds to the 
glycosylated monomer of fibronectin. IL-ȕVWLPXODWHVUHOHDVHRIDN'DGHJUDGDWLRQSURGXFW
of fibronectin. 50µl of each cartilage supernatant sample was lyophilised, then resuspended in 
20 µl Laemmli buffer and loaded onto gels. (B) Densitometry results for the 60 kDa fibronectin 
band. Explant cultures were carried out in 3 animals with 3 technical replicates per animal 
(n=9). Standard deviation is shown by error bars. ***= P<0.001. Culture treatments: untreated 
(control), IL-ȕQJPOFDUSURIHQPJml) or carprofen (100 mg/ml) + IL-ȕQJPO 
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5.3.7. IL-1ɴ and carprofen treatments cause alterations in clusterin release 
 As well as catabolic proteins (MMP-1, -3, -13) and ECM components (TSP, 
fibronectin), the explant secretome contains secreted inflammatory related proteins. 
Clusterin is a chaperone that functions to protect proteins during inflammatory stress, 
therefore its secretion into explant supernatant was studied. The positive control of 
crushed cartilage produced bands in two positions: 70 kDa and 35 kDa, while 
detected bands in supernatants only gave bands at 35 kDa. The 70 kDa band in 
positive controls represents the full form before it is cleaved (de Silva et al., 1990). 
Clusterin is cleaved when secreted, hence no observation of the 70 kDa band and 
presence of the 35 kDa band in all secretome samples (Wilson and Easterbrook-
Smith, 2000). Clusterin bands were most intense for untreated culture samples. IL-ȕ
stimulated explants displayed reduced levels of clusterin release. Carprofen treatment 
alone also significantly decreased clusterin levels. When carprofen + IL-ȕWUHDWPHQWV
were combined, there was a further decrease in clusterin levels. With this combination 
clusterin was almost undetectable, and was significantly lower compared to IL-ȕ
alone. 
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Figure 33. Clusterin release from cartilage explants is decreased by IL-1ȕ stimulation and 
carprofen treatment 
(A) Representative western blot image with clusterin precursor band at 70 kDa and 36-39 
kDa representing secreted form. 50µl of each cartilage supernatant sample was lyophilised, 
then resuspended in 20 µl Laemmli buffer and loaded onto gels. (B) Graphical representation 
of densitometry for clusterin. Explant cultures were completed for 6 days in 3 separate 
animals, with 3 treatment replicates on each occasion (n=9). Explant treatments: untreated 
control, IL-1E (10 ng/ml), carprofen (100 µg/ml), or carprofen (100 µg/ml) + IL-1E  (10 ng/ml). 
Error bars indicate Standard Deviation. A one-ZD\$129$XVLQJ7XNH\¶VPXOWLSOH
comparison test was applied to assess significance. **** = P < 0.0001, *** = P < 0.001. M = 
molecular weight markers (Bio-Rad), + = positive control prepared by crushing articular 
cartilage with a mortar and pestle in liquid nitrogen then resuspending in Laemmli buffer. 
Positive control stock was diluted 5-fold before loading. 
kDa 
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5.3.8. Nitric Oxide (NO) release is induced by IL-ȕWUHDWPHQWDQGFDUSURIHQ
does not decrease NO release 
 Nitrite levels in explant conditioned media were measured across all 
treatment groups. NO is a free radical known to be produced by stimulation with pro-
inflammatory cytokines (Taskiran et al., 1994). NO synthesized will be converted into 
nitrite, which is measured by the Griess assay (Griess, 1879). Treating explants with 
IL-ȕ RU FDUSURIHQ  ,/-ȕ caused significantly higher levels of NO synthesis, 
compared to untreated and carprofen alone. Carprofen alone showed a slight non-
significant increase in NO levels compared to untreated explants. There was no 
significant difference in NO levels between IL-1ȕ and carprofen + IL-1ȕ, therefore 
carprofen¶s anti-inflammatory mechanism did not reduce cytokine stimulated NO 
release.  
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Figure 34. IL-ȕWUHDWPHnt causes an increase in the presence of nitrites in cartilage explant 
supernatant. Carprofen did not significantly decrease cytokine stimulated nitrite levels 
Griess assays were completed on explant supernatants collected from three individual horses 
with three treatment replicates per animal (n=9). Explant treatments: untreated control, IL-1E (10 
ng/ml), carprofen (100 µg/ml), or carprofen (100 µg/ml) + IL-1E (10 ng/ml). Absorbance at 540 
nm was measured in triplicate per sample. Error bars indicate Standard Deviation. One-way 
$129$XVLQJ7XNH\¶VPXOWLSOHFRPSDULVRQWHVWXVHGWRDVVHVVVLJQLILFDQFH P < 0.0001. 
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5.4. Discussion 
This chapter describes use of an equine cartilage explant model to screen 
anti-inflammatory therapeutics. Release of candidate biomarkers were monitored with 
western blotting, along with NO measured indirectly via Griess assays. Carprofen is 
applied here as an example therapeutic to assess anti-inflammatory effects on IL-ȕ
stimulated explants. Inflammation of articular cartilage is stimulated by pro-
inflammatory cytokines such as IL-ȕWKHUHE\FDXVLQJGHJUDGDWLRQDQGORVVRI(&0
in diseases like OA (Goldring, 2000). IL-ȕ ELQGV WR UHFHSWRUV RQ FHOO VXUIDFHV
initiating inflammatory signalling pathways including active NF-ț% translocation into 
the nucleus. Transcription of pro-inflammatory and pro-apoptotic genes causes the 
release of catabolic proteins including MMPs, cathepsins and ADAMTS (Martel-
Pelletier et al., 2008b). To simulate the environment within OA synovial joints, IL-ȕ
stimulation is therefore often applied to culture models (Goldring et al., 2008). 
Studying cartilage explant models can provide mechanistic insights into inflammatory 
cartilage responses whilst providing alternatives to in vivo models. Candidate proteins 
(MMPs, ECM components, clusterin) identified in chapter 3 were selected for further 
western blot quantification. This provided further details on IL-ȕ VWLPXODWLRQ RI
cartilage, and the abilities of explant models to screen anti-inflammatories such as 
carprofen. 
5.4.1. MMP -1, -3 and -13 secretion from cartilage cultures and the effects of 
carprofen on these MMPs 
MMP-1, MMP-3 and MMP-13 were released into the secretome of the equine 
articular cartilage model. Western blots confirmed release levels of all three MMPs 
were significantly raised after IL-ȕ WUHDWPHQW These findings are consistent with 
iTRAQ reported increases in MMP-1, -3 and -13 release after cytokine stimulation 
of bovine explants (Stevens et al., 2009). IL-ȕ DQG MMP mediated enzymatic 
breakdown of cartilage explants contributes towards proteoglycan and collagen type II 
degradation (Mort et al., 1993, Billinghurst et al., 1997). The delicate balance between 
ECM synthesis and degradation could therefore be tipped in favour of OA cartilage 
degradation during inflammatory conditions.  
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Western blotting detected release of MMP-3 from untreated explants, but 
significantly higher levels and a band 10 kDa lower were stimulated by IL-ȕ,QDFWLYH
proMMP-3 is cleaved into the active form via protease activity (Nagase et al., 1990). 
The MMP-3 band 10 kDa lower is likely to be active MMP-3 released by IL-ȕ
stimulation. This highlights the ability of western blotting approaches to potentially 
identify active forms of catabolic proteins. 
This study shows that measurements of MMP-1, MMP-3 and MMP-13 
released from IL-ȕ VWLPXODWHG H[SODQWV in vitro can help screen anti-inflammatory 
compounds. Significant decreases in IL-ȕVWLPXODWed release of all three MMPs were 
associated with carprofen presence. The effects of new and existing therapeutics on 
MMP release can therefore be screened via this western blotting approach. 
Researchers have shown in previous equine explant studies that carprofen decreases 
IL-ȕVWLPXODWHG3*(2 and GAG release in vitro (Benton et al., 1997, Armstrong and 
Lees, 1999). Inflammatory stimulated MMPs were also decreased by hyaluronan 
treatment in a similar human cartilage explant model (Julovi et al., 2004). Degradation 
products of ECM components such as fibromodulin can be specifically attributed to 
MMP-13 (Heathfield et al., 2004). Thus, carprofen¶s inhibition of MMP-13 could 
decrease release of certain ECM degradation products. 
Carprofen¶s actions as a COX-2 inhibitor have been shown here to have 
downstream effects on MMP release in equine cartilage explant cultures. 
Prostaglandins including PGE2 are produced via COX-2 enzymatic activity in the 
arachidonic acid signalling pathway (Hardy et al., 2002), and PGE2 will induce release 
of MMP-1, MMP-13 and other inflammatory effects (Attur et al., 2008). Carprofen may 
therefore reduce catabolic processes during OA and slow down loss of cartilage.  
5.4.2. Nitric Oxide release from equine cartilage culture 
This chapter also monitored levels of NO production in response to IL-ȕDQG
carprofen, via Griess assay measurements of nitrite. NO has complicated roles in 
mediation of apoptosis, catabolic signalling and pain perception (Abramson, 2008). 
Progression of OA is associated with death of chondrocytes, therefore NO control of 
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apoptosis could have implications in the disease. Significantly higher levels were 
recorded due to IL-ȕVLJQDOOLQJwhilst carprofen did not appear to decrease levels of 
NO in cartilage conditioned media. Increases in NO release are observed from OA 
cartilage explants (Amin et al., 1995), therefore this cytokine causes similar 
inflammatory processes to be initiated. IL-ȕ VWLPXODWHG 12 UHOHDVH IURP HTXLQH
chondrocytes has also been reported (Benton et al., 2002). As carprofen inhibition of 
COX-2 does not decrease NO levels, alternative pathways activated by IL-ȕ
contribute to production of NO. This has consequences in OA as synthesis of 
proteoglycans in cartilage is inhibited by increased levels of NO (Mastbergen et al., 
2008). An alternative pathway involving MAPK/ERK signalling can be activated by 
cytokines and causes expression of various pro-inflammatory processes during OA 
(Loeser et al., 2008). While this chapter concentrated on inhibition of COX-2 
signalling, explant models can be utilized to distinguish between different 
inflammatory/anti-inflammatory mechanisms. For example, ERK inhibitors applied to 
bovine explants assessed this signalling pathways role in responses to mechanical 
compression (Ryan et al., 2009). 
5.4.3. ECM proteins and release of degradation fragments in response to IL-ȕ 
After finding that carprofen decreases levels of MMPs secreted, the 
consequences on release of specific ECM proteins: fibronectin, TSP and COMP were 
assessed. In this study there was no convincing evidence that IL-ȕ VWLPXODWHG
release of TSP or COMP was effected by carprofen treatment. TSP was undetectable 
by western blotting in untreated cultures, yet was identified in untreated cultures by 
MS in chapter 3. IL-ȕVWLPXODWLRQFRXOG therefore be causing increased release of a 
specific form of TSP that the primary antibody recognises. Alternatively, a more 
accurate quantitative MS approach may have demonstrated differential release of 
TSP comparing untreated or IL-ȕVWLPXODWHGFXOWXUHVFour bands detected at 120, 
110, 90 and 80 kDa molecular weights were visible with COMP western blots. COMP 
is known to be glycosylated, therefore this relates to the 120 kDa band. The 90 kDa 
band is potentially non-glycosylated COMP. IL-ȕ VWLPXODWLRQ ZDV UHVSRQVLEOH IRU
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presence of 110 and 80 kDa bands, which are likely to be degradation projects of 
COMP. Additional COMP fragments have been reported in western blots of diseased 
equine synovial fluid, including OA (Misumi et al., 2001). As carprofen has significantly 
inhibited MMP secretion, IL-ȕVWLPXODWHGUHOHDVHRI763DQG&203PD\EHSULPDULO\
caused by other catabolic proteins.  
Studies on human OA cartilage explants have demonstrated that release of 
collagen neoepitopes is reduced by MMP inhibition, but GAG release is not decreased 
(Dahlberg et al., 2000). This demonstrates that degradation of certain ECM 
components are controlled by different catabolic proteins, which has been observed in 
this thesis. Inhibition of MMPs in bovine explants can reduce IL-ȕVWLPXODWHG&203
fragmentation (Ganu et al., 1998). ADAMTS-4 has also been identified as another 
mediator of COMP degradation (Dickinson et al., 2003). Therefore multiple catabolic 
proteins can contribute towards COMP breakdown. Novel therapeutics inhibiting 
specific catabolic processes including ADAMTS family proteins, could be screened 
within an explant model to assess effects on TSP and COMP release. 
Fibronectin proved a useful candidate marker for assessing IL-ȕstimulation 
and the beneficial properties of carprofen treatment. Cartilage explants stimulated with 
IL-ȕ UHOHDVHG VLJQLILFDQW DPRXQWV RI D  N'D fibronectin degradation product, 
indicating ECM degeneration in vitro. Bands at 230 kDa representing the fibronectin 
monomer were visually reduced with cytokine stimulation. This suggests degradation 
of this monomer form is occurring. Carprofen was able to significantly decrease 
generation of 60 kDa fragments when added along with IL-ȕ)LEURQHFWLQLVWKHUHIRUH
an appropriate marker for assessing certain anti-inflammatory processes within the 
explant model.  
This western blotting approach offered additional details on the degradation 
profile of fibronectin induced by IL-ȕ Distinct bands at 230 kDa and 60 kDa 
displayed differences associated with treatment types. In chapter 3, MS analysis 
alone did not provide this degradation information on fibronectin. The merits of 
western blotting ECM proteins to assess degradative information from cartilage 
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explants have also been shown in a study by (Monfort et al., 2006). In that study, 
MMP-13 induced specific degradative profiles of small leucine-rich proteoglycans 
including decorin, biglycan, fibromodulin and lumican (Monfort et al., 2006). 
Fibronectin data in this chapter has also demonstrated an advantage of western 
blotting analysis of cartilage conditioned media over MS analysis. 
In previous studies, explant models have shown the role of fibronectin 
fragments in IL-ȕ VWLPXODWLRQ RI 003-13 release and collagen type II degradation 
(Yasuda and Poole, 2002). Fibronectin fragments also cause MMP-3 and MMP-13 
release, and decreases in proteoglycan synthesis in explant models (Homandberg et 
al., 1997, Homandberg et al., 2006). Therapeutic screening of hyaluronic acid, 
glucosamine-HCL and chondroitin sulphate demonstrated reduced MMP activity in 
these fibronectin stimulated models (Homandberg et al., 1997, Homandberg et al., 
2006). Stimulation of equine cartilage with two fibronectin fragments has also reported 
differences in release of NO, COMP and chondroadherin (Johnson et al., 2004). 
These studies and findings in this chapter, emphasize the importance of fibronectin 
degradation in OA, and therefore the utility of cartilage explant models for monitoring 
its release. 
5.4.4. Clusterin release within explant models and OA 
The equine cartilage explant model exhibited highest clusterin secretion in 
untreated cultures. IL-ȕRUFDUSURIHQWUHDWPHQWDORQHFDXVHGDUHGXFWLRQLQFOXVWHULQ
secretion, whilst in combination these treatments caused another significant decrease. 
Clusterin acts as a chaperone to aid protein refolding in situations of stress and is 
constitutively secreted by mammalian cells (Wilson and Easterbrook-Smith, 2000). IL-
ȕ DQG FDUSURIHQ both appear to interrupt clusterin secretion and therefore the 
protection it offers from healthy functioning cells. Normal COX activity may have a role 
in constitutive clusterin secretion, therefore inhibition of COX by carprofen may affect 
its release. An additive inhibition by actions of IL-ȕ DQG FDUSURIHQ FRPELQHG
contributed to a more significant reduction of clusterin release.  
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Previous studies have reported that clusterin levels were decreased by IL-ȕ
treatment compared to untreated controls in mouse femoral head cartilage culture 
media (Wilson et al., 2008). In another study, increases in clusterin levels in culture 
media were observed with IL-ȕDQG71)-Į WUHDWPHQWVRQERYLQHDUWLFXODU FDUWLODJH
(Stevens et al., 2008). During investigations on chondrocyte mitochondrial 
deregulation, clusterin levels appeared decreased in OA chondrocyte mitochondrial 
fractions compared to healthy cartilage (Ruiz-Romero et al., 2009). As indicated in this 
FKDSWHU¶VLQWURGXFWLRQclusterin association with OA needs to be further investigated. 
This thesis provides some insights on clusterin release during in vitro cartilage 
cultures. 
5.4.5. Conclusions 
 Studies in this chapter described the applications of equine cartilage explant 
models to monitor degradation of ECM proteins, catabolic processes and 
inflammatory related proteins in response to stimuli. Carprofen decreased release of 
candidate biomarkers MMP-1, MMP-3, MMP-13 from IL-ȕVWLPXODWHGH[SODQWV7KH
reduced release of MMPs was correlated with the decrease of an IL-ȕVWLPXODWHG
kDa fibronectin product. Although, carprofen did not affect COMP or TSP release from 
IL-ȕ H[SODQW FXOWXUHV Certain processes instigated by IL-ȕ DUH QRW DIIHFWHG E\
carprofen, such as raised NO levels that were not lowered with carprofen treatment. 
Secretion of the protective chaperone clusterin was decreased by IL-ȕ DQG
carprofen, which could have implications on protein folding and aggregation in OA 
affected joints. New anti-inflammatory drugs or nutraceuticals can be screened for 
their effects on MMP activity in this in vitro approach. Effects on other essential 
proteins involved in cartilage metabolism could also be monitored with this model if 
effective and specific antibodies are available. This model provides an alternative to in 
vivo animal models of OA, delivering insights into cartilage degeneration, responses 
to inflammatory stimuli and assessing the potential effects of new therapeutics. 
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CHAPTER 6 
GENERAL DISCUSSION 
6.1. Introduction  
The aim of this thesis was to apply high-throughput proteomic approaches to 
the secretome of cultured equine articular cartilage explants. This approach 
investigated protein release from untreated healthy cartilage and in response to 
inflammatory stimulation with IL-1ɴ and anti-inflammatory treatment with carprofen. It 
was hypothesised that proteomic investigations would identify candidate biomarkers 
associated with OA, to then monitor treatment efficacy and degradative processes in 
this explant model using more sensitive, quantitative approaches. Carprofen was 
shown to have advantageous effects on IL-1ɴ stimulated cartilage, such as 
decreasing release of GAG and ECM proteins as well as decreasing secretion of 
catabolic proteins (e.g. MMPs). This suggests there are beneficial properties of this 
NSAID for OA treatment. These studies advanced biological understanding of 
cartilage explant cultures and OA, allowing biomarker discovery and screening of anti-
inflammatory compounds.  
These studies were completed on an equine derived cartilage model and 
were initiated because of an interest in veterinary and equine health. Moreover, joint 
disease in horses is a common clinical issue with lameness often associated with OA 
(Clegg and Booth, 2000). Equine OA therefore has a significant economic impact, 
through veterinary costs to owners of companion animals, or via financial losses in the 
horse racing industry (Neundorf et al., 2010). The ability to screen putative anti-
inflammatory compounds for treatment of horses is therefore of importance. For 
scientific study purposes, equine joints allow high numbers of homologous explant 
discs to be processed. Horses are active animals compared to other large animals, 
therefore cartilage harvested will have been exposed to an active lifestyle like 
humans. Sourcing human tissue has added ethical complications and normal/healthy 
cartilage is not easily available. The thickness of articular cartilage from humans and 
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horses was reported to be most similar compared to cartilage from rabbits, sheep, 
dogs and goats, therefore studying OA pathological processes in equine cartilage 
could provide pre-clinical insights that are also relevant to humans (Frisbie et al., 
2006). 
6.2. The secretome of articular cartilage 
Proteomic studies on the secretome of articular cartilage have been reported 
on human (Hermansson et al., 2004, De Ceuninck et al., 2005, Nemirovskiy et al., 
2007, Polacek et al., 2010, Peffers et al., 2013), murine (Wilson et al., 2008, Haglund 
et al., 2008), bovine (Stevens et al., 2008, Stevens et al., 2009), equine (Clutterbuck 
et al., 2011) and canine (Swan et al., 2013) derived tissues. Highly abundant ECM 
proteins reported here in equine secretome, such as COMP, aggrecan core protein 
and various small proteoglycans are consistently identified across all these studies. In 
chapter 3, time course studies were performed to gain a better understanding of 
progression of pro-inflammatory and anti-inflammatory processes, and their effects on 
the cartilage secretome. Interrogation of time courses aimed to assess the most 
suitable time to maximise differentiation between treatments. An initial time course 
over 27 days (time course A) demonstrated altered protein release from cartilage 
between untreated and pro-inflammatory cytokine (IL-ȕ DQG 71)-Į stimulated 
cartilage. The NSAID, carprofen caused gradually more substantial decreases in a 
cytokine stimulated MMP-3. Initial results suggested that further optimisation of the 
time course was required. Therefore as described in chapter 3, a 24 day time course 
(time course B) was completed and high-throughput MS analysis was performed on 
day 6 and day 18 time points. Proteomic high-throughput MS analysis of a time 
course of cartilage secretome has not previously been reported in the literature.  
A previous study was published using high-throughput MS on cultured equine 
articular cartilage (Clutterbuck et al., 2011). In the mentioned publication, IL-1ɴ 
stimulation and carprofen treatment were applied to the cultured explants, but no 
correlation with treatment groups was reported in the MS data, whilst MS data in this 
thesis showed specific treatment group effects. All ECM and non-ECM secreted 
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proteins previously found were also identified throughout this thesis, with additional 
identifications attained here including MMP-13, TIMP-1, collagen type II, PCOC-2, 
CXCL6 and SFRP. Various different intracellular proteins were reported in the 
secretome of equine cartilage compared to this thesis (Clutterbuck et al., 2011). The 
secretome studies in chapter 3 have expanded the range of protein identifications and 
provided further information on proteins released in an equine model of articular 
cartilage. 
Release of collagen has been reported to occur at higher levels after 
extended incubation times of bovine explants up to 14 days (Sztrolovics et al., 1999), 
and feline explants up to 28 days (Gabriel et al., 2010)). In equine cartilage explants, 
collagen peptides were identified in supernatant after both 6 and 18 days, although no 
specific quantitative measure of collagen release was employed in this thesis. The 
continued identification of small proteoglycans and collagen later in the time course, 
agrees with the study by (Sztrolovics et al., 1999), which showed release of these 
ECM components up to 14 days. IL-1ɴ stimulated release of biglycan, decorin and 
lumincan had previously been shown to occur at consistent levels over a time course 
using bovine cartilage explants (Sztrolovics et al., 1999), whilst this thesis also 
reported similar release after 6 and 18 days of culture. Monitoring carprofen treatment 
on IL-1ɴ stimulated cultures showed that carprofen reduced levels of small 
proteoglycan release, especially after 18 days (chapter 3). This suggests that these 
small proteoglycans may be useful biomarkers of treatment efficacy.  
 Analysis of cartilage secretome of untreated and IL-ȕ WUHDWHG H[SODQWV
revealed differences in protein release (chapter 3.3.3.). These differences between 
treatments could benefit from quantitative analytical approaches LQFOXGLQJ L75$4
SILAC and QconCAT, which are described later in this discussion section. In chapter 
3, a variety of ECM components, inflammatory related proteins, cytokines, 
chemokines, catabolic proteases and intracellular proteins were identified. Previous 
2DE human OA cartilage secretome analysis highlighted the identification of activin A, 
cytokine-like protein 17 and CTGF (Hermansson et al., 2004), whilst data in this thesis 
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only identified CTGF in untreated culture (Table 7). Another study on human OA 
cartilage secretome using 2DE and protein microarrays identified several ECM 
proteins and secreted proteins MMP-3, TIMP-1 and PCOC (De Ceuninck et al., 2005), 
which were also detected in the equine secretome MS in chapter 3. The OA 
associated cytokine IL-6 and chemokine IL-8 were not identified in this thesis, but 
were found in human OA secretome (De Ceuninck et al., 2005). Comparison with 
these previous studies demonstrates the differences in studying OA diseased 
cartilage and healthy cartilage cultures.  
Identification of collagen types VI and X only in untreated controls suggests 
that IL-ȕ VWLPXODWLRQ interferes with normal collagen synthesis. Alternatively, 
increased release of other degraded proteins due to IL-ȕ obscured detection of 
these collagen types. Future studies with increased sample numbers could further 
support this observation, as previous studies have reported that collagen type VI 
release into supernatant is increased by cytokine treatment of cartilage (Stevens et 
al., 2009) and chondrocytes (Calamia et al., 2011). 
Catabolic factors contribute to OA within synovial joints (Troeberg and 
Nagase, 2012) and the main MMPs secreted by IL-ȕVWLPXODWHGcartilage were MMP-
1, MMP-3 and MMP-13. It has been suggested that MMP-2 is secreted from cartilage 
explants that were analysed via gelatin zymography (Clegg et al., 1997), but gelatin 
classified MMPs -2 and -9 were not identified in the cartilage secretome in this thesis. 
Overall, these secretome studies identified expected ECM proteins and metabolic 
proteins as reviewed in (Williams et al., 2011). Certain proteases associated with OA 
such as cathepsins and ADAMTS (Troeberg and Nagase, 2012) were not identified in 
any secretome MS analysis in this thesis. 
 To increase the depth of coverage of the secretome, depletion strategies 
were considered to remove abundant proteins from cartilage cultures. It was 
hypothesised that by targeting and depleting abundant proteins, identification of 
additional low level proteins could be achieved. Three methods were applied prior to 
high-throughput MS analysis: CPC precipitation, Con A lectin chromatography and 
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3URWHRPLQHUWHFKQRORJ\ Abundant proteins were removed with these applications, 
and comparison with unprocessed samples concluded that identification of certain 
proteins was facilitated. CPC precipitation assisted identification of HAPLN1, CILP-1 
and MMP-10, while Con A chromatography supported HAPLN1 and IL-9 detection. 
CPC precipitation has previously been applied to cartilage proteomic studies to 
increase resolution with 2DE (Hermansson et al., 2004, Catterall et al., 2006, 
Hermansson et al., 2007, Ruiz-Romero et al., 2010a), while there are no reports in the 
literature of depletion methods being applied to cartilage secretome before high-
throughput MS analysis. Various intracellular proteins were identified after the 
depletion processes, but these are most likely indicators of cell death and have limited 
value to understanding cartilage metabolism. 3URWHRPLQHUDQDO\VLVGLGQRWproduce 
additional identifications that had not been previously reported in the thesis. The 
3URWHRPLQHU WHFKQLTXH has potential in cartilage proteomics but requires further 
development for secretome analysis. Co-extraction of low abundance proteins along 
with the abundant ECM proteins could be responsible for the difficulties in application 
of the depletion methods. ECM constituents can bind to smaller proteins such as 
growth factors and cytokines (Heinegard, 2009), therefore low abundance proteins 
may remain bound during depletion procedures and also be removed. 
6.2.1. Quantitative secretome MS analysis 
 Secretome studies have identified the most abundant proteins being released 
in cartilage explant cultures (Table 1). To improve proteomics analysis and 
comparisons of different treatment conditions, future studies could benefit from 
quantitative analysis. Traditional 2DE analysis or DIGE techniques can differentiate 
between protein levels within acrylamide gels, while there are several options to 
quantify high-throughput MS approaches (Bantscheff et al., 2012). Discussed below, 
are the latest studies on cartilage secretome that have applied quantitative techniques 
such as label-free spectral counting and bioinformatics methods (Mateos et al., 2012, 
Swan et al., 2013), or labelled approaches including iTRAQ (Stevens et al., 2009) and 
QconCAT (Peffers et al., 2013).  
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 Application of bioinformatics approaches to generate data would aid 
interpretation of these complex data sets. Throughout this thesis, MS data from 
Mascot searches was manually organised into tables for comparison between 
different treatments and/or time points. Semi-quantitative analysis suggested by 
Mascot scores alluded to differences between treatment groups, but there is no 
statistical comparison of these differences. Peptide spectral counting and 
exponentially modified protein abundance index (emPAI) scores could be used for 
bioinformatics approaches to provide statistically verified relative quantitative 
measures of proteins in different sample types. An emPAI score is calculated to 
provide a relative quantitative score of proteins in a mixture (Ishihama et al., 2005). 
Larger data sets are likely to be required for application and validation of 
bioinformatics methods of label-free quantification. An analysis of synovial fluid from 
RA and OA patients which quantified peptides with spectral counting discovered 
differential ECM proteins associated with OA, including COMP, fibronectin and YKL-
40 (Mateos et al., 2012). Fibronectin release was shown to be a useful marker of 
carprofen efficacy in chapter 5 of this thesis, whilst COMP western blots were 
inconclusive. Machine learning and network analysis on MS data generated from a 
canine explant model has been published (Swan et al., 2013). These bioinformatics 
approaches classified samples into treatment groups: untreated control, IL-ȕ
carprofen or carprofen + IL-ȕ (Swan et al., 2013). MMP-3, IL-8 and matrix Gla 
protein were highlighted as important proteins for treatment classification (Swan et al., 
2013). The explant model applied in this study was essentially the same as within this 
thesis, apart from the use of canine cartilage rather than equine tissue. The absence 
of IL-8 and matrix Gla protein identification in all Swiss-Prot searches of equine 
derived secretome in this thesis may underline the influence of species differences. It 
should be noted that the equine IL-8 sequence is present in the Swiss-Prot database. 
The matrix Gla protein was identified in NCBInr searches of data in this thesis 
(Chapter 3, Table 8), but the equine sequence to this protein is currently not in the 
Swiss-Prot database. Such apparent species differences could be due to variability in 
peptide sequences causing protein identifications to be missed if there is insufficient 
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sequence identity in the peptides detected by MS. Alternatively there may be genuine 
species specific biological responses. Follow-up western blot studies on canine and 
equine cultured cartilage could be used to confirm or disprove these observations. 
The bioinformatics approaches described by (Swan et al., 2013), could be applied to 
equine explant secretome studies if suitable sample numbers are available. 
 Labelling peptides with isobaric tags such as L75$4 to provide relative 
quantitation of peptide levels has been applied to cartilage secretome (Stevens et al., 
2009), as well as whole cartilage (Onnerfjord et al., 2012, Ikeda et al., 2013) and 
serum (Fernandez-Puente et al., 2011). Many of the proteins identified by MS analysis 
in this thesis were also reported in another study, which found cartilage stimulated 
with IL-ȕ 71)-Į RU PHFKDQLFDO VWLPXODWLRQ VKRZHG TXDQWLWDWLYH GLIIHUHQFHV LQ
release of aggrecan, collagens, MMPs, cytokines and chemokines (Stevens et al., 
2009). As reported in this thesis, differential release of MMP-1, -3, -9 and -13 also 
occurred upon cytokine stimulation (Stevens et al., 2009). Only one peptide from 
ADAMTS-4 was detected with cytokine stimulation (Stevens et al., 2009). High-
throughput analysis of equine cartilage secretome did not detect ADAMTS family 
proteins in this thesis. Chemically synthesised peptide standards such as QconCAT 
allow absolute quantification of proteins in complex samples, and this approach has 
been applied to the OA cartilage secretome (Peffers et al., 2013). Comparison of 
human OA cartilage stimulated with IL-ȕ RU XQVWLPXODWHG UHSRUWHG WKDW ,/-ȕ
increased MMP-3 and decreased TIMP-1 levels (Peffers et al., 2013). Absolute 
quantitative analysis did not report significant differences in release of COMP, 
fibromodulin, plasminogen, aggrecan and MMP-1 when OA cartilage was stimulated 
with IL-1ɴ (Peffers et al., 2013). This previous QconCAT study utilized OA diseased 
cartilage, whilst the equine model in this thesis used healthy cartilage, therefore this 
may account for certain differences observed between these studies.  
In chapter 3, the effects of carprofen on IL-ȕFXOWXUHVDQDO\VHGE\06JDYH
semi-quantitative indications that ECM proteins like fibronectin were reduced by the 
NSAID. Screening of anti-inflammatories on IL-ȕVWLPXODWHGFDUWLODJHH[SODQWFXOWXUHV
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could be assisted with quantitative analysis such as iTRAQ or a similar approach, 
coupled with appropriate bioinformatics analysis. 
6.2.2. Consequences of differences in species protein sequence  
 Relatively few antibodies directed specifically against equine proteins are 
available as compared to the vast array of antibodies that recognise human or mouse 
proteins. The majority of available primary antibodies produced are directed against 
human derived protein sequences, rather than equine proteins. Cartilage ECM 
proteins and MMPs have similar sequences in humans and horses, allowing 
successful western blotting against these proteins. However, a number of potentially 
relevant secreted proteins may not be detected unless equine-specific primary 
antibodies are available. For example, a primary antibody against PCOC-2 did not 
recognise this protein in equine cartilage conditioned media (data not shown). PCOC-
2 is involved in collagen maturation and its release was suggested to be inhibited by 
IL-ȕ LQ data shown in chapter 3. With a lack of quantifiable MS data, cartilage 
metabolism insights could have been provided by western blots of PCOC-2, but this 
was not possible using equine cartilage models. This limitation could apply to other 
proteins therefore this represents a challenge in studying proteins in equine derived 
tissues. Human protein directed primary antibodies are more readily available, 
therefore utilising human cartilage models could improve opportunities to study 
cartilage degradation and OA. Alternatively, equine protein specific antibodies could 
be raised for use in equine cartilage explant models. 
 Proteins identified during MS analysis relied on detected peptide sequences 
being searched against databases of known proteins/peptides. Human and other 
species proteins have been entered into these databases more extensively than 
equine entries. Conserved protein sequences across many species allowed equine 
derived proteins to be matched to other species entries. Species differences in protein 
sequences will impact on Mascot scores achieved, as just one different residue will 
cause variation in Mascot scores. Proteins could potentially be missed if sequence 
differences are substantial and equine entries are missing. If only a few peptides of a 
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certain protein are detected, even small differences in the sequence of equine 
proteins could cause failure to match, when otherwise protein identification would 
have occurred if there was no species sequence variation. 
6.3. The effects of carprofen on IL-1ɴ stimulated cartilage and 
biomarkers of treatment efficacy 
This thesis studied release of candidate biomarkers of efficacy within the 
explant model in response to pro-inflammatory cytokine IL-ȕDQG16$,'FDUSURIHQ
These included catabolic MMP-1, MMP-3, MMP-13, ECM components fibronectin, 
TSP, COMP, and clusterin. IL-ȕVWLPXODWLRQLQFUHDVHd release of MMP-1, -3 and -13, 
and degradative products of cartilage ECM proteins. ECM degradation products such 
as fibromodulin have been associated with MMP-13 activity (Heathfield et al., 2004). 
Therefore, the observed carprofen reduction of MMP-13 could decrease release of 
certain ECM proteins that could be efficacy biomarkers. Here, the IL-ȕ LQLWLDWHG
release of MMPs and a fibronectin degradation fragment were all significantly 
decreased by carprofen treatment. This data therefore showed these three MMPs can 
help screen therapeutic effects on IL-ȕ VWLPXODWHG H[SODQWV in vitro. MMP-1 and 
MMP-3 have been shown as prognostic biomarkers of OA, as levels of these two 
MMPs in serum were correlated with cartilage volume loss in human patients 
(Pelletier et al., 2010). A previous study reported stimulated release of MMPs was 
reduced by hyaluronan treatment in an explant model using human cartilage (Julovi et 
al., 2004). In chapter 5, a fibronectin degradation fragment was assessed as a 
biomarker of treatment efficacy, with carprofen able to significantly decrease 
generation of the 60 kDa fragment stimulated by IL-ȕ)LEURQHFWLQSURYHG WREHDQ
appropriate marker for assessing certain anti-inflammatory processes in equine 
explant cultures.  
Carprofen decreased the release of other IL-1ɴ stimulated proteins from the 
ECM including biglycan, fibromodulin, chondroadherin and CILP. This observed effect 
in response to carprofen, suggests these ECM proteins could be further investigated 
as biomarkers of treatment efficacy. Other potential biomarkers of efficacy include 
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PCOC-2, HSP-70, CXCL6 and MIF as release of these proteins was effected by IL-1ɴ 
stimulation. Carprofen was also shown to have beneficial effects on chondrocyte 
survival as the numbers of intracellular proteins identified by MS on cultures 
stimulated with IL-1ɴ were lower when carprofen was present. Thus, cultured equine 
cartilage explants provide a useful model to evaluate potential anti-catabolic and anti-
inflammatory effects in vitro, in accordance with the 3Rs. 
 The effect of carprofen and IL-1ɴ on other factors associated with pro-
inflammatory cytokine stimulation and OA were also assessed in the explant model, 
including measurements of sulphated GAG release and NO synthesis. Measurement 
of GAG release evaluated degradation of cartilage, while NO free radical production 
gave an indication of inflammation. The explant model therefore provided evidence of 
additional aspects of IL-ȕ DQG FDUSURIHQ WUHDWPHQW Increased levels of GAG were 
detected with IL-ȕ VWLPXODWLRQ LQGLFDWLQJ breakdown of cartilage components. 
Carprofen has previously been shown to decrease IL-1ɴ stimulated PGE2 release 
from equine explants (Benton et al., 1997), which will reduce inflammatory signalling 
and associated degradation of the ECM. A study published in 2013, has also shown 
that carprofen (at the concentration applied in this thesis of 100 µg/ml), significantly 
decreases IL-1ɴ stimulated release of GAGs and PGE2 from equine cartilage explants 
(Clutterbuck et al., 2013). Increases in proteoglycan synthesis have also been 
revealed in equine cartilage explants treated with carprofen enantiomers (Frean et al., 
1999). In this thesis, carprofen significantly delayed IL-ȕinitiated GAG release over 6 
days. Monitoring GAG release through a time course revealed this effect to be 
transient.  
NO synthesis in explant culture was increased by IL-ȕWUHDWPHQWFRPSDUHG
with untreated cultures. Carprofen treatment had no effect on NO levels, suggesting 
IL-ȕ initiation of certain signalling processes is not influenced by COX inhibition. 
Other researchers also found that treatment of cartilage explants with the NSAID 
celecoxib did not decrease cytokine stimulated GAG and NO release, but inhibited 
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PGE2 levels (Mastbergen et al., 2008). This shows that NSAIDs do not inhibit all 
cytokine stimulated processes that cause inflammation and cartilage break down. 
 Overall, these studies have contributed to understanding of equine cartilage 
secretome and the capability of this model for screening anti-inflammatory effects. By 
studying the effects of carprofen on IL-1ɴ stimulated protein release, a number of 
potential biomarkers of treatment efficacy were identified. There continues to be 
certain limitations to the work described and several amendments could assist future 
studies with cartilage cultures are discussed in more detail below. 
6.4. Prospective adaptations to the explant model 
 The explant model was chosen to study responses to stimuli because it 
maintains chondrocytes within an ECM environment. This is closer to the in vivo 
environment when compared to monolayer and high density cultures. It also provides 
the opportunity to study metabolic effects on the existing cartilage matrix that would 
otherwise be absent. Explant models have been historically applied to study cartilage 
degradation in response to pro-inflammatory cytokines (Saklatvala, 1986, Hubbard et 
al., 1988). Culture of healthy and OA affected cartilage is also suitable to demonstrate 
metabolic changes in diseased tissue (Lafeber et al., 1992). Additional treatment with 
proposed therapeutics on IL-1 stimulated explants can then assess beneficial 
properties. For example, sodium hyaluronate or glucosamine HCL can reduce IL-1 
stimulated proteoglycan degradation in explant cultures (Morris et al., 1992, Fenton et 
al., 2000). This thesis has shown effects on release of selected ECM proteins and 
MMPs by utilizing an IL-ȕ VWLPXODWHG HTXLQH FDUWLODJH PRGHO 7KH KLJK-throughput 
MS analysis showed variation in proteins released due to treatment with IL-ȕ as 
compared with IL-ȕ  carprofen, although it would benefit from quantitative 
approaches (discussed above). The explant model applied throughout this thesis 
remains a relatively simple model, which is missing several components that 
contribute natural conditions in synovial joints. Adaptations to the explant model that 
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could further advance the studies in this thesis and the OA literature are discussed 
below. 
6.4.1. Alternative stimuli 
Inflammation of the synovial joint has an important role in OA progression 
(Scanzello and Goldring, 2012). Toll-like receptors, complement activation and pro-
inflammatory mediators are all associated with OA (Scanzello and Goldring, 2012). 
Alternative pro-inflammatory stimuli TNF-Į&KDSWHUDQG/36(which activates Toll-
like receptors) (Appendix 3) were also introduced to equine cartilage cultures during 
this project. The responses to these stimuli were assessed on silver stained SDS-
PAGE gels. The protein profiles produced after treatment with TNF-Į RU /36 ZHUH
visually indistinguishable from those after IL-ȕVWLPXODWLRQOther studies on bovine 
cartilage secretome (Stevens et al., 2009) and human chondrocyte proteome (Cillero-
Pastor et al., 2010) have reported differential protein responses to IL-ȕ RU 71)-Į 
Stimulating the equine cartilage explant model with alternative stimuli such as IL-6 
could highlight differences in initiated protein release. 
Obesity is a risk factor associated with OA (Coggon et al., 2001). Adipokines 
secreted from adipose tissue potentially have roles in OA progression. Serum 
adipokines: adiponectin, leptin and resistin have been associated with inflammation in 
OA patients (de Boer et al., 2012). Another adipokine, visfatin caused increased 
synthesis of MMP-3, MMP-13, ADAMTS-4, ADAMTS-5 and PGE2 in chondrocyte 
monolayers (Gosset et al., 2008). The equine model utilized in this thesis proved 
successful for measuring release of several MMPs, therefore a similar approach could 
monitor responses to adipokines.  
Growth factors that initiate ECM synthesis and cartilage repair include IGF-1, 
BMPs, TGF-ȕDQG&7*) (Alcaraz et al., 2010). Responses to these growth factors 
could be studied on IL-ȕ VWLPXODWHG cartilage. MS analysis identified CTGF in 
untreated explant supernatants (Table 7) but it was not detected in IL-ȕVWLPXODWHG
cultures. Release of anabolic growth factors could be reduced by IL-ȕZKLOHDGGLWLRn 
of additional growth factors to the model may instigate cartilage repair processes. 
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6.4.2. Mechanical loading 
Mechanical loading has not been applied in this equine explant model, but is 
known to have important effects on healthy chondrocyte and cartilage metabolism 
(Grodzinsky et al., 2000). Injurious compression of cartilage explants causes 
increased loss of GAGs, and stimulates chondrocyte apoptosis and catabolic MMP 
release (Loening et al., 2000, Stevens et al., 2009). Dynamic loading of cartilage and 
chondrocytes affects the turnover and synthesis of aggrecan and smaller 
proteoglycans (Sah et al., 1989, Valhmu et al., 1998). Beneficial anti-catabolic effects 
of moderate dynamic compression has been shown on mechanically injured, TNF-Į
and IL-6/soluble IL-6 receptor stimulated explants (Li et al., 2013). Integrating 
mechanical loading into the equine explant model could simulate moderate forces 
usually present in synovial joints. Alternately, excessive mechanical load could initiate 
cartilage degradation, which therapeutic compounds could be screened against.  
6.4.3. Co-culture models 
 Multiple tissues contribute to the environment within synovial joints and OA 
progression, therefore co-culture models have been developed to incubate cartilage 
explants and synovial cells together (Haupt et al., 2005, Pretzel et al., 2009). 
Transduction of insulin-like growth factor-1 and IL-1 receptor antagonist protein 
together into synoviocytes co-cultured with cartilage explants showed protection 
against IL-1 catabolic induction (Haupt et al., 2005). A co-culture model containing 
cartilage and synovial fibroblasts stimulated with TNF-ĮDQG,/-ȕKDVGHPRQVWUDWHG
increases in aggrecanase, MMP-1 and MMP-3 activity, and up-regulation of IL-6 and 
IL-8 (Pretzel et al., 2009). Significantly higher responses were reported in co-cultures 
compared to mono-cultures of these tissues (Pretzel et al., 2009). These models still 
lack inflammatory cells like macrophages that will be present in vivo, but are a step 
towards improved models to replace live animal usage. Screening of therapeutics 
within co-culture models represents a potential strategy for future studies. 
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6.4.4. Physiological oxygen conditions 
 Articular cartilage and the chondrocytes within it are physiologically exposed 
to hypoxic conditions, which are not taken into account in the current equine model. 
Chondrocyte survival and differentiation is maintained by hypoxia-inducible factors 
(HIFs), which are up-regulated within a hypoxic environment (Schipani et al., 2001). In 
hypoxic conditions, HIF-Į DQG +,)-Į protect against cartilage deterioration by 
inhibiting catabolic proteins, and promote anabolic processes by up-regulating SOX-9 
(Thoms et al., 2013). Future studies on cartilage explant responses to cytokines and 
anti-inflammatories could be completed in hypoxic conditions to provide a more 
accurate and realistic environment. 
6.5. Additional analysis approaches to study inflammatory processes 
and degradation in cartilage cultures  
 The equine cartilage explant model has provided cartilage conditioned media 
after incubation with various treatments. In future studies, the following techniques 
could be applied to analyse collected samples to improve understanding of cartilage 
degradation and biological processes in response to stimuli or therapeutics. 
6.5.1. Hydroxyproline assays 
Hydroxyproline assays can provide a measurement of collagen 
concentrations and could assess release of collagen into cartilage conditioned media. 
The reported anti-MMP effect of carprofen could have been assessed with these 
assays. Significant collagen release due to cytokine stimulation may require extended 
culture time over 14 days (Gabriel et al., 2010, Sztrolovics et al., 1999). Analysis of 
collagen release throughout the 24 day time course B in response to IL-ȕ DQG
carprofen could contribute further information on cartilage degradation within this 
model. Unlike aggrecan loss, collagen degradation is not reversible therefore the 
collagenase events mediated by MMPs are especially important for long term 
cartilage damage and OA (Karsdal et al., 2008). 
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6.5.2. PGE2 Assays 
 During this project, PGE2 assays were also attempted on cartilage explant 
cultures to assess release of this bioactive lipid from untreated, IL-ȕVWLPXODWHGDQG
carprofen treated cultures, as described in Chapter 2.11. Carprofen is known to 
reduce PGE2 production in horses in vivo (Beretta et al., 2005) and in vitro studies 
(Goodrich and Nixon, 2006), and it would have been useful to have reported PGE2 
levels in this thesis. Despite several attempts to quantify PGE2 concentrations in 
supernatant samples, the immunocompetitive ELISA method used did not provide 
measurements that were consistently within the values of the standard curve. Whilst 
the kit protocol stated that all samples must be diluted, even with undiluted cultures 
from untreated, carprofen alone and most carprofen + IL-ȕ VDPSOHV 3*( OHYHOV
were below the detection threshold. Samples from IL-ȕ VWLPXODWHG FXOWXUHV JDYH
readings too high to be accurately quantified. Although this indicated carprofen could 
reduce IL-ȕ VWLPXODWHG 3*(2 release, data generated could not provide accurate 
measurements that could be graphically displayed or statistically analysed. PGE2 
measurement kits are available from alternative manufacturers, but due to time 
restraints and costs these could not be applied for this thesis. 
6.5.3. Zymography 
 Presence of MMP-1, -3 and -13 in the cartilage secretome has been 
confirmed by western blotting. Additional information on the activity of these MMPs 
within the model could be achieved with zymography. An MMP substrate such as 
gelatin can be incorporated into polyacrylamide gels, and subsequent staining can 
display areas of digestion and catabolic activity (Vandooren et al., 2013). The 
cartilage secretome has been shown to contain various catabolic proteins, therefore 
the mixture of proteases will all contribute towards different digestion regions. Data in 
this thesis suggests release of active MMP-3 with its pro-region cleaved (chapter 5), 
although presence of MMPs does not necessarily equate to enzyme activity. 
Zymography would provide an assessment of enzymatic activity, allowing studies to 
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monitor the effects of therapeutics such as carprofen within samples generated from 
cytokine stimulated explant models.  
6.5.4. Microarrays and ELISAs 
 Antibody microarrays are another alternative that could provide high-
throughput quantitative measurements of specific proteins in secretome samples. OA 
cartilage (De Ceuninck et al., 2005) and LPS stimulated cartilage (Haglund et al., 
2008) secretomes have been studied with protein microarrays, but comparison of 
normal and cytokine stimulated tissues may provide new insights (Marzoq et al., 
2013). Specifically targeting aggrecan and collagen fragments, or MMPs with ELISAs, 
could also provide information on degradative activities in cartilage culture (Wang et 
al., 2009a). ELISAs can be designed with specific degradation product neoepitopes 
that could be used to assay specific OA biomarkers. MMP inhibition was shown with 
ELISA approaches to have no effect on aggrecanase activity on cartilage (Wang et 
al., 2009a). This agrees with findings in this thesis that MMP inhibiting activity of 
carprofen cannot totally suppress loss of GAG and aggrecanase activity.  
 Arrays used to study MMP profiles of synovial fluid show differences between 
advanced OA compared with normal or early OA (Heard et al., 2012). No differences 
in MMP profiles could be distinguished between normal or early OA (Heard et al., 
2012). Significant increases in MMP-1, MMP-3 and MMP-13 were reported in this 
thesis on IL-ȕVWLPXODWHGFDUWLODJHVHFUHWRPH, which suggests the model represents 
late OA, rather than early OA.  
6.5.5. Metabolomics and Lipidomics 
 Whilst studying proteins as biomarkers of OA provides a significant 
contribution to OA research, insights could also be gained through metabolomic and 
lipidomic studies. The metabolic profile of end-stage OA and early/no OA was 
compared in media conditioned by synovial tissue samples (Adams et al., 2012). 
Significant differential alterations in pro-hydroxyproline, branched chain amino acids 
catabolic products and energy production associated metabolites were reported 
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(Adams et al., 2012). Hydroxyproline is abundant in collagen fibres therefore changes 
in its release could be of functional importance. Urinary and serum profiles of 
metabolites associated with arthritic diseases have been studied using NMR 
spectroscopy (Lamers et al., 2005, Young et al., 2013). Metabolites identified will give 
an indication of the cellular products generated by OA diseased cartilage. Metabolites 
will be produced by protein-regulated mechanisms, therefore providing another 
dimension to proteomic studies. It is worth noting that analysis of these systemic fluids 
may be complicated by many other factors such as a person¶s nutritional status 
impacting on their metabolome.  
 Bioactive lipids play an important role in inflammatory signalling through 
arachidonic acid signalling pathways during OA, therefore differential lipidomic 
analysis will provide relevant insights. Lipidomic analysis of equine synovial fluid has 
assessed eicosanoid profiles of normal and LPS treatment with/without meloxicam (de 
Grauw et al., 2011). Fourteen eicosanoids were identified in synovial fluid, some of 
which were significantly increased in inflamed joints (de Grauw et al., 2011). LPS 
induced increases in eicosanoids including PGE2 were reduced by meloxicam 
displaying in vivo anti-inflammatory effects of this NSAID (de Grauw et al., 2011). 
Serum analysis from OA patients has also detected alterations in lipids involved in the 
arachidonic acid pathway (Castro-Perez et al., 2010). Immunoassays detected a 
range of eicosanoids in cartilage explant conditioned media (Attur et al., 2012). OA 
cartilage released significantly higher levels of PGE2 and LTB4, while further 
accumulation of LTB4 was recorded with COX-2 inhibitors (Attur et al., 2012).  
Extra information into mechanisms of OA progression can be achieved by 
studying the metabolome and lipidome of OA relevant tissues. Changes in metabolite 
or lipid profiles may occur more quickly than alterations in the protein secretome, 
allowing changes to be seen before chondrocyte lysis. The explant model of articular 
cartilage could be adapted to collect and prepare samples appropriately so that they 
would be compatible with metabolite or lipid analysis in the future.  
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6.6. Summary 
 Work described in this thesis studied the secretome of equine cartilage 
explants in response to inflammatory and anti-inflammatory stimuli. The secretome 
was assessed over a time course by SDS-PAGE with silver staining and high-
throughput MS proteomic approaches. Identifications of ECM, non-ECM secreted and 
intracellular proteins were made in equine cartilage explant secretome by MS 
analysis. These identifications provided information on cartilage degradation, release 
and secretion of proteins within the explant model. This model has potential to be 
adapted to study alternative pro-inflammatory stimuli, mechanisms of cartilage 
degeneration and actions of anti-inflammatory treatments.  
 Exploratory candidate biomarkers including proteases MMP-1, MMP-3 and 
MMP-13 were identified from high-throughput MS analysis, and showed semi-
quantitative differences between untreated control and IL-ȕ VWLPXODWHG cartilage. 
These three MMPs are associated with OA and contribute towards cartilage 
catabolism and disease progression (Troeberg and Nagase, 2012). The suitability of 
the model to study effects on MMPs was supported by western blotting and reported 
quantitative differences due to carprofen treatment of IL-ȕ VWLPXODWHG H[SODQWV
Fibronectin western blotting showed a specific degradation product in response to IL-
ȕCarprofen treatment significantly reduced this IL-ȕVWLPXODWHGSURGXFWWKHUHIRUH
this fibronectin fragment is a suitable marker to assess certain anti-inflammatory 
properties. Monitoring release of these MMPs and fibronectin is indicated to be a 
useful approach for screening efficacy of novel therapeutics. One future hypothesis is 
that multiplexing approaches will be able to measure multiple biomarkers of OA.  
Evaluation of numerous biomarkers could indicate changes occurring in the various 
tissues of the synovial joint such as bone, synovium and cartilage. Multiple biomarkers 
may be quantified that also indicate the cause of OA disease (e.g. traumatic or 
overuse), helping to provide increasingly accurate prognosis knowledge and treatment 
options. 
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The main original findings of this thesis are summarised here: 
x High-throughput MS analysis with nanoLC-MS/MS indicated differences in 
equine cartilage explant secretome in response to IL-ȕ IL-ȕ  carprofen 
treatments and in untreated controls. 
x Depletion of abundant secretome proteins by CPC precipitation, Con A lectin 
FKURPDWRJUDSK\ RU 3URWHRPLQHU DSSURDFKHV ZHUH DVVHVVHG E\ KLJK-
throughput MS. Identification and coverage of intracellular proteins was 
increased by depletion. Additional identifications of MMP-10 and IL-9 were 
made with CPC precipitation and Con A lectin chromatography respectively.  
x Carprofen was shown to decrease the release of MMPs in IL-ȕVWLPXODWHG
equine cartilage explants. Release of a fibronectin degradation product 
associated with IL-ȕVWLPXODWLRQZDVDOVRUHGXFHGE\FDUSURIHQWUHDWPHQW 
x Carprofen delayed GAG release and did not affect NO production in IL-ȕ
stimulated equine cartilage cultures. 
 
This thesis has explored the capability of an equine explant model to study 
release of proteins in response to cytokine stimulation and NSAID treatment. It 
has demonstrated that assessment of catabolic processes and properties of anti-
inflammatory therapeutics can be screened and assessed within an in vitro model. 
Utilising equine cartilage has shown these effects in a model for addressing horse 
joint health, which may ultimately benefit therapy of this companion animal. 
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APPENDICES 
Appendix 1ȕ-actin western blotting 
ȕ-actin western blotting 
 See Materials and Methods for general western blotting protocol (Chapter 2). 
7KHVH LQYHVWLJDWLRQV XWLOLVHG D SULPDU\ DQWLERG\ DJDLQVW ȕ-actin (1:7000 dilution, 
Sigma) and secondary anti-mouse HRP conjugate (1:100,000, Cell Signalling). 
ȕ-actin release initiated by IL-ȕVKRZVQRVLJQLILFDQWGLIIHUHQFHZLWKFDUSURIHQ
present 
 Chondrocyte death and lysis within cartilage explants was indirectly measured 
E\DVVHVVLQJUHOHDVHRIȕ-actin into cartilage conditioned media. Untreated control, IL-
ȕDQGFDUSURIHQWUHDWHGVXSHUQDWDQWVZHUHDQDO\VHGE\ZHVWHUQEORWWLQJDJDLQVWȕ-
actin (Figure 35 ȕ-actin was detected in IL-ȕ DQG FDUSURIHQ  ,/-ȕ VWLPXODWHG
explant supernatants after the first 6 days incubation. Explants cultures with carprofen 
WUHDWPHQWDORQHRUXQWUHDWHGFRQWUROVGLGQRWUHOHDVHGHWHFWDEOHOHYHOVRIȕ-actin over 
0-6 days. Western blotting of time course supernatants at 6-12 and 12-18 did not 
reveal detectaEOH OHYHOV RI ȕ-actin with any treatment groups. These western blot 
investigations indicate that IL-ȕ KDV F\WRWR[LF HIIHFWV OHDGLQJ WR FKRQGURF\WH O\VLV
&DUSURIHQGLGQRWLQFUHDVHF\WRWR[LFLW\DQGFKRQGURF\WHO\VLVDVOHYHOVRIȕ-actin were 
reduced, although not significantly. 
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Figure 35. Cartilage explant cultures treated with IL-1ȕ or carprofen + IL-1ȕ do not show 
significant differences in release of ȕ-actin  
(A) ȕ-actin western blotting images for time course supernatants from 0-6, 6-12 and 12-18 
days. There was no detection of ȕ-actin from explant cultures untreated or treated with 
carprofen alone. Positive control produced an expected band corresponding to ȕ-actin ~42 
kDa. Bands can be detected for 0-6 days with IL-1ȕ and carprofen + IL-1ȕ treatments. ɴ-actin 
was not detected after 6-12 or 12-18 days. (B) Graphical representation of densitometry of ȕ-
actin bands. An unpaired t-test was applied to assess significance with ns = P > 0.05. + = 
positive control of chondrocyte lysate. Explant cultures were completed for 6 days with 3 
treatment replicates from two animals (n=6). Explant treatments: untreated control, IL-1ȕ (10 
ng/ml), carprofen (100 µg/ml), or carprofen (100 µg/ml) + IL-1ȕ (10 ng/ml). 
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Appendix 2. CPC precipitation depletes GAGs in explant culture 
supernatant 
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Figure 36. DMMB assay showing depletion of GAG from cartilage explant conditioned 
media  
GAG concentration was measured before and after CPC precipitation, showing that 
GAG levels are reduced after CPC precipitation. Technical replicates from an individual 
animal explant culture assayed (n=2). Error bars = standard deviation. 
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Appendix 3. LPS and IL-ȕVWLPXODWHVLPLODUSURWHLQUHOHDVHIURP
cartilage explant cultures 
 
  
 
Figure 37. Representative image of cartilage conditioned media after IL-1ȕ/36
and carprofen treatments 
Protein release profiles were similar in explant cultures set up on two separate 
occasions from two individual horses. Treatments: IL-ȕQJPO/36
ng/ml), carprofen (100 µg/ml). 
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Appendix 4. Full images of western blotting images contained in figures 
in Chapter 5 
Full image of MMP-1 western blot from Figure 27 
 
Full image of MMP-3 western blot from Figure 28 
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Full image of MMP-13 western blot from Figure 29 
 
Full image of thrombospondin western blot from Figure 30 
 
 As stated in the results section (chapter 5.3.4), thrombospondin blotting was 
completed on a membrane where MMP-3 had previously been blotted, therefore only 
the band at band at 125 kDa was attributed to thrombospondin. All other bands visible 
were previously associated with MMP-3 detection. 
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Full image of clusterin western blot from Figure 33 
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